Search Result
Results for "
cancer
" in MedChemExpress (MCE) Product Catalog:
9799
Inhibitors & Agonists
63
Biochemical Assay Reagents
249
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
-
- HY-U00300
-
|
|
Others
|
Cancer
|
|
Cancer-Targeting Compound 1 is used in the research of hormone-related cancer, extracted from patent WO 2008021331 A2.
|
-
- HY-153909
-
|
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
SMP-33693 is an Antibody-Drug Conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer.
|
-
- HY-153908
-
|
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
SMP-93566 is a kind of antibody-drug conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer.
|
-
- HY-153907
-
|
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
SMP-88480 is an Antibody-Drug Conjugates (ADCs). SMP-88480 is stable in mouse, monkey and human plasma and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer.
|
-
- HY-126412
-
|
|
Apoptosis
|
Cancer
|
|
Neochamaejasmine A is a biflavonoid that can be isolated from the roots of Stellera chamaejasme L.. Neochamaejasmine A inhibits proliferation, induces cell cycle arrest and apoptosis in tumor cells. Neochamaejasmine A can be used in the research of cancers such as prostate cancer, hepatoma cancer.
|
-
- HY-P99188
-
|
CNTO 888
|
CCR
|
Cancer
|
|
Carlumab (CNTO 888) is a humanised anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer.
|
-
- HY-N9954
-
|
|
Apoptosis
|
Cancer
|
|
Isoharringtonine is a natural alkaloid that can be purified from Cephalotaxus koreana Nakai. Isoharringtonine can inhibit cancer cell proliferation and migration, and induce cancer cell apoptosis. Isoharringtonine can be used for the research of cancers.
|
-
- HY-P99239
-
|
HJ 591
|
PSMA
|
Cancer
|
|
Rosopatamab (HJ 591) is a humanised anti-PSMA monoclonal antibody that can be used in cancer research, particularly in prostate cancer.
|
-
- HY-145571
-
|
D-1553
|
Ras
|
Cancer
|
|
Garsorasib is a potent inhibitor of KRAS G12C with an IC50 of 10 nM. Garsorasib has the potential for the research of various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (non-small cell lung cancer) (extracted from patent WO2020233592A1, compound 2).
|
-
- HY-16034
-
|
|
Akt
|
Cancer
|
|
AKT-IN-20 is an AKT inhibitor, and can be used for research of cancer
|
-
- HY-144898
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
SB-216 is a potent tubulin polymerization inhibitor. SB-216 shows strong antiproliferative potency in a panel of human cancer cell lines, including melanoma, lung cancer, and breast cancer. SB-216 can be used for cancer research.
|
-
- HY-N10491
-
|
|
P-glycoprotein
|
Cancer
|
|
Spongionellol A is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A can be used in the research of cancers, such as prostate cancer.
|
-
- HY-119694
-
|
|
Others
|
Cancer
|
|
Rotenolone is an antiproliferative agent. Rotenolone shows antiproliferative activity against the ovarian cancer A2780, breast cancer BT-549, prostate cancer DU 145, NSCLC NCI-H460, and colon cancer HCC-2998 cell lines, with IC50s of 0.95, 1.6, 2.7, 2.0, and 2.9 μM, respectively.
|
-
- HY-13442AS
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Eribulin-d3 (mesylate) is a deuterium labeled Eribulin mesylate. Eribulin mesylate is a microtubule targeting agent that is used for the research of cancer[1][2].
|
-
- HY-153943
-
|
|
DNA-PK
|
Cancer
|
|
DNA-PK-IN-10 is a DNA-PK inhibitor. DNA-PK-IN-10 can be used for the research of breast cancer and non-small cell lung cancer.
|
-
- HY-153873
-
|
|
Reactive Oxygen Species
Keap1-Nrf2
|
Cancer
|
|
MSU38225 is an Nrf-2 inhibitor that increases levels of reactive oxygen species (ROS). MSU38225 inhibits the growth of human lung cancer cells and enhances the sensitivity of human lung cancer cells to chemotherapy in vitro and in vivo. MSU38225 can be used in cancer research.
|
-
- HY-N10492
-
|
|
P-glycoprotein
|
Cancer
|
|
Spongionellol A analog 1, an analog of Spongionellol A (HY-10491), is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A analog 1 has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A analog 1 can be used in the research of cancers, such as prostate cancer.
|
-
- HY-P5297
-
|
|
CXCR
|
Cancer
|
|
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer.
|
-
- HY-156419
-
|
|
PARP
|
Cancer
|
|
PARP7-IN-16 (compound 36) is a potent, selective and orally active inhibitor of PARP-1/2/7, with IC50s of 0.94, 0.87 and 0.21 nM, respectively. PARP7-IN-16 can be used for the research of breast cancer and prostate cancer.
|
-
- HY-N8619
-
|
|
Others
|
Cancer
|
|
Minimolide F is a sesquiterpene lactone. Minimolide F has inhibitory activity against human nasopharyngeal cancer cells. Minimolide F can be used for the research of cancer.
|
-
- HY-16045
-
|
Hexyl 5-aminolevulinate hydrochloride; P-1206; 5-Aminolevulinic acid hexyl ester hydrochloride
|
Fluorescent Dye
|
Cancer
|
|
Hexaminolevulinate hydrochloride is a fluorescent agent, and can be used with a light test to check for bladder cancer.
|
-
- HY-154959
-
|
|
Ras
|
Cancer
|
|
AZD4747 is a selective, blood-brain barrier-permeable mutant GTPase KRAS G12C inhibitor. AZD4747 has the potential to study cancer.
|
-
- HY-153214
-
|
|
Wnt
β-catenin
|
Cancer
|
|
YW2036 (compound 2a) is a potent Wnt/β-Catenin signaling pathway inhibitor with an IC50 value of 637 nM. YW2036 can be used in research of cancer.
|
-
- HY-114243
-
|
|
Others
|
Cancer
|
|
DpC is an anti-tumor agent. DpC inhibits cancer cell proliferation (IC50: 0.007-0.096 渭M). DpC synergizes with multiple anti-cancer therapeutics.
|
-
- HY-156029
-
|
|
Others
|
Cancer
|
|
IA1-8H2 is a non-covalent, non-competitive inhibitor of PHPT1 (IC50: 3.4 μM). IA1-8H2 can be used for research of lung cancer, hepatocarcinoma, and renal cancer.
|
-
- HY-145565
-
|
TPX-0046
|
RET
|
Cancer
|
|
Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer.
|
-
- HY-N10631
-
|
|
Others
|
Cancer
|
|
Paucimannose is a common mannosidic N-glycoepitope that exists in invertebrates and plants. paucimannosidic glycans are expressed in cancers.
|
-
- HY-138295
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-10 (compound 11) selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1.
|
-
- HY-151580
-
|
|
CDK
|
Cancer
|
|
CDK2-IN-14 (compound 4f) is a highly selective CDK2 inhibitor. CDK2-IN-14 can be used in research of cancer.
|
-
- HY-15434A
-
|
|
MAP4K
MAP3K
|
Cancer
|
|
NG25 trihydrochloride is a dual TAK1 and MAP4K2 inhibitor (IC50: 149 nM and 21.7 nM respectively). NG25 sensitizes the breast cancer cells to Doxorubicin (HY-15142A), and enhances apoptosis. NG25 trihydrochloride can be used for research of various cancers.
|
-
- HY-150730
-
|
|
FAK
|
Cancer
|
|
FAK-IN-6 is a potent FAK inhibitor with an IC50 value of 1.415 nM. FAK-IN-6 has anti-proliferative activity against certain cancer cell lines. FAK-IN-6 can be used for researching pancreatic cancer.
|
-
- HY-P99558
-
|
GEXMab73; GT-MAb7.3-GEX; TrastuzuMab-GEX
|
EGFR
|
Cancer
|
|
Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer.
|
-
- HY-151564
-
|
|
Others
|
Cancer
|
|
Anticancer agent 85 (compound 6j) is an anticancer agent that shows good cytotoxicity against MCF7 cells. Anticancer agent 85 can be used in breast cancer and other cancer studies.
|
-
- HY-128172
-
|
NBA
|
TRP Channel
|
Cancer
|
|
TRPM4-IN-2 (NBA) is a potent transient receptor potential melastatin 4 (TRPM4) inhibitor with an IC50 value of 0.16 μM. TRPM4-IN-2 can be used for researching prostate cancer and colorectal cancer.
|
-
- HY-145572B
-
|
(S)-LY-3484356 tosylate
|
Others
|
Cancer
|
|
(S)-Imlunestrant ((S)-LY-3484356) tosylate is an (S)-enantiomer of Imlunestrant (HY-145572). (S)-Imlunestrant tosylate can be used in research of cancer.
|
-
- HY-156680
-
|
|
Histone Methyltransferase
|
Cancer
|
|
TNG-462 (Compound 1143) is an orally active PRMT5 inhibitor for investigation of MTAP-deficient and/or MTA-accumulating cancers.
|
-
- HY-13673
-
|
ICI 118630
|
GnRH Receptor
Apoptosis
|
Cancer
Endocrinology
|
|
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
|
-
- HY-13673A
-
|
ICI-118630 acetate
|
GnRH Receptor
Apoptosis
|
Endocrinology
Cancer
|
|
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
|
-
- HY-W077292
-
|
|
CDK
|
Cancer
|
|
2,4,6-Trihydroxybenzoic acid, the flavonoid metabolite, is a CDK inhibitor. 2,4,6-Trihydroxybenzoic acid can be used for the research of cancer.
|
-
- HY-115718A
-
|
|
PROTACs
Bcl-2 Family
|
Cancer
|
|
PZ703b TFA is a Bcl-xl PROTAC degradation agent that induces apoptosis and inhibits cancer cell proliferation for bladder cancer research.
|
-
- HY-N1156A
-
|
|
Others
|
Cancer
Cardiovascular Disease
|
|
α-Thevetin B（Compound 24） is a cardiac glycoside that can be isolated from Thevetia peruviana. α-Thevetin B（Compound 24） can be used in lung cancer, gastric cancer and pancreatic cancer research.
|
-
- HY-P99681
-
|
IMMU 130; hMN-14-SN-38
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer.
|
-
- HY-147802
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
EGFR-IN-59 (Compound 8c) is a EGFR inhibitor (IC50=190 nM) and apoptosis inducer. EGFR-IN-59 exhibits cytotoxicity against non-small lung cancer cell lines (A549) and normal lung fibroblasts (WI38) with IC50s of 8.62 and 52.6 µM, respectively. EGFR-IN-59 can be used for the research of various cancers such as non-small cell lung cancer (NSCLC), head and neck cancer, breast cancer and colorectal cancer.
|
-
- HY-P99672
-
|
MM 141; MM-005
|
IGF-1R
EGFR
|
Cancer
|
|
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers.
|
-
- HY-N2547
-
|
|
Others
|
Cancer
|
|
Steviolbioside is a rare sweetener that exists in stevia rebaudiana leaves. Steviolbioside presents inhibition on several human cancer cells and acts as potential remedy for human breast cancer.
|
-
- HY-145967A
-
|
|
Others
|
Cancer
|
|
(R)-FT709 is an active compound. (R)-FT709 can be used for the research of cancers.
|
-
- HY-153423
-
|
|
Bcl-2 Family
|
Cancer
|
|
Mcl-1 inhibitor 12 (Example 10) is a MCL-1 inhibitor (Ki: 0.22 nM). Mcl-1 inhibitor 12 can be used for the research of cancers.
|
-
- HY-145120
-
|
|
Raf
|
Cancer
|
|
B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer.
|
-
- HY-153423A
-
|
|
Bcl-2 Family
|
Cancer
|
|
Mcl-1 inhibitor 13 (Example 9) is a MCL-1 inhibitor (Ki: 8.2 nM). Mcl-1 inhibitor 13 can be used for the research of cancers.
|
-
- HY-P99593
-
|
DMUC5754A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer.
|
-
- HY-149497
-
|
|
HDAC
|
Cancer
|
|
HDAC6-IN-19 (Compound 14g) is a HDAC6 inhibitor (IC50: 2.68 nM). HDAC6-IN-19 also inhibits HDAC1, HDAC2 and HDAC3 with IC50s of 61.6 nM, 98.7 nM and 103 nM. HDAC6-IN-19 potently inhibits multiple cancer cell proliferation, including leukemia, colon cancer, melanoma, and breast cancer cell lines.
|
-
- HY-155078
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-27 (compound 6) is a BRD4 inhibitor with IC50 of 9.6 and 11.3 μM for BRD4 BD1 and BRD4 BD2, respectively. BRD4 Inhibitor-27 has the potential to study cancer.
|
-
- HY-16375
-
|
D-63153
|
GnRH Receptor
Apoptosis
|
Cancer
|
|
Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer.
|
-
- HY-120786
-
|
6-(3′,4′,5′-Trimethoxybenzoyl)quinoline
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
MPT0B014 is a tubulin polymerization inhibitor. MPT0B014 induces cancer cell apoptosis. MPT0B014 can be used for the research of cancer.
|
-
- HY-156606
-
|
|
Phosphatase
|
Cancer
|
|
Anticancer agent 142 (compound 235) is a PTPN inhibitor, with the potential to study cancer.
|
-
- HY-148816
-
|
|
Calcium Channel
|
Cancer
|
|
SG-094 is a potent TPC2 inhibitor with antiproliferative effects. SG-094 can be used for the research of cancer.
|
-
- HY-14372
-
|
|
CDK
|
Cancer
|
|
BS-194 is an orally active, selective and potent CDK inhibitor. BS-194 inhibits CDK2, CDK1, CDK5, CDK7, CDK9 (IC50s: 3, 30, 30, 250, and 90 nM respectively). BS-194 potently inhibits cancer cells proliferation. BS-194 can be used in the research of cancers like breast cancer, colon cancer.
|
-
- HY-107191
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
Sildenafil Mesylate is an orally active and selective phosphodiesterase type 5 (PDE5) inhibitor. Sildenafil Mesylate can be used in studies of erectile dysfunction and cancer.
|
-
- HY-145825A
-
|
|
Bcl-2 Family
|
Cancer
|
|
(E)-Mcl-1 inhibitor 7 (Example 34) is a Mcl-1 inhibitor (Ki: <1 nM, IC50: <500 nM). (E)-Mcl-1 inhibitor 7 can be used for research of cancers.
|
-
- HY-149469
-
|
|
BCRP
|
Cancer
|
|
BCRP/ABCG2-IN-1 is the inhibitor of breast cancer resistance protein (BCRP/ABCG2), with IC50 of 5.98 μM, that can be used in multidrug resistance of breast cancer.
|
-
- HY-146208
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-20 is a potent orally active bromodomain protein 4 (BRD4) inhibitor. BRD4 Inhibitor-20 has inhibitory activity for BRD4 (BD1) and BRD4 (BD2) with IC50 values of 19 nM and 28 nM, respectively. BRD4 Inhibitor-20 also has anti-proliferation activities in cancer cell lines. BRD4 Inhibitor-20 can be used for the research of kinds of cancer, such as colon cancer.
|
-
- HY-12204
-
PFK-015
2 Publications Verification
|
Autophagy
|
Cancer
Metabolic Disease
Inflammation/Immunology
|
|
PFK-015, a derivative of 3PO, is a specific PFKFB3 inhibitor. PFK-015 inhibits recombinant PFKFB3 with an IC50 value of 110 nM and inhibits PFKFB3 activity in cancer cells with an IC50 value of 20 nM. PFK-015 can be used for the research of multiple cancers such as lung cancer, stomach cancer, colon cancer and esophageal squamous cell carcinoma (ESCC).
|
-
- HY-14249
-
|
|
Androgen Receptor
Autophagy
|
Cancer
|
|
Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer.
|
-
- HY-16514
-
|
|
Others
|
Cancer
|
|
Vindesine is a semisynthetic derivative of vinblastine. Vindesine is a potent anticancer agent. Vindesine can be used for the research of melanoma and lung cancers.
|
-
- HY-115718B
-
|
|
PROTACs
Apoptosis
Bcl-2 Family
|
Cancer
|
|
PZ703b hydrochloride is a Bcl-xl PROTAC degrader that induces apoptosis and inhibits cancer cell proliferation. PZ703b hydrochloride can be used for the research of bladder cancer research.
|
-
- HY-115718
-
PZ703b
1 Publications Verification
|
PROTACs
Bcl-2 Family
|
Cancer
|
|
PZ703b is a Bcl-xl PROTAC degrader that induces apoptosis and inhibits cancer cell proliferation. PZ703b can be used for the research of bladder cancer research.
|
-
- HY-P99808
-
|
|
VEGFR
|
Cancer
|
|
Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers.
|
-
- HY-W013272
-
|
HFT
|
Androgen Receptor
|
Cancer
|
|
Hydroxyflutamide (HF), an active metabolite of Flutamide, is a potent androgen receptor antagonist (IC50=700 nM). Hydroxyflutamide can be used for the research of prostate cancer.
|
-
- HY-147307
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan is a agent-linker conjugate for ADC, contains the ADC linker (MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic acid) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan synthesized ADC can be used in study of cancer.
|
-
- HY-154799
-
|
|
Others
|
Cancer
|
|
Anticancer agent 112 is a potent anti-cancer agent for cancer research, extracted from patent WO2020198567.
|
-
- HY-143323
-
|
|
EGFR
|
Cancer
|
|
HER2-IN-9 is an orally active HER2 inhibitor, with an IC50 value of 0.03 μM. HER2-IN-9 inhibits HER-2 positive breast cancer cells proliferation and migration. HER2-IN-9 can be used in the research of breast cancers.
|
-
- HY-144875
-
|
|
CDK
|
Cancer
|
|
CTX-712 is a potent inhibitor of cdc2-like kinase (CLK). CTX-712 inhibits CLK kinase activity, and thus inhibits cancer survival and cancer cell growth. CTX-712 has the potential for the research of cancer disease (extracted from patent JPWO2017188374A1, compound 286).
|
-
- HY-155200
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-84 (Compound 6g) is an EGFR inhibitor (IC50: 24 nM). EGFR-IN-84 inhibits A549 cell growth (IC50: 1.537 μM). EGFR-IN-84 can be used for research of lung cancer.
|
-
- HY-149828
-
-
- HY-144987
-
|
|
CD38
|
Cancer
|
|
RBN013209 is a potent CD38 inhibitor with an IC50 of 0.01-0.1 μM for human CD38. RBN013209 can be used for the research of of cancer.
|
-
- HY-148313
-
|
|
Pyruvate Kinase
|
Cancer
|
|
PKM2 activator 4 is a PKM2 activator with an AC50 value of 1-10 μM. PKM2 activator 4 can be used for the research of cancer.
|
-
- HY-149828A
-
-
- HY-N10469
-
|
Phleomycin F
|
Antibiotic
|
Cancer
|
|
Bleomycin B4 (Phleomycin F) is an antibiotic. Bleomycin B4 has antitumor activity. Bleomycin B4 can be used for the research of cancer.
|
-
- HY-N7486
-
|
|
Others
|
Cancer
|
|
Chamaejasmenin B can be extracted from Stellera chamaejasme L. Chamaejasmenin B suppresses cancer cells migration and invasion. Chamaejasmenin B inhibits tumor metastasis. Chamaejasmenin B can be used in the research of cancers, such as breast cancers.
|
-
- HY-N3495
-
|
|
Others
|
Cancer
|
|
Isocoronarin D is a diterpene that can be isolated from rhizomes of Hedychium coronarium. Isocoronarin D can be used for the research of cancer.
|
-
- HY-P99229
-
|
|
ADC Antibody
|
Cancer
|
|
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer.
|
-
- HY-W478102
-
|
|
CDK
|
Cancer
|
|
CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC50 of 12 µM. CDK2-IN-13 can be used in research of cancer.
|
-
- HY-118263
-
|
PF-00299804 hydrate; PF-299804 hydrate
|
EGFR
|
Cancer
|
|
Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC).
|
-
- HY-122878
-
|
|
HSP
|
Cancer
|
HS-131, a near infrared dye tethered Hsp90 inhibitor, is able to detect oncogene-driven breast cancers, including multiple different molecular subtypes of human breast cancers.
|
-
- HY-19549
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
RX-37 is a selective BET inhibitor. RX-37 binds to BET bromodomain proteins (BRD2, BRD3, and BRD4) with Ki values of 3.2-24.7 nM. RX-37 can be used for research of cancers.
|
-
- HY-110154
-
|
|
Histone Demethylase
|
Cancer
|
|
NSC636819 is a competitive and selective inhibitor of KDM4A/KDM4B. KDM4A/KDM4B are potential progression factors for prostate cancer. NSC636819 has the potential for the research of cancer diseases, especially prostate cancer.
|
-
- HY-138641
-
|
ARV-110
|
Androgen Receptor
|
Cancer
|
|
Bavdegalutamide (ARV-110) is an orally active, specific androgen receptor (AR) PROTAC degrader. Bavdegalutamide promotes ubiquitination and degradation of AR. Bavdegalutamide can be used for the research of prostate cancer.
|
-
- HY-151570
-
|
|
Others
|
Cancer
|
|
Anticancer agent 87 is a potent anticancer agent. Anticancer agent 87 can be used in the research of breast adenocarcinoma and liver cancer.
|
-
- HY-16395
-
|
CGC-11047
|
Others
|
Cancer
|
|
PG-11047 (CGC-11047) is a polyamine analogue. PG-11047 can be used for the research of breast cancer.
|
-
- HY-P99295
-
|
RG 7160; RO 5083945; Anti-EGFR Recombinant Antibody
|
EGFR
|
Cancer
|
|
Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer.
|
-
- HY-151572
-
|
|
Others
|
Cancer
|
|
Anticancer agent 88 is a potent anticancer agent. Anticancer agent 88 can be used in the research of breast adenocarcinoma and liver cancer.
|
-
- HY-153580
-
|
|
Wnt
|
Cancer
|
|
WIC1 is a potent Wnt inhibitor. WIC1 can be used for the research of cancer.
|
-
- HY-50879
-
|
GF120918; GW0918; GG918; GW120918
|
P-glycoprotein
BCRP
|
Cancer
|
|
Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer.
|
-
- HY-149970
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
ER degrader 5 is a potent estrogen receptor (ER) degrader. ER degrader 5 shows anti-proliferation activity. ER degrader 5 can be used for the research of breast cancer.
|
-
- HY-155233
-
|
|
Others
|
Cancer
|
|
Steroid sulfatase-IN-5 (compound 10b) is a steroid sulfatase (STS) inhibitor (IC50: 0.32 nM). Steroid sulfatase-IN-5 inhibits T-47D cell proliferation with an IC50 of 35.7 μM. Steroid sulfatase-IN-5 can be used for research of breast cancer.
|
-
- HY-148184
-
|
|
Deubiquitinase
|
Cancer
|
|
USP1-IN-3 is a selective USPI inhibitor. USP1-IN-3 inhibits USPI-UAFI with an IC50 value of ＜30 nM. USP1-IN-3 can be used for the research of cancer.
|
-
- HY-145444
-
-
- HY-103367
-
|
|
Checkpoint Kinase (Chk)
|
Cancer
|
|
CHK1-IN-7 (Compound 10c) is a potent human CHK1 inhibitor. CHK1-IN-7 shows no single agent effect, potentiates the antiproliferative effect of Gemcitabine HY-17026 in both prostate and breast cancer cell lines. CHK1-IN-7 can be used for the research of cancer.
|
-
- HY-156790
-
|
|
FGFR
|
Cancer
|
|
FGFR3-IN-6 is a potent and selective FGFR3 inhibitor with IC50 value less than 350 nM. FGFR3-IN-6 can be used in research of cancer.
|
-
- HY-154962
-
|
|
Bcl-2 Family
|
Cancer
|
|
Mcl-1 inhibitor 15 (Compound (Ra)-15) is a Mcl-1 inhibitor (Ki: 0.02 nM). Mcl-1 inhibitor 15 can be used for research of cancer.
|
-
- HY-138795
-
|
|
Others
|
Cancer
|
|
Curcumin-β-D-glucuronide is a major metabolite after oral intake of Curcumin in hepatic tissue and portal blood. Curcumin-β-D-glucuronide can be used for the research of colon cancer.
|
-
- HY-156791
-
|
|
FGFR
|
Cancer
|
|
FGFR3-IN-7 is a potent and selective FGFR3 inhibitor with IC50 value less than 350 nM. FGFR3-IN-7 can be used in research of cancer.
|
-
- HY-153767
-
|
|
MDM-2/p53
|
Cancer
|
|
PK095 is a p53 mutant stabilizer. PK095 can be used for research of cancer.
|
-
- HY-P99011
-
|
|
CD3
|
Cancer
|
|
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research.
|
-
- HY-148669A
-
|
Menin-MLL inhibitor 24 oxalate
|
Epigenetic Reader Domain
|
Cancer
|
|
Menin-MLL inhibitor 24 (compound A) oxalate is a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor, and can be used for the research of cancer.
|
-
- HY-13442
-
|
B1939; E7389; ER-086526
|
Microtubule/Tubulin
Apoptosis
ADC Cytotoxin
|
Cancer
|
|
Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
|
-
- HY-P99118
-
|
HLX 10
|
PD-1/PD-L1
|
Cancer
|
|
Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer.
|
-
- HY-13442A
-
|
B1939 mesylate; E7389 mesylate; ER-086526 mesylate
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
|
-
- HY-143257
-
|
|
CDK
|
Cancer
|
|
CDK4/6-IN-7 is a potent, selective and orally active CDK4/6 inhibitor, with IC50s of 1.58 and 4.09 nM, respectively. CDK4/6-IN-7 can be used for the research of breast cancer.
|
-
- HY-147714
-
|
|
FGFR
VEGFR
|
Cancer
|
|
FGFR3-IN-2 (compound 18b) is a potent and selective FGFR3 inhibitor, with IC50s of 4.1 nM and 570 nM for FGFR3 and VEGFR2, respectively. FGFR3-IN-2 can be used for the research of bladder cancer.
|
-
- HY-153692
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
WRN inhibitor 1 (example 7) is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor that inhibits WRN helicase domain activity. WRN inhibitor 1 has the potential to study cancer.
|
-
- HY-151516
-
|
|
MicroRNA
|
Cancer
|
|
microRNA-21-IN-2 is a potential miR-21 inhibitor with an AC50 value of 3.29 μM. microRNA-21-IN-2 can be used for the research of cancer.
|
-
- HY-P99016
-
|
|
ADC Antibody
|
Cancer
|
|
Enfortumab is a monoclonal antibody targeting Nectin-4. Enfortumab can used for researching urothelial cancer.
|
-
- HY-P990055
-
|
|
EGFR
|
Cancer
|
|
Nezutatug is an anti-HER3 antibody, and used for cancer research.
|
-
- HY-N3210
-
|
|
Others
|
Cancer
|
|
Nb-Demethylechitamine is an alkaloid isolated from the methanol extract of Alstonia rostrata twigs. Nb-Demethylechitamine has in vitro cytotoxic activity against several human cancer cell lines, including human myeloid leukemia HL-60, liver cancer SMMC-7721, lung cancer A-549, breast cancer MCF-7, and colon cancer SW480 cells.
|
-
- HY-147713
-
|
|
FGFR
|
Cancer
|
|
FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor, with IC50s of 40 nM, 5.1 nM, and 12 nM for FGFR1, 2, and 3, respectively. FGFR3-IN-1 can be used for the research of bladder cancer.
|
-
- HY-P9964
-
|
|
EGFR
|
Cancer
|
|
Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc.
|
-
- HY-149324
-
-
- HY-P5005
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
VIPhyb (compound VIPhyb) is a vasoactive intestinal polypeptide (VIP) receptor antagonist that can be used in the study of cancers such as non-small cell lung cancer (NSCLC).
|
-
- HY-111533
-
|
|
Others
|
Cancer
|
|
Ingenol 3-Hexanoate, an ingenol semi-synthetic derivative, is a potent anticancer agent. Ingenol 3-Hexanoate can be used in research of cancer.
|
-
- HY-N2059
-
|
|
Others
|
Cancer
|
|
Santalol is a mixture of α and β-isomer santalol. α-santalol is isolated from sandalwood oil. α-santalol is a promising anti-cancer agent against cancers such as oral, breast, prostate and skin cancer.
|
-
- HY-156970
-
|
|
Others
|
Cancer
|
|
Phosphatase Binder-1 (comppund i-196) provides bifunctional compounds that efficiently dephosphorylate certain phospho-activated target proteins. Phosphatase Binder-1 plays an important role in cancer.
|
-
- HY-145484
-
|
|
PROTACs
|
Cancer
|
|
PROTAC IRAK4 ligand-3 is a ligand of PROTAC IRAK4 degrader-7 (HY-145483). PROTAC IRAK4 ligand-3 can be used for the research of cancer.
|
-
- HY-114988
-
|
tetranor-PGEM
|
Endogenous Metabolite
|
Cancer
Inflammation/Immunology
|
|
PGE-M is a metabolite of prostaglandin E2 (PEG2) as a biomarker of inflammation and cancer including advanced colorectal neoplasia, ovarian cancer, prostate cancer and so on. Urinary PGE-M is positively associated with obesity, smoking and lung metastases with breast cancer.
|
-
- HY-147011
-
|
|
Fat Mass and Obesity-associated Protein (FTO)
|
Cancer
|
|
FTO-IN-7 is an inhibitor of FTO. FTO-IN-7 can be used in study Alzheimer's diseases, breast cancers, small-cell lung cancers,a human bone marrow striated muscle cancer, a pancreatic cancer, malignant glioblastoma.
|
-
- HY-156704
-
|
|
FGFR
|
Cancer
|
|
FGFR4-IN-16 (CY-15-2) is a covalent inhibitor of FGFR-4 for cancer research.
|
-
- HY-W335254
-
|
|
Phosphodiesterase (PDE)
Ras
|
Cancer
|
|
Deltarasin is an inhibitor of KRAS-PDEδ interaction with Kd of 38 nM for binding to purified PDEδ. Deltarasin can be used in the study of cancer.
|
-
- HY-N8034
-
|
|
Apoptosis
Autophagy
|
Cancer
|
|
Glychionide A is a flavonoside that can be found in the roots of Glychirriza glabra. Glychionide A promotes apoptosis and autophagy of PANC-1 pancreatic cancer cells. Glychionide A can be used for the research of cancer.
|
-
- HY-155026
-
|
|
p97
|
Cancer
|
|
UPCDC30766 is a potent allosteric inhibitor of p97, with an IC50 of 12 nM. UPCDC30766 can be used for the research of colon cancer. UPCDC30766 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-B2099A
-
|
1-Butylbiguanide hydrochloride
|
AMPK
|
Cancer
|
|
Buformin hydrochloride (1-Butylbiguanide hydrochloride), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin hydrochloride decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin hydrochloride also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al).
|
-
- HY-50880
-
|
GF120918A
|
P-glycoprotein
BCRP
|
Cancer
|
|
Elacridar hydrochloride (GF120918A) is an orally active P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar hydrochloride can be used to examine the influence of efflux transporters on agent distribution to brain and it can be used for the research of cancer.
|
-
- HY-156554
-
|
|
Raf
|
Cancer
|
|
Raf inhibitor 3 (Example 30) is a Raf inhibitor. Raf inhibitor 3 inhibits B-Raf and C-Raf with IC50 values less than 15 nM. Raf inhibitor 3 can be used for research of cancers.
|
-
- HY-149231
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 104 has anticancer activity, and induces cancer cell apoptosis.
|
-
- HY-148368
-
|
|
Bcl-2 Family
Apoptosis
|
Cancer
|
|
CYD-4-61 is a novel Bax activator used for breast cancer research. CYD-4-61 inhibits triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation. CYD-4-61 activates Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis.
|
-
- HY-P99968
-
|
|
Mucin
|
Cancer
|
|
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers.
|
-
- HY-147715
-
|
|
FGFR
|
Cancer
|
|
FGFR3-IN-3 (compound 40a) is a potent and pan-FGFR inhibitor, with IC50s of 2.1 nM, 3.1 nM, 4.3 nM and 74 nM for FGFR1, 2, 3, and 4, respectively. FGFR3-IN-3 can be used for the research of bladder cancer.
|
-
- HY-101152
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SG3199-Val-Ala-PAB is an intermediate of Tesirine synthesis. Tesirine is a agent-linker conjugate for ADC which can be used for the research of several cancers.
|
-
- HY-137267
-
|
|
Antifolate
|
Cancer
|
|
10-Methyl-10-deazaaminopterin is a folate analog and an antifolate. 10-Methyl-10-deazaaminopterin can be used for the research of cancer.
|
-
- HY-P99296
-
|
CNTO 95; Anti-Human CD51 Recombinant Antibody
|
EGFR
|
Cancer
|
|
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer.
|
-
- HY-154997
-
|
|
METTL3
|
Cancer
|
|
7OQL (compound 54) is a selective METTL3 inhibitor (IC50=0.054 µM). 7OQL has the potential to be used in the study of cancer.
|
-
- HY-151171
-
|
|
MDM-2/p53
|
Cancer
|
|
MDM2/4-p53-IN-3 is a MDM2/4-p53 protein-protein interactions (PPIs) inhibitor (IC50s: 18.5 nM for MDM2-p53, 14.8 nM for MDM4-p53). MDM2/4-p53-IN-3 can be used in the research of cancers, such as colon cancer.
|
-
- HY-W412264
-
|
|
Pim
|
Cancer
|
|
Pim-1/2 kinase inhibitor 1 is an orally active pim-1/2 kinase inhibitor. Pim-1/2 kinase inhibitor 1 blocks the ability of Pim kinases to phosphorylate peptides, and inhibits the pim protein kinase directed phosphorylation of 4E-BP1 and p27 Kip1. Pim-1/2 kinase inhibitor 1 can be used in study of cancer, especially prostate cancer.
|
-
- HY-160063
-
|
|
Others
|
Cancer
|
|
SW1 aptamer sodium is a high-affinity DNA aptamer (Kd: 123.62 nM) that targets liver cancer SMMC-7721 cells and targets intracellular components within the nucleus. SW1 aptamer sodium can also identify various other types of cancer cells and tissues, serving as an effective molecular probe for clinical cancer diagnosis.
|
-
- HY-144094
-
|
|
Histone Methyltransferase
|
Cancer
|
|
EZH2-IN-9 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-9 has the potential for the research of cancer diseases (extracted from patent WO2021180235A1, compound 17).
|
-
- HY-143616
-
|
|
Histone Methyltransferase
|
Cancer
|
|
EZH2-IN-7 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-7 has the potential for the research of cancer diseases (extracted from patent WO2021129629A1, compound 259).
|
-
- HY-B1460B
-
|
(±)-Sulconazole
|
Fungal
|
Cancer
|
|
Sulconazole is a potent antifungal agent in the imidazole class. Sulconazole blocks the NF-κB/IL-8 signaling pathway and CSC (Cancer stem cells) formation. Sulconazole inhibits tumor growth, and can be used for breast cancer research.
|
-
- HY-15673
-
KP372-1
1 Publications Verification
|
Akt
Reactive Oxygen Species
Apoptosis
|
Cancer
|
|
KP372-1 is an Akt inhibitor that inhibits proliferation and induces apoptosis and anoikis. KP372-1 is also an NQO1 redox cycling agent that causes DNA damage (including DNA breakage) by generating ROS. KP372-1 can be used in cancer research (such as head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer).
|
-
- HY-144295
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3Kα-IN-5 (compound 6 ab) is a potent PI3Kα/mTOR inhibitor, with an IC50 of 0.7 nM and 3.3 nM, respectively. PI3Kα-IN-5 can be used for the research of colorectal cancer.
|
-
- HY-N9489
-
|
|
Others
|
Cancer
|
|
Phoyunnanin E, isolated from Dendrobium venustum, possesses anti-migration activity. Phoyunnanin E can be used for the research of cancer.
|
-
- HY-149897
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Antitumor agent-108 (compound 5) is an Hyaluronic acid (HA)-CD44 interaction inhibitor that effectively disrupts the integrity of cancer spheroids. Antitumor agent-108 also exhibits antiproliferative activity against cancer cells.
|
-
- HY-123085
-
|
Isoalloxazine
|
Adenosine Receptor
|
Cancer
|
|
Alloxazine is a selective A2b antagonist. Alloxazine completely block 5’N-Ethylcarboxamido adenosine (NECA)-mediated cyclic AMP accumulation with an IC50 of 2.9 μM. Alloxazine can be used for the research of cancer.
|
-
- HY-120025
-
|
|
LIM Kinase (LIMK)
|
Cancer
|
|
CRT0105950 is a potent LIMK inhibitor, with IC50s of 0.3 nM and 1 nM for LIMK1 and LIMK2 respectively. CRT0105950 can be used for the research of cancer.
|
-
- HY-144669
-
|
|
Aldehyde Dehydrogenase (ALDH)
|
Cancer
|
|
ALDH1A3-IN-2 (Compound 15) is a potent inhibitor of ALDH1A3 with an IC50 of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH1A3-IN-2 has the potential for the research of cancer diseases.
|
-
- HY-144671
-
|
|
Aldehyde Dehydrogenase (ALDH)
|
Cancer
|
|
ALDH3A1-IN-2 (Compound 19) is a potent inhibitor of ALDH3A1 with an IC50 of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH3A1-IN-2 has the potential for the research of cancer diseases.
|
-
- HY-E70188
-
|
EC:3.1.6.4; GALNS
|
Biochemical Assay Reagents
|
Cancer
|
|
N-Acetylgalactosamine-6-Sulfatase (GALNS) is a potential general biomarker for multiple malignancies (such as lung cancer, breast cancer, head and neck cancer, etc.). N-Acetylgalactosamine-6-Sulfatase deficiency causes mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. N-Acetylgalactosamine-6-Sulfatase can be used in MPS IVA as well as cancer research.
|
-
- HY-N10948
-
|
|
Others
|
Cancer
|
|
Justin C (compound 14) is a nature product that could be isolated from Justicia procumbens. Justin C can be used in research of cancer.
|
-
- HY-153629
-
|
|
Ferroptosis
|
Cancer
|
|
FSEN1 is a potent and non-competitive FSP1 inhibitor with an IC50 value of 313 nM. FSEN1 triggers iron death in cancer cells by inhibiting FSP1. FSEN1 can be used in research of cancer.
|
-
- HY-148255
-
|
|
Apoptosis
Autophagy
|
Cancer
|
|
QN523 is a novel scaffold with agent-like properties, showing potent in vitro cytotoxicity in a panel of 12 cancer cell lines. QN523 induces apoptosis and autophagy. QN523 can be used in research of cancer.
|
-
- HY-144096
-
|
|
Histone Methyltransferase
|
Cancer
|
|
EZH2-IN-11 is a potent inhibitor of E2HZ. The oncogenic activities of EZH2 have been shown by a number of studies in various different cancer types. EZH2-IN-11 has the potential for the research of cancer diseases (extracted from patent WO2019204490A1, compound 17).
|
-
- HY-N3451
-
|
|
Lipoxygenase
|
Cancer
|
|
Isothymusin is a potent anti-oxidant agent. Isothymusin shows radical scavenging activities. Isothymusin shows anti-proliferative activities in cancer cell lines. Isothymusin inhibited the enzymes associated with the promotion stage of cancer, including cycloxygenase- 2 and lipoxygenase-5.
|
-
- HY-143398
-
|
|
PARP
|
Cancer
|
|
PARP10/15-IN-1 (compound 8l) is a potent inhibitor of dual inhibitor of PARP10 and PARP15, with IC50s of 160 nM and 370 nM, respectively. PARP10/15-IN-1 can be used for cancer.
|
-
- HY-111246
-
|
|
Androgen Receptor
|
Cancer
|
|
MK-3984 is a selective androgen receptor modulator (SARM). MK-3984 can be used for the research of muscle wasting associated with cancer.
|
-
- HY-P99852
-
|
ABT165; PR1283233
|
VEGFR
|
Cancer
|
|
Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.. Dilpacimab can be used in research of cancer.
|
-
- HY-150269
-
|
|
Others
|
Cancer
|
|
RS5517 is a specific PDZ1-domain antagonist of NHERF1 that prevented its ectopic nuclear entry. RS5517 can be used for the research of colorectal cancer.
|
-
- HY-103665A
-
|
|
STING
|
Cancer
|
|
STING agonist-3 trihydrochloride, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pEC50 of 7.5 and 9.5, respectively. STING agonist-3 trihydrochloride has durable anti-tumor effect and tremendous potential to improve treatment of cancer.
|
-
- HY-W392925
-
|
d-Aminoglutethimide
|
Cytochrome P450
|
Cancer
|
|
(R)-(+)-Aminoglutethimide is a potent and orally active aromatase inhibitor. (R)-(+)-Aminoglutethimide has the potential for the research of breast cancer.
|
-
- HY-41648
-
-
- HY-106204
-
|
|
EGFR
|
Cancer
|
|
Nelipepimut-S is a peptide vaccine which targets HER2. Nelipepimut-S has immune activity against HER2 positive breast cancer.
|
-
- HY-18301
-
|
|
JAK
|
Cancer
|
|
JAK-IN-35 (compound TG46) is a JAK2 inhibitor that canb be used in cancer research.
|
-
- HY-19445
-
|
JB95008
|
Cholecystokinin Receptor
|
Cancer
|
|
Gastrazole (JB95008) is potent and selective CCK2/gastrin receptor antagonist. Gastrazole can decrease the level of gastric acid. Gastrazole inhibits the Gastrin-stimulated growth of pancreatic cancer.
|
-
- HY-13299
-
MK-8033
2 Publications Verification
|
c-Met/HGFR
|
Cancer
|
|
MK-8033 is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs).
|
-
- HY-13299A
-
|
|
c-Met/HGFR
|
Cancer
|
|
MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs).
|
-
- HY-P0039
-
|
|
Bombesin Receptor
|
Cancer
|
|
BIM-26226, gastrin-releasing peptide, is a potent and selective antagonist of bombesin receptor. BIM-26226 inhibits BN- or GRP-stimulated amylase release with IC50s in the nanomolar range. BIM-26226 can be used for the research of cancer.
|
-
- HY-155068
-
|
|
Reactive Oxygen Species
Apoptosis
Microtubule/Tubulin
|
Cancer
|
|
FC-11 is a Tubulin inhibitor that effectively inhibits tumor growth in mice. FC-11 can also induce endoplasmic reticulum (ER) stress to generate excess reactive oxygen species (ROS), leading to mitochondrial damage, thereby promoting apoptosis in colorectal cancer (CRC) cells by targeting microtubules. FC-11 can be used in cancer research.
|
-
- HY-P3099
-
|
|
Guanylate Cyclase
|
Cancer
|
|
Uroguanylin (human) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) has anti-tumor actions in an animal model for human colon cancer.
|
-
- HY-N0707
-
|
1-Methyl-L-tryptophan; (S)-NLG-8189
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
(S)-Indoximod (1-Methyl-L-tryptophan) is an inhibitor of indoleamine 2,3-dioxygenase (IDO). (S)-Indoximod can be used for the research of cancer.
|
-
- HY-141453
-
|
|
RIP kinase
|
Cancer
|
|
Desmethyl-WEHI-345 analog is a protein kinase inhibitor extracted from patent WO2012003544A1, example 12. Desmethyl-WEHI-345 analog can be used for the research of colon cancer.
|
-
- HY-W287569
-
|
|
Atg4
Autophagy
|
Cancer
|
|
STK683963 is a strong activator of cellular ATG4B activity. STK683963 can act as a mediator of redox-regulation of ATG4B in cells. STK683963 can be used for the research of cancer.
|
-
- HY-P99463
-
|
AVB-S6-500
|
TAM Receptor
|
Cancer
|
|
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer.
|
-
- HY-151618
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-79 shows good antiproliferative activities against hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM. Antitumor agent-79 induces cancer cells apoptosis and shows in vivo antitumor effects. Antitumor agent-79 can be used for the research of cancer.
|
-
- HY-147386
-
|
|
CDK
|
Cancer
|
|
CDK-IN-10 (example 54) is a cyclin dependent kinase (CDK) inhibitor that can be used in cancer research.
|
-
- HY-106174
-
|
CS 891
|
5 alpha Reductase
|
Cancer
|
|
Lapisteride (CS 891) is an orally active 5α-reductase inhibitor. Lapisteride can be used in cancer research.
|
-
- HY-N1823
-
|
|
Apoptosis
|
Cancer
Metabolic Disease
Inflammation/Immunology
|
|
Pygenic acid A is a natural compound that can be found in Prunella vulgaris. Pygenic acid A induces apoptosis in metastatic breast cancer cells. Pygenic acid A can be used for the research of diabetes, inflammatory diseases, and cancers.
|
-
- HY-151162
-
|
|
EGFR
|
Cancer
|
|
HER2-IN-12 is a HER2 inhibitor (IC50: 121 nM). HER2-IN-12 can be used in the research of cancers, such as breast cancer.
|
-
- HY-146433
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 55 is a potent anticancer agent. Anticancer agent 55 shows anticancer activity via reducing the cell viability and cell migration in a dose-dependent manner. Anticancer agent 55 induces apoptosis. Anticancer agent 55 has the potential for the research of prostate cancer and breast cancer.
|
-
- HY-108447
-
|
|
PAI-1
SARS-CoV
Ser/Thr Protease
|
Cancer
Infection
|
|
BC-11 hydrobromide is a selective TMPRSS2 inhibitor (TMPRSS2 is a key host cellular factor for viral entry and SARS-CoV-2 pathogenesis), and a selective urokinase (uPA) inhibitor (IC50=8.2 μM). BC-11 hydrobromide is cytotoxic to triple-negative MDA-MB231 breast cancer cells. BC-11 hydrobromide is used in research on viral infections and cancer.
|
-
- HY-14248
-
|
CGS 20267
|
Cytochrome P450
Autophagy
|
Cancer
|
|
Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer.
|
-
- HY-155023
-
|
|
Reactive Oxygen Species
Apoptosis
|
Cancer
|
|
Apoptosis inducer 13 (Compound Ru4) can induce cancer cell apoptosis, and inhibits cancer cell migration and invasion. Apoptosis inducer 13 converts coenzyme NADH to NAD +, and increases intracellular ROS levels.
|
-
- HY-145312
-
|
|
ATM/ATR
|
Cancer
|
|
ATR-IN-4 is a potent ATR (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC50s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13).
|
-
- HY-N10361
-
|
|
Others
|
Cancer
|
|
Drupanin is a compound isolated from green propolis. Drupanin can selectively inhibit the AKR1C3 enzyme. Drupanin has the potential for the research of breast cancer.
|
-
- HY-106009
-
|
|
Checkpoint Kinase (Chk)
|
Cancer
|
|
VRX0466617, a selective Chk2 inhibitor, inhibits the phosphorylation of Chk2 Ser 19 and Ser 33-35. VRX0466617 can be used in the study of cancer.
|
-
- HY-153034
-
|
|
Others
|
Cancer
|
|
LONP1-IN-2 (compound 9d) is a potent and selective LONP1 inhibitor with IC50 values of 0.187 μM and >10 μM for LONP1 and 20S proteasome, respectively. LONP1-IN-2 can be used in research of cancer.
|
-
- HY-153445
-
|
|
ERK
MEK
|
Cancer
|
|
MEK-IN-6 (Example 69) is a MEK inhibitor. MEK-IN-6 inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells (IC50: 2 nM). MEK-IN-6 can be used for research of cancer.
|
-
- HY-160061
-
|
|
Others
|
Cancer
|
|
P12FR2 aptamer sodium is a 2'-fluoropyrimidine-modified RNA aptamer targeting human PAUF with an estimated apparent KD of 77 nM. P12FR2 aptamer sodium inhibits PAUF-induced migration of PANC-1 (human pancreatic cancer cells) in wound healing assays and suppresses tumor growth in a mouse CFPAC-1 pancreatic cancer model.
|
-
- HY-151381
-
|
|
Dihydroorotate Dehydrogenase
|
Cancer
|
|
hDHODH-IN-10 is a selective, potent and orally active hDHODH inhibitor, with an IC50 value of 10.9 nM. hDHODH-IN-10 forms hydrogen bonds with key residues Arg136 and Gln47. hDHODH-IN-10 inhibits the proliferation of cancer cells. hDHODH-IN-10 can be used in the research of cancers, such as AML, colorectal cancer.
|
-
- HY-120284
-
|
|
Others
|
Cancer
|
|
CCCI-01 is a centrosome clustering inhibitor. CCCI-01 has selective effects on cancer. CCCI-01 can be used for the research of non-cross-resistant anti-cancer agents with blocking centrosome clustering.
|
-
- HY-149869
-
|
|
PSMA
|
Cancer
|
|
PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC50 value of 13 nM. PSMA-IN-3 is suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate cancer.
|
-
- HY-133118
-
6RK73
1 Publications Verification
|
Deubiquitinase
|
Cancer
|
|
6RK73 is a covalent irreversible and specific UCHL1 inhibitor with an IC50 of 0.23 µM. 6RK73 shows almost no inhibition of UCHL3 (IC50=236 µM). 6RK73 specifically inhibit UCHL1 activity in breast cancer.
|
-
- HY-120220
-
|
A-20968; Ancyte
|
Others
|
Cancer
|
|
Piposulfan (Ancyte) is a methanesulfonate, alkylating derivative of piperazine. Piposulfan has potential antineoplastic activity. Piposulfan can be used for the research of cancer.
|
-
- HY-N3709
-
|
|
Others
|
Cancer
|
|
Dehydrocrebanine is an alkaloid that can be isolated from the tuber and leaves of Stephania venosa. Dehydrocrebanine has in vitro anti-cancer activity.
|
-
- HY-151609
-
|
|
PARP
|
Cancer
|
|
PARP7-IN-12 is a potent PARP7 Inhibitor with an IC50 value of 7.836 nM. PARP7-IN-12 can be used in research of cancer.
|
-
- HY-139536
-
-
- HY-146064
-
|
|
Others
|
Cancer
|
|
OPN expression inhibitor 1 (Compound 11) is an osteopontin (OPN) expression inhibitor. OPN expression inhibitor 1 can be used for breast cancer research.
|
-
- HY-117821
-
-
- HY-139139
-
|
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
|
MAT2A inhibitor 3 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1, compound 24, has an IC50 of <200 nM. MAT2A inhibitor 3 can be used for the research of cancers.
|
-
- HY-150542
-
|
|
Others
|
Cancer
|
|
Steroid sulfatase -IN-2 is an active steroid sulfatase (STS) inhibitor with an IC50 value of 109.5 nM. Steroid sulfatase-IN-2 can be used for the research of hormone-dependent cancers, such as estrogen-dependent breast and endometrial cancer.
|
-
- HY-132840
-
|
AMG 650
|
Microtubule/Tubulin
|
Cancer
|
|
Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC50 value of 0.071 μM. Sovilnesib can be used for the research of cancer.
|
-
- HY-139458
-
|
|
MDM-2/p53
|
Cancer
|
|
MDM2-IN-21 is a potent MDM2 inhibitor. MDM2-IN-21 can be used for the research of cancer.
|
-
- HY-153443
-
|
|
CDK
|
Cancer
|
|
CDK4-IN-2 (A17) is a CDK4 inhibitor, with Ki and IC50 values of <10 nM. Used in cancer research.
|
-
- HY-145907
-
|
|
MDM-2/p53
|
Cancer
|
|
p53-HDM2-IN-1 is a potent inhibitor of p53-HDM2 protein-protein interaction, with an IC50 of 0.103 μM. p53-HDM2-IN-1 can be used for the research of cancer.
|
-
- HY-P99270
-
|
CS-1008; Anti-Human TRAIL-R2 Recombinant Antibody
|
Apoptosis
|
Cancer
|
|
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer.
|
-
- HY-142929
-
|
|
Somatostatin Receptor
|
Cancer
|
|
MAT2A-IN-2 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2020243376A1, compound 172).
|
-
- HY-142928
-
|
|
Somatostatin Receptor
|
Cancer
|
|
MAT2A-IN-1 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-1 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021139775A1, compound 64).
|
-
- HY-142930
-
|
|
Somatostatin Receptor
|
Cancer
|
|
MAT2A-IN-3 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-3 has the potential for the research of cancer diseases (extracted from patent WO2019191470A1, compound 265).
|
-
- HY-147595
-
|
|
Ras
|
Cancer
|
|
KRAS G12D inhibitor 15 is a potent inhibitor of KRAS G12D. KRAS G12D inhibitor 15 has the potential for the research of various diseases or disorders, such as cancer or cancer metastasis (extracted from patent WO2022042630A1, compound 243). KRAS G12D inhibitor 15 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-118091A
-
|
LY300502
|
Others
|
Cancer
|
|
Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer.
|
-
- HY-115915
-
|
|
Glyoxalase (GLO)
|
Cancer
|
|
TS010 is a potent inhibitor of GLO-I with IC50 of 0.57 μM. TS010 has the potential for the research of cancer disease.
|
-
- HY-128617
-
|
|
Legumain
|
Cancer
|
|
Legumain inhibitor 1 is a potent and selective Legumain inhibitor with an IC50 of 3.6 nM. Legumain inhibitor 1 can be used for cancer research.
|
-
- HY-129909
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 173 (compound 19) is a potent thioxodihydroquinazolinone analogs when combined with platinum drugs in inducing apoptotic cancer cells death.
|
-
- HY-149266
-
|
|
ROCK
|
Cancer
|
|
THK01 is a potent ROCK2 inhibitor with IC50 values of 5.7 and 923 nM for ROCK2 and ROCK1, respectively. THK01 inhibits breast cancer metastasis through the ROCK2-STAT3 signaling pathway. THK01 can be used in research of breast cancer.
|
-
- HY-151519
-
|
|
Sirtuin
|
Cancer
|
|
SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC50 value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer.
|
-
- HY-P99592
-
|
AMG 110; MT110
|
CD3
|
Cancer
|
|
Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer.
|
-
- HY-P99269
-
|
BIBH 1; Anti-Human FAP Recombinant Antibody
|
FAP
|
Cancer
|
|
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC).
|
-
- HY-P99517
-
|
JNJ-63898081
|
CD3
|
Cancer
|
|
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research.
|
-
- HY-D1673
-
|
|
Fluorescent Dye
|
Cancer
|
|
Tetrabromorhodamine 123 (TBR) bromide is a photosensitizer. Tetrabromorhodamine 123 bromide can be used for the research of photo dynamic therapy (PDT) and cancer.
|
-
- HY-144745
-
|
|
NF-κB
|
Cancer
|
|
HSR1304 (Compound 5d) is a potent inhibitor of NFκB. The multifunctional transcription factor, nuclear factor-κB (NF-κB), is broadly involved in multiple human diseases, such as cancer and chronic inflammation. HSR1304 has the potential for the research of cancer diseases.
|
-
- HY-P99577
-
|
|
CD19
|
Cancer
|
|
Taplitumomab paptox is an anti-CD19 monoclonal antibody. Taplitumomab paptox can be used in cancer research.
|
-
- HY-153863
-
|
|
MEK
|
Cancer
|
MS934 is a novel improved VHL-recruiting MEK 1/2 degrader. MS934 has anti-proliferation potency at inhibiting the growth of HT-29 cells with a GI50 value of 0.023 μM. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma.
|
-
- HY-153607
-
|
|
Others
|
Cancer
|
|
HDAC-IN-55(8j) is a small molecular compound that can increase the expression of E-cadherin and inhibit the proliferation of cancer cells.
|
-
- HY-B0008
-
|
MK-231
|
NF-κB
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer.
|
-
- HY-112162
-
|
|
Mps1
|
Cancer
|
|
BOS-172722 is an inhibitor of monopolar spindle 1 (MPS1) checkpoint with an IC50 of 11 nM and 63 nM for MPS1 (1 mM ATP) and P-MPS1, respectively. BOS-172722 also has potential for the study of various forms of breast cancer.
|
-
- HY-148669B
-
|
(S)-Menin-MLL inhibitor 24 oxalate
|
Epigenetic Reader Domain
|
Cancer
|
|
(S)-Bleximenib ((S)-Menin-MLL inhibitor 24) oxalate is a S-Enantiomer of (S)-Menin-MLL inhibitor 24 oxalate (HY-148669A). (S)-Bleximenib oxalate is a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor, and can be used for the research of cancer.
|
-
- HY-149375
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 37 (Compound 12) is a Tubulin inhibitor that can effectively inhibit Tubulin aggregation (IC50=1.3 µM). Tubulin inhibitor 37 exhibits antiproliferative activity against human tumor cell lines and has potential for studying cancer.
|
-
- HY-148053
-
|
|
Drug Metabolite
|
Cancer
|
|
Rezivertinib analogue 1 is a process impurity of osimertinib mesylate. Rezivertinib analogue 1 can be used in the study of non-small cell lung cancer.
|
-
- HY-153604
-
|
|
Histone Acetyltransferase
|
Cancer
|
|
MC4171 (compound 34) is a selective KAT8 inhibitor (IC50=8.1 µM). MC4171 has been shown to exhibit moderate micromolar antiproliferative activity in different cancer cell lines, including NSCLC and AML, with potential for studying cancer.
|
-
- HY-19330
-
-
- HY-W017186
-
|
|
Aldehyde Dehydrogenase (ALDH)
|
Cancer
|
|
ALDH1A3-IN-3 (compound 16) is a potent inhibitor of ALDH1A3, with an IC50 of 0.26 μM. ALDH1A3-IN-3 is also a good ALDH3A1 substrate. ALDH1A3-IN-3 can be used for the research of prostate cancer.
|
-
- HY-145111
-
|
|
Tyrosinase
|
Cancer
|
|
TNK2-IN-1 is a TNK2 inhibitor. TNK2-IN-1 has an IC50 of 224 nM for TNK2. TNK2-IN-1 can be used for the research of cancer.
|
-
- HY-110182
-
SP-141
1 Publications Verification
|
MDM-2/p53
|
Cancer
|
|
SP-141 is a specific inhibitor of MDM2. SP-141 promotes MDM2 auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells.
|
-
- HY-128224
-
|
|
Others
|
Cancer
|
|
Antiproliferative agent-13 (compound 16c) shows an antiproliferative activity against human A375 cells with an IC50 value of 32.7 nM. Antiproliferative agent-13 can be used for the research of cancer.
|
-
- HY-B2099
-
|
1-Butylbiguanide
|
AMPK
|
Cancer
Metabolic Disease
|
|
Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al).
|
-
- HY-P99183
-
|
EMD 525797; DI17E6
|
Integrin
|
Cancer
|
|
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer.
|
-
- HY-W276106
-
|
|
Others
|
Cancer
|
|
KM02894 is an inhibitor of glutamate release. Cancer cells release high levels of glutamate, which disrupts normal bone turnover and may lead to cancer-induced bone pain. KM02894 can be used for cancer related research.
|
-
- HY-152248
-
|
|
Ras
|
Cancer
|
|
ARS-2102 is a potent covalent KRAS G12C inhibitor for use in cancer research.
|
-
- HY-124643
-
|
|
RIP kinase
|
Cancer
|
|
RIPK2-IN-3 (FCG806791773) is a RIPK2 inhibitor. RIPK2-IN-3 inhibits recombinant truncated RIPK2 with an IC50 of 6.39 μM. RIPK2-IN-3 can be used for research of inflammation and cancer.
|
-
- HY-149348
-
|
|
Topoisomerase
PARP
Apoptosis
|
Cancer
|
|
DiPT-4 is a dual TOP1/PARP1 inhibitor that induces massive DNA double-strand breaks (DSBs), cell cycle arrest, and apoptosis in cancer cells. DiPT-4 has the potential to overcome cancer drug resistance.
|
-
- HY-139301
-
|
|
HSP
|
Cancer
|
|
DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer.
|
-
- HY-128207
-
|
|
Others
|
Cancer
|
|
SID7970631, as an isoquinolinone analog, is a potent and selective submicromolar SF-1 inhibitor (IC50=255 nM). SID7970631 can be used for the research of cancer.
|
-
- HY-137432A
-
|
BEY1107 trihydrochloride
|
CDK
|
Cancer
|
|
Avotaciclib (BEY1107) trihydrochloride is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib trihydrochloride can be used for the research of locally advanced or metastatic pancreatic cancer.
|
-
- HY-137432
-
|
BEY1107
|
CDK
|
Cancer
|
|
Avotaciclib (BEY1107) is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib can be used for the research of locally advanced or metastatic pancreatic cancer.
|
-
- HY-B1000A
-
|
|
Endogenous Metabolite
Apoptosis
|
Cancer
|
|
L-SelenoMethionine, an L-isomer of Selenomethionine, is a major natural food-form of selenium. L-SelenoMethionin is a cancer chemopreventive agent that can reduce cancer incidence by dietary supplementation and induce apoptosis of cancer cells. L-SelenoMethionine also can increase expression of glutathione peroxidase.
|
-
- HY-50895B
-
|
ZD 1839 dihydrochloride
|
EGFR
Autophagy
Apoptosis
|
Cancer
|
|
Gefitinib (ZD 1839) dihydrochloride is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib dihydrochloride selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib dihydrochloride also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
|
-
- HY-50895
-
|
ZD1839
|
EGFR
Autophagy
Apoptosis
|
Cancer
|
|
Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
|
-
- HY-132294
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
GNE-502 is an orally active and potent degrader for estrogen receptor (ER). GNE-502 can be used for the research of breast cancer.
|
-
- HY-N3996
-
|
|
Apoptosis
Microtubule/Tubulin
|
Cancer
|
|
Moroidin is a tubulin polymerization inhibitor and has a potent inhibitory effect on purified tubulin polymerization. Moroidin is a bicyclic octapeptide belonging to the Urticaceae-type cyclopeptide family. Moroidin has cytotoxic effects for several cancer cells and can induce apoptosis in A549 human lung cancer cells.
|
-
- HY-149607
-
|
|
SHP2
|
Cancer
|
|
SHP2-IN-22 is SHP2 allosteric inhibitor with an IC50 value of 17.7 nM. SHP2-IN-22 inhibits the proliferation, migration, and invasion of MIA PaCa-2 pancreatic cancer cells. SHP2-IN-22 can be used for Kirsten rat sarcoma viral oncogene (KRAS) mutant cancer research.
|
-
- HY-P99788
-
|
|
ADC Antibody
ALCAM/CD166
|
Cancer
|
|
Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers.
|
-
- HY-118590A
-
|
|
Topoisomerase
|
Cancer
|
|
ICRF-196 is an racemic mixture of the (S,S)- and (R,R)-isomers of ICRF-193 (HY-118590). ICRF-193 is an TopoII inhibitor. ICRF-196 can be used for the research of cancer.
|
-
- HY-148953
-
|
|
G-quadruplex
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
MTR-106 is a potent and orally active G-quadruplex stabilizer and RNA polymerase I inhibitor. MTR-106 induces apoptosis and inhibits cell growth. MTR-106 can be used in research of cancer.
|
-
- HY-153221
-
|
|
CDK
|
Cancer
|
|
QR-6401 is an orally active and selective macrocyclic CDK2 inhibitor with IC50 values of 0.37, 10, 22, 34 and 45 nM for CDK2/E1, CDK9/T1, CDK1/A2, CDK6/D3 and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer.
|
-
- HY-P0058B
-
-
- HY-P0058
-
-
- HY-139319
-
|
|
Lactate Dehydrogenase
|
Cancer
|
|
LDHA-IN-3, as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC50=145.2 nM). LDHA-IN-3 can be used for the research of cancer.
|
-
- HY-148150
-
|
|
Others
|
Cancer
|
|
Cyclocreatine phosphate is an anti-tumor agent. Cyclocreatine phosphate is the proposed active form of cyclocreatine (CCr), a substrate analogue of creatine kinase. Cyclocreatine phosphate has anti-tumour activity and can be used for the research of cancer.
|
-
- HY-136447
-
ASP4132
1 Publications Verification
|
AMPK
|
Cancer
|
|
ASP4132 is an orally active, potent AMPK activator with an EC50 of 18 nM. ASP4132 has anti-cancer activity and makes tumor regression in breast cancer xenograft mouse models.
|
-
- HY-150757
-
|
|
Autophagy
Apoptosis
|
Cancer
|
|
Autophagy-IN-2 (Compound 7h) is an autophagic flux inhibitor. Autophagy-IN-2 induces cancer cell apoptosis and can be used for triple-negative breast cancer research.
|
-
- HY-N9983
-
|
|
Others
|
Cancer
|
|
Effusanin E is a diterpenoid. Effusanin E, a 7α, 20-Epoxy-ent-kauranoid, can be obtained from Isodon parvifolius. Effusanin E can be used for the research of cancer.
|
-
- HY-143592
-
|
|
Ras
|
Cancer
|
|
KRAS G12C inhibitor 39 is a potent inhibitor of KRAS G12C. KRas is a highly attractable target of the pharmaceutical industry for cancer research. KRAS G12C inhibitor 39 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2019099524A1, compound 494).
|
-
- HY-N10588
-
|
10-epi-Nardoguaianone J
|
Others
|
Cancer
|
|
Nardoguaianone K, a guaiane-type compound, can be isolated from Nardostachys chinensis roots. Nardoguaianone K cam be used in the research of pancreatic cancer.
|
-
- HY-125067
-
|
|
Others
|
Cancer
|
Yadanzioside P is an antileukemic quassinoid glycoside. Yadanzioside P can be isolated from the seeds of Brucea javanica (L.). Yadanzioside P can be used for the research of cancer.
|
-
- HY-N12415
-
|
|
Apoptosis
|
Cancer
|
|
Amoxetamide A is an anoikis inducer that exhibits anoikis-inducing activity in human colorectal cancer HT-29 cells. Amoxetamide A may be used in cancer research.
|
-
- HY-N8293
-
|
|
Others
|
Cancer
|
|
Eupalinolide I inhibits the viability of breast cancer cells. Eupalinolide I can be isolated from Eupatorium lindleyanum.
|
-
- HY-150412
-
|
|
Phospholipase
|
Cancer
|
|
VU0364739 is a selective PLD2 inhibitor (IC50: 22 nM). VU0364739 decreases cancer cell proliferation.
|
-
- HY-144283
-
|
|
Btk
|
Cancer
|
|
BLK-IN-1 (compound 1) is a selective and covalent inhibitor of B-Lymphoid tyrosine kinase (BLK) and BTK, with IC50s of 18.8 nM and 20.5 nM, respectively. BLK-IN-1 can be used for the research of cancer.
|
-
- HY-49597
-
|
|
Wnt
β-catenin
|
Cancer
|
|
Pin1 modulator 1 (compound IIb-219) is a modulator that specifically targets β-Catenin and inhibits the Wnt pathway. Pin1 modulator 1 can be used in the study of Wnt-mediated related diseases, such as cancer.
|
-
- HY-153400
-
|
|
ATM/ATR
|
Cancer
|
|
ATR-IN-22 (Compound 34) is an orally active ATR inhibitor. ATR-IN-22 inhibits MIAPaCa-2 proliferation (IC50 <1 μM). ATR-IN-22 shows anti-tumor activity in colon cancer.
|
-
- HY-147779
-
|
|
VEGFR
|
Cancer
|
|
VEGFR-2-IN-20 (Compound 7) is a potent inhibitor of VEGFR. VEGFR-2-IN-20 has the potential for the research of cancer diseases.
|
-
- HY-141890
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BAZ1A-IN-1 is a potent inhibitor of BAZ1A (bromodomain-containing protein). BAZ1A-IN-1 shows a KD value of 0.52 μM against BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-viability activity against cancer cell lines expressing a high level of BAZ1A, but weak or no activity against cancer cells with a low expression level of BAZ1A.
|
-
- HY-160064
-
|
|
Others
|
Cancer
|
|
SW1-A aptamer sodium is an optimized aptamer based on SW1 aptamer (HY-160063) that specifically targets liver cancer SMMC-7721 cells (Kd: 133.73 nM). SW1-A aptamer maintains strong affinity to liver cancer tissues and cells.
|
-
- HY-139204
-
-
- HY-109574
-
|
|
Raf
|
Cancer
|
|
Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research.
|
-
- HY-136506
-
|
|
Others
|
Cancer
|
|
NUC-7738, an aryloxy phosphoramidate of 3′-Deoxyadenosine, is a 5′-aryloxy phosphoramidate prodrug of 3′-Deoxyadenosine (3′-dA). NUC-7738 has potent cytotoxic activity against a panel of hematological cancer cell lines. NUC-7738 can be used in research of cancer.
|
-
- HY-B0008A
-
|
MK-231 sodium
|
NF-κB
PD-1/PD-L1
|
Cancer
Infection
Inflammation/Immunology
|
|
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer.
|
-
- HY-139376
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor-2 is a FGFR1 inhibitor (IC50 is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer.
|
-
- HY-118590
-
|
|
Topoisomerase
|
Cancer
|
|
ICRF-193 is an TopoII inhibitor. (S,S)- and (R,R)-isomers ICRF-193 make up an racemic mixture, ICRF-196 (HY-118590A). ICRF-196 can be used for the research of cancer.
|
-
- HY-149402
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCA XII-IN-6 (compound 4d) is a potent hCA XII inhibitor with a Ki value of 84.2 nM. hCA XII-IN-6 has anti-proliferative activity. hCA XII-IN-6 can be used in research of cancer.
|
-
- HY-144179
-
|
|
Others
|
Cancer
|
|
MAT2A-IN-4 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1 compound 426 . MAT2A-IN-4 can be used for the research of cancer.
|
-
- HY-146179
-
|
|
Others
|
Cancer
|
|
IMP2-IN-2 (compound 6) is a potent and selective IMP2 inhibitor, with IC50s of 120.9 μM and 236.7 μM for IMP2 interaction with RNA_A and RNA_B, respectively. IMP2-IN-2 can be used for the research of cancer.
|
-
- HY-147214
-
|
|
YAP
|
Cancer
|
|
GNE-7883 is a pan-TEAD inhibitor with anti-cell proliferation activity. GNE-7883 overcomes resistance to KRAS G12C inhibitors in multiple preclinical models by inhibiting YAP/TAZ activation. GNE-7883 may be used in the study of YAP/TAZ-dependent cancers.
|
-
- HY-149878
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BD-9136 is a highly selective BRD4 degrader. BD-9136 can inhibit tumor growth without adverse effects on mice. BD-9136 can be used for the research of cancer. BD-9136 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-148699
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Werner syndrome RecQ helicase-IN-1 (example 42) is a potent Werner syndrome RecQ DNA helicase enzyme (WRN) inhibitor and can be used in cancer research.
|
-
- HY-148700
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Werner syndrome RecQ helicase-IN-2 (example 57) is a potent Werner syndrome RecQ DNA helicase enzyme (WRN) inhibitor and can be used in cancer research.
|
-
- HY-156705
-
|
|
CDK
|
Cancer
|
|
CDK7-IN-25 (CY-16-1) is a CDK-7 inhibitor (IC50<1nM) that can be used in cancer research.
|
-
- HY-144652
-
-
- HY-156603
-
|
|
c-Met/HGFR
|
Cancer
|
|
Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib has the potential for cancer study.
|
-
- HY-149911
-
|
|
MDM-2/p53
|
Cancer
|
|
GY1-22 is an inhibitor of DNAJA1-mutP53 R175H interacting pocket. GY1-22 can be used for the research of cancer.
|
-
- HY-151393
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin polymerization-IN-32 is a tubulin polymerization inhibitor. Tubulin polymerization-IN-32 inhibits cancer cell proliferation. Tubulin polymerization-IN-32 can be used in the research of cancers like lymphomas.
|
-
- HY-W354498
-
|
|
Endogenous Metabolite
|
Cancer
|
|
L-Octanoylcarnitine hydrochloride is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine hydrochloride can be used for the research of breast cancer.
|
-
- HY-113161
-
|
|
Endogenous Metabolite
|
Cancer
|
|
L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer.
|
-
- HY-115994
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 10 is a potent hCA IX inhibitor with a Ki value of 6.2 nM. Carbonic anhydrase inhibitor 10 exhibits anti-proliferative activity against MCF-7 cancer cell line with an IC50 of 11.9 μM. Carbonic anhydrase inhibitor 10 can be used for cancer research.
|
-
- HY-156555
-
|
|
Ras
|
Cancer
|
|
pan-KRAS-IN-3 (Example 84) is a pan-KRAS inhibitor. pan-KRAS-IN-3 can be used for research of cancers. pan-KRAS-IN-3 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-16229
-
|
|
ROS Kinase
Apoptosis
|
Cancer
|
|
GGTI-2154 is a potent and selective inhibitor of geranylgeranyltransferase I (GGTase I), with an IC50 of 21 nM. GGTI-2154 shows more than 200-fold selectivity for GGTase I over FTase (IC50=5600 nM). GGTI-2154 can be used for the research of cancer.
|
-
- HY-16229A
-
|
|
ROS Kinase
Apoptosis
|
Cancer
|
|
GGTI-2154 hydrochloride is a potent and selective inhibitor geranylgeranyltransferase I (GGTase I), with an IC50 of 21 nM. GGTI-2154 hydrochloride shows more than 200-fold selectivity for GGTase I over FTase (IC50=5600 nM). GGTI-2154 hydrochloride can be used for the research of cancer.
|
-
- HY-P99241
-
|
PF 06946860
|
TGF-beta/Smad
|
Cancer
|
|
Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers.
|
-
- HY-P0058A
-
-
- HY-118134
-
|
|
Others
|
Cancer
|
|
Hepln-13 is a potent and orally active Hepsin inhibitor with an IC50 of 0.33 µM. Hepln-13 can be used for the research of metastatic prostate cancer.
|
-
- HY-110286
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
6-Hydroxy-DOPA is a selective and effective allosteric inhibitor of the RAD52 ssDNA binding domain. 6-Hydroxy-DOPA can be used for the research of cancer.
|
-
- HY-139813
-
-
- HY-101996
-
|
|
Bcl-2 Family
|
Cancer
|
|
SMBA1 is a potent Bax agonist with a Ki value of 43.3 nM. SMBA1 enhances the Bax expression. SMBA1 shows anti-tumor activity. SMBA1 has the potential for the research of lung cancer.
|
-
- HY-148151
-
|
|
HBV
|
Cancer
|
|
(-)-5′-Noraristeromycin is an antiviral agent. (-)-5′-Noraristeromycin also is an enantiomer of 5'-noraristeromycin and can inhibit intracellular HBV replication and virion production. (-)-5′-Noraristeromycin can be used for the research of cancer.
|
-
- HY-148570
-
|
|
Phosphoglycerate Dehydrogenase (PHGDH)
|
Cancer
|
|
PHGDH-IN-3 is an orally active phosphoglycerate dehydrogenase (PHGDH) inhibitor. PHGDH-IN-3 inhibits PHGDH with an IC50 value of 2.8 μM. PHGDH-IN-3 can be used for the research of cancer.
|
-
- HY-151890
-
|
|
Fluorescent Dye
|
Cancer
|
|
NIR-βgal-2 is a β-galactosidase-activated near-infrared fluorescent probe with superior sensitivity. NIR-βgal-2 can be used for visualizing β-galactosidase in breast cancer.
|
-
- HY-132247
-
|
|
Others
|
Cancer
|
|
ErSO is a selective anticipatory unfolded protein response (a-UPR) activator. ErSO acts through ERα to elicit strong and sustained cytotoxic activation of the a-UPR. ErSO can be used for the research of cancer.
|
-
- HY-155675
-
|
|
Others
|
Cancer
|
|
TPPC, a porphyrin cholesterol conjugate, can render cancer cells more sensitive to ICIs. TPPC can enhance photodynamic immunotherapy toward lung cancer.
|
-
- HY-N3446
-
|
|
Apoptosis
|
Cancer
|
|
IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research.
|
-
- HY-133034
-
|
|
Complement System
|
Cancer
|
|
NRP1 antagonist 1 (compound 12a) is a potent NRP1 antagonist with an IC50 of 19.1 μM. NRP1 antagonist 1 has the potential for cancer research.
|
-
- HY-123607
-
|
|
Ephrin Receptor
|
Cancer
|
|
UniPR129 is a potent Eph/ephrin antagonist with IC50s of 0.84-3.01 μM. UniPR129 has the potential for the research of cancer disease.
|
-
- HY-118672
-
|
|
HDAC
MMP
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
HNHA is a potent histone deacetylase (HDAC) inhibitor. HNHA arrests the cell cycle at the G1/S phase via p21 induction. HNHA inhibits tumor growth and tumor neovascularization. HNHA may be a potent anti-cancer agent against breast cancer.
|
-
- HY-136530
-
|
|
KLF
|
Cancer
|
|
SR18662 is a potent inhibitor of Krüppel-like factor five (KLF5) with an IC50 of 4.4 nM and an analogue of ML264 (HY-19994) with improved inhibitory potency against colorectal cancer cells. SR18662 can be used for the study of colorectal cancer.
|
-
- HY-108638
-
|
|
MDM-2/p53
Apoptosis
|
Cancer
|
|
NSC 146109 hydrochloride is a small-molecule p53 activator that target MDMX and can be used for breast cancer research. NSC 146109 hydrochloride is a pseudourea derivative, promotes breast cancer cells to undergo apoptosis through activating p53 and inducing expression of proapoptotic genes.
|
-
- HY-15185
-
|
PF-3084014; PF-03084014
|
γ-secretase
Apoptosis
|
Cancer
|
|
Nirogacestat (PF-3084014) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers.
|
-
- HY-15134
-
|
OC 144-093; OC 144093
|
P-glycoprotein
|
Cancer
|
|
ONT-093 is a potent inhibitor of P-glycoprotein pump. ONT-093 has the potential for the research cancer diseases.
|
-
- HY-156604
-
|
|
Btk
|
Cancer
|
|
Cinsebrutinib is a Bruton's tyrosine kinase inhibitor, extracted from patent WO2021207549 (compound 5-6). Cinsebrutinib has the potential for cancer study.
|
-
- HY-107665
-
|
|
NF-κB
|
Cancer
|
|
Ro 106-9920 is a potent inhibitor of NF-kappaB. Ro 106-9920 has the potential for the research of tumor and cancer diseases.
|
-
- HY-136582
-
|
Androgen receptor-IN-2
|
Androgen Receptor
|
Cancer
|
|
Masofaniten (Androgen receptor-IN-2) is a potent and orally active androgen receptor inhibitor. Masofaniten has antitumor activity against prostate cancer.
|
-
- HY-132829
-
|
GC4711
|
Reactive Oxygen Species
|
Cancer
|
|
Rucosopasem manganese (GC4711) is a selective superoxide dismutase mimetic that converts superoxide to hydrogen peroxide. Rucosopasem manganese can be used for the research of cancer.
|
-
- HY-155502
-
|
|
Aldose Reductase
|
Cancer
|
|
AKR1C3-IN-10 (compound 5r) is a selective AKR1C3 inhibitor (IC50=51 nM). AKR1C3-IN-10 shows good activity in a prostate cancer xenograft model.
|
-
- HY-16187
-
|
|
HIF/HIF Prolyl-Hydroxylase
Apoptosis
|
Cancer
|
|
EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis, inhibits tubulin polymerisation and shows activities against prostate cancer. EL-102 can be used for the research of cancer.
|
-
- HY-125486
-
|
|
P-glycoprotein
|
Cancer
|
|
Reversin 121 is a P-glycoprotein inhibitor. Reversin 121 increases the ATPase activity of MDR1. Reversin 121 reverses P-glycoprotein-mediated multidrug resistance. Reversin 121 can be used in the research of cancers.
|
-
- HY-119734
-
|
|
Others
|
Cancer
|
|
Gossypolone is an RNA-binding protein Musashi-1 inhibitor with a Ki of 12 nM. Gossypolone disrupts the Musashi-numb RNA interaction and directly binds to the RBD1 of MSI1 protein. Gossypolone can be used for the research of cancer.
|
-
- HY-13545B
-
|
|
Apoptosis
|
Cancer
Inflammation/Immunology
|
|
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD).
|
-
- HY-P4858
-
|
|
GSK-3
|
Cancer
|
|
C-Peptide 1 (rat), a peptide, is aβ-catenin/GSK-3β activator. C-Peptide 1 (rat) can regulate the Wnt/β-catenin signaling pathway. C-Peptide 1 (rat) can be used for the research of cancer.
|
-
- HY-12182
-
|
|
Prostaglandin Receptor
|
Cancer
|
|
ONO-8711 is a potent and selective competitive antagonist of EP1 receptor (Ki = 0.6 and 1.7 nM for human and mouse EP1 respectively). ONO-8711 effectively reduces tumor incidence and multiplicity in mouse models of colon, breast, and oral cancer.
|
-
- HY-156512
-
|
|
TGF-beta/Smad
|
Cancer
|
|
DT-6 is an effective TGF-β1 inhibitor. DT-6 inhibits M2 macrophage induced epithelial to mesenchymal transition and invasive migration of cancer cells. DT-6 can be used for cancer diseases research.
|
-
- HY-151295
-
|
|
Others
|
Cancer
|
|
Antitumor agent-75 is a novel potent antitumor agent. Antitumor agent-75 has cytotoxic effects on cancer and normal human cell lines. Antitumor agent-75 shows a highly selective cytotoxic effect against human lung adenocarcinoma (cell line A549) when combined with Antitumor agent-74 (HY-151292), the IC50 value of 2.8 μM. Antitumor agent-75 can be used for the research of cancer.
|
-
- HY-115887
-
-
- HY-103009
-
MSX-127
1 Publications Verification
|
CXCR
|
Cancer
|
|
MSX-127 is a CXCR4 antagonist. MSX-127 inhibits cancer metastasis.
|
-
- HY-103010
-
|
|
CXCR
|
Cancer
|
|
MSX-130 is a CXCR4 antagonist. MSX-130 inhibits cancer metastasis.
|
-
- HY-N3415
-
|
|
Apoptosis
|
Cancer
|
|
Kumatakenin, a flavonoid that is isolated from cloves shows the effect of inducing apoptosis in ovarian cancer cells.
|
-
- HY-N8743
-
|
A 65190; Cyclo-(leucyl-prolyl)
|
Endogenous Metabolite
|
Cancer
|
|
Cyclo(Pro-Leu) (A 65190) is an active metabolite. Cyclo(Pro-Leu) can be isolated from Streptomyces sp. BM8. Cyclo(Pro-Leu) can be used for the research of cancer.
|
-
- HY-131724
-
|
p-DDAP; p-Dodecylaminophenol
|
Apoptosis
|
Cancer
|
|
4-(Dodecylamino)phenol (p-DDAP) is an anticancer agent. 4-(Dodecylamino)phenol has anti-tumor activity and can suppress proliferation, arrest the cell cycle and induce apoptotic cell death. 4-(Dodecylamino)phenol can be used for the research of cancer, such as prostate cancer.
|
-
- HY-N6255
-
|
|
Others
|
Cancer
Inflammation/Immunology
|
|
Ilexgenin A is a pentacyclic triterpenoid, which extracted from Ilex hainanensis Merr. Ilexgenin A can be used for the research of inflammation and cancer.
|
-
- HY-100538
-
DTP3
1 Publications Verification
|
DNA/RNA Synthesis
JAK
|
Cancer
|
|
DTP3 TFA is a potent and selective GADD45β/MKK7 inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway.
|
-
- HY-19324
-
|
|
Histone Methyltransferase
|
Cancer
|
|
EPZ031686 is an potent and orally active SMYD3 inhibitor and with an IC50 value of 3 nM. EPZ031686 can be used for cancer research.
|
-
- HY-N9500
-
|
|
Apoptosis
Topoisomerase
|
Cancer
|
|
Ganoderic acid X is a lanostanoid triterpene that can be extracted from Ganoderma amboinense. Ganoderic acid X inhibits topoisomerases and induces apoptosis of cancer cells.
|
-
- HY-118328
-
|
|
5-HT Receptor
Potassium Channel
|
Cancer
|
|
Hymenidin is a natural antagonist of serotonergic receptor and inhibitor of voltage-gated potassium channels. Hymenidin also induces cancer cell apoptosis.
|
-
- HY-156677
-
|
|
METTL3
|
Cancer
|
|
STC-15 (example 70) is an orally active METTL3 inhibitor used in the study of proliferative diseases such as cancer and autoimmune diseases.
|
-
- HY-P99944
-
|
Retlirafusp alfa
|
PD-1/PD-L1
TGF-β Receptor
|
Cancer
|
|
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research.
|
-
- HY-146183
-
|
|
Bcl-2 Family
|
Cancer
|
|
BCL6-IN-9 (compound 1) is a potent B-cell lymphoma 6 protein (BCL6) inhibitor, with an IC50 of 3.9 nM. BCL6-IN-9 can be used for the research of cancer.
|
-
- HY-N11912
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Soladulcoside A is a steroidal glycoside and antineoplastic agent that can be obtained from the whole plant of Solanum nigrum. Soladulcoside A can inhibit A549 cells and has the potential to study cancers such as non-small cell lung cancer (NSCLC).
|
-
- HY-N5014
-
|
|
Apoptosis
|
Cancer
Inflammation/Immunology
|
|
Liensinine Perchlorate is a constituent of Nelumbo nucifera Gaertn, with ani-hypertension and anti-cancer activities. Liensinine Perchlorate induces colorectal cancer (CRC) cell apoptosis.
|
-
- HY-148518
-
|
|
SRPK
|
Cancer
|
|
MSC-1186 is a highly selective pan-SRPK inhibitor. MSC-1186 has activity for SRPK1, SRPK2 and SRPK3 with IC50 values of 2.7 nM, 81 nM and 0.6 nM, respectively. MSC-1186 can be used for the research of cancer.
|
-
- HY-149372
-
|
|
HDAC
|
Cancer
|
|
HDAC6-IN-17 (compound 5b) is a potent HDAC6 inhibitor with IC50 values of 150 nM, 1400 nM, and 2300 nM for HDAC6, HDAC8, and HDAC4, respectively. HDAC6-IN-17 has cytotoxic activity on human cancer cell lines. HDAC6-IN-17 can be used in research of cancer.
|
-
- HY-14653
-
|
TAC-101; Am 555S
|
RAR/RXR
Apoptosis
|
Cancer
|
|
Amsilarotene (TAC-101; Am 555S), an orally active synthetic retinoid, has selective affinity for retinoic acid receptor α (RAR-α) binding with Ki of 2.4, 400 nM for RAR-α and RAR-β. Amsilarotene induces the apoptotic of human gastric cancer, hepatocellular carcinoma and ovarian carcinoma cells. Amsilarotene can be used for the research of cancer.
|
-
- HY-160030
-
|
|
IAP
|
Cancer
|
|
XIAP BIR2/BIR2-3 inhibitor-3 is a dual inhibitor of BIR2 and BIR2-3 with IC50s less than 1 nM. XIAP BIR2/BIR2-3 inhibitor-3 can used in study cancers.
|
-
- HY-103665
-
|
|
STING
|
Cancer
|
|
STING agonist-3, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pIC50 of 7.5 and 9.5, respectively. STING agonist-3 has durable anti-tumor effect and tremendous potential to improve treatment of cancer.
|
-
- HY-153459
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
PROTAC BRD4 Degrader-19 (compound 176) is a PROTAC that targets BRD4 protein for degradation. PROTAC BRD4 Degrader-19 can be used in cancer research.
|
-
- HY-156715
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
MASTL-IN-1 is a MASTL (microtubule-associated serine/threonine kinase-like) inhibitor, which is involved in cell proliferation, migration, and invasion. MASTL-IN-1 has potential in cancer research.
|
-
- HY-P5840
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Cyclo(RGDyC) is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo(RGDyC) can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer.
|
-
- HY-P99262
-
|
BAX69; Anti-Human MIF Recombinant Antibody
|
Macrophage migration inhibitory factor (MIF)
|
Cancer
|
|
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer.
|
-
- HY-136383
-
|
Rac1/Cdc42-IN-1
|
Ras
Apoptosis
|
Cancer
|
|
AZA1 is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induces prostate cancer cells apoptosis and inhibits prostate cancer cells proliferation, migration and invasion.
|
-
- HY-154970
-
|
|
TGF-β Receptor
|
Cancer
|
|
BMPR2-IN-1 (Compound 8a) is a BMPR2 inhibitor with an IC50 of 506 nM and a KD of 83.5 nM. BMPR2-IN-1 can be used for research of pulmonary arterial hypertension, Alzheimer’s disease and cancer.
|
-
- HY-W016889
-
|
|
Ras
|
Cancer
|
|
CFL-137 is a potent KRas G12C inhibitor. CFL-137 shows an antiproliferative effect. CFL-137 shows anticancer activity. CFL-137 has the potential for the research of lung cancer.
|
-
- HY-157047
-
|
|
Others
|
Cancer
|
|
Anticancer agent 171 (Compound 6a) is an oxime analogue. Anticancer agent 171 has anticancer activity against HCT116 cells with an IC50 value of 3.43 μM. Anticancer agent 171 can be used for the research of cancer.
|
-
- HY-W041315
-
|
|
Ras
|
Cancer
|
|
CFL-120 is a potent KRas G12C inhibitor. CFL-120 shows an antiproliferative effect. CFL-120 shows anticancer activity. CFL-120 has the potential for the research of lung cancer.
|
-
- HY-146030
-
|
|
Others
|
Cancer
|
|
Anticancer agent 46 (compound 2) is a potent anticancer agent. Anticancer agent 46 shows antiproliferative activity with an IC50 of 0.986 µM for MGC803 cells. Anticancer agent 46 has the potential for the research of gastric cancer.
|
-
- HY-136541
-
YB-0158
2 Publications Verification
Wnt pathway inhibitor 2
|
Wnt
Apoptosis
|
Cancer
|
|
YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities.
|
-
- HY-15185B
-
|
PF-3084014 dihydrobromide; PF-03084014 dihydrobromide
|
γ-secretase
Apoptosis
|
Cancer
|
|
Nirogacestat dihydrobromide (PF-3084014 dihydrobromide) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat dihydrobromide while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers.
|
-
- HY-19985
-
|
|
EGFR
|
Cancer
|
|
PF-06459988 is an orally activity, irreversible and mutant-selective inhibitor of EGFR mutant forms. PF-06459988 demonstrates high potency and specificity to the T790M-containing double mutant EGFRs. PF-06459988 can be used for the research of cancer.
|
-
- HY-N3800
-
|
|
Others
|
Cancer
|
|
Eichlerialactone is a sesquiterpene compound isolated from Chisocheton penduliflorus. Eichlerialactone is weakly cytotoxic to breast cancer cells.
|
-
- HY-143380
-
|
|
CDK
|
Cancer
|
|
Cdc7-IN-9 is a potent Cdc7 inhibitor and can be used for cancer research.
|
-
- HY-14281
-
|
Win 24540
|
Others
|
Endocrinology
Cancer
|
|
Trilostane (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane is a synthetic nonhormonal steroid. Trilostane can be used for the research of breast cancer and prostate cancer.
|
-
- HY-101120
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
666-15 is a potent and selective CREB inhibitor with an IC50 of 81 nM. 666-15 suppresses tumor growth in a breast cancer xenograft model.
|
-
- HY-156590
-
|
|
Raf
|
Cancer
|
|
B-Raf IN 16 (Compound I) is a BRAF inhibitors that belongs a cyclic iminopyrimidine derivative. B-Raf IN 16 can be used for cancer research.
|
-
- HY-16189
-
|
NSC 264137; Celiptium
|
DNA Stain
|
Cancer
|
|
Elliptinium acetate (NSC 264137) is a DNA intercalating agent that is highly cytotoxic to L1 210 cells and covalently binds to nucleic acids from L1210 cells. Elliptinium acetate can be used in cancer research, particularly in metastatic breast cancer.
|
-
- HY-110109
-
|
|
PI3K
DNA-PK
mTOR
|
Cancer
|
|
ETP-45658 is a potent PI3K inhibitor, with IC50s of 22.0 nM, 39.8 nM, 129.0 nM and 717.3 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. ETP-45658 also can inhibit DNA-PK (IC50=70.6 nM) and mTOR (IC50=152.0 nM). ETP-45658 can be used for the research of cancer.
|
-
- HY-146396
-
|
|
Others
|
Cancer
|
|
Anticancer agent 51 (compound 3d) is a potent anticancer agent with an Ki of 731.62 nM. Anticancer agent 51 shows anticancer activity. Anticancer agent 51 has the potential for the research of prostate cancer.
|
-
- HY-145263
-
|
|
Ser/Thr Protease
|
Cancer
|
|
VD2173 is a side chain cyclized macrocyclic peptide inhibitor of HGF-activating serine proteases. VD2173 potently inhibits matriptase and hepsin. VD2173 can be used for the research of lung cancer.
|
-
- HY-132293
-
|
|
DNA-PK
|
Cancer
|
|
BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (IC50=81 nM). BAY-8400 can be used for the research of cancer.
|
-
- HY-112870
-
|
Alflutinib; Furmonertinib; AST2818
|
EGFR
|
Cancer
|
|
Firmonertinib (Alflutinib) is a potent inhibitor of EGFR. Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC).
|
-
- HY-112870A
-
|
Alflutinib mesylate; Furmonertinib mesylate; AST2818 mesylate
|
EGFR
|
Cancer
|
|
Firmonertinib (Alflutinib) mesylate is is a potent inhibitor of EGFR. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC).
|
-
- HY-12182A
-
|
|
Prostaglandin Receptor
|
Cancer
|
|
ONO-8711 dicyclohexylamine is a selective and orally active EP1 competitive antagonist with Ki value of 0.6 nM and 1.7 nM for human and mouse EP1 respectively. ONO-8711 dicyclohexylamine effectively reduces tumor incidence and multiplicity in mouse models of colon, breast, and oral cancer.
|
-
- HY-153422
-
|
|
Histone Methyltransferase
|
Cancer
|
|
PRMT5-IN-29 is a potent and orally active PRMT5 Inhibitor with an IC50 of 1.5 μΜ. PRMT5-IN-29 has the potential for advanced cancers research.
|
-
- HY-148838
-
|
|
c-Myc
|
Cancer
|
|
c-Myc inhibitor 8 (compound 56) is a c-Myc inhibitor. c-Myc inhibitor 8 effectively inhibits cell viability of a variety of cancer cells. c-Myc inhibitor 8 inhibits human prostate and lung cancer growth in mouse models. c-Myc inhibitor 8 can be used for cancer research.
|
-
- HY-144072
-
-
- HY-143475
-
-
- HY-143474
-
-
- HY-119418
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
Desketoraloxifene is an estrogen receptors alpha (ERα) activator at an AP-1 site. Desketoraloxifene can be used for the research of osteoporosis and breast cancer.
|
-
- HY-153415
-
|
|
PROTACs
Bcr-Abl
|
Cancer
|
|
PROTAC BCR-ABL Degrader-1 (compound PROTAC 1) is a PROTAC with a 2-oxoethyl linker. PROTAC BCR-ABL Degrader-1 induces Bcr-Abl degradation in a ubiquitinproteasom-dependent manner. PROTAC BCR-ABL Degrader-1 exhibits antiproliferative activity against K562 cells, and has the potential to study cancer.
|
-
- HY-D1876
-
|
|
Fluorescent Dye
|
Cancer
|
|
ZY-2 is a specific fluorescent probe for pyruvate kinase M2 (PKM2). ZY-2 can image in PKM2-positive cells in a time- and concentration-dependent manner. ZY-2 can be used for the detection of cancer cells.
|
-
- HY-144904
-
|
|
HDAC
|
Cancer
|
|
MC4343 is a potent and dual inhibitor of EZH2 and histone deacetylase. MC4343 has the potential for the research of cancer disease.
|
-
- HY-105529
-
|
(+)-Indicine N-oxide; NSC 132319
|
Others
|
Cancer
|
|
Indicine N-oxide (NSC 132319), a pyrrolizidine alkaloid, is an antitumor agent for pediatric cancer and solid tumors research.
|
-
- HY-N10160
-
|
12-Oleanene-3,6-diol
|
Others
|
Cancer
|
|
Daturadiol (12-Oleanene-3,6-diol), a triterpenoid, displays moderate cytotoxic activity against human cancer cell lines.
|
-
- HY-143446
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin polymerization-IN-7 (compound 5) is a potent inhibitor of tubulin polymerization. Tubulin polymerization-IN-7 has the potential for the research of cancer diseases.
|
-
- HY-126370
-
|
|
Endogenous Metabolite
|
Cancer
|
|
Geranylgeranyl pyrophosphate is a metabolite involved in protein geranylgeranylation. Geranylgeranyl pyrophosphate is the common precursor of diterpenoids, for example, Paclitaxel. Geranylgeranyl pyrophosphate can be used for cancer research.
|
-
- HY-148377
-
|
|
Others
|
Cancer
|
|
Abiraterone sulfate N-oxide is a carboxylic acid. Abiraterone sulfate N-oxide also is a major metabolite of Abiraterone (HY-70013). Abiraterone sulfate N-oxide can be used for the research of prostate cancer.
|
-
- HY-12970A
-
|
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
|
EPZ020411 hydrochloride is a selective inhibitor of PRMT6 with an IC50 of 10 nM, it has >10 folds selectivity for PRMT6 over PRMT1 and PRMT8. EPZ020411 hydrochloride can be used for the research of cancer.
|
-
- HY-141520
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
ART558 is a nanomolar potent, selective, low molecular weight, allosteric DNA polymerase activity of Polθ inhibitor (IC50=7.9 nM). ART558 can be used for the research of cancer.
|
-
- HY-125170
-
|
|
STAT
|
Cancer
|
|
Galiellalactone is a is a small non-toxic and non-mutagenic fungal metabolite, a selective inhibitor of STAT3 signaling, with an IC50 of 250-500 nM. Galiellalactone can be used to research castration-resistant prostate cancer.
|
-
- HY-122496
-
|
Syringidin
|
Apoptosis
|
Cancer
|
|
Malvidin (chloride) is a bioactive compound isolated from grape. Malvidin shows cytotoxicity through the arrest of the G2/M phase of cell cycle and induction of apoptosis. Malvidin can be used for the research of cancer.
|
-
- HY-P99117
-
|
AK104
|
PD-1/PD-L1
|
Cancer
|
|
Cadonilimab (AK104) is a targeting PD1/CTLA4 IgG1 scaffold Fc-engineered humanized antibody. Cadonilimab can be used for researching metastatic cervical cancer.
|
-
- HY-W727999
-
|
|
Apoptosis
|
Cancer
|
|
Koenimbine is an anticancer agent that can be obtained from the leaves and fruits of Murraya koenigii. Koenimbine can induce apoptosis and necrosis in HT-29 and SW48 cells. Koenimbine can be used in the research of cancer.
|
-
- HY-12970
-
|
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
|
EPZ020411 is a selective inhibitor of PRMT6 with an IC50 of 10 nM, has >10 folds selectivity for PRMT6 over PRMT1 and PRMT8. EPZ020411 can be used for the research of cancer.
|
-
- HY-155596
-
|
|
Phosphatase
|
Cancer
|
|
h-NTPDase-IN-1 (Compound 3i) is a h-NTPDase inhibitor (IC50: 2.88 μM and 0.72 μM for h-NTPDase1 and h-NTPDase3 respectively). h-NTPDase-IN-1 can be used for research of thrombosis, inflammation, diabetes, and cancer.
|
-
- HY-136464
-
|
|
β-catenin
|
Cancer
|
|
β-catenin-IN-2 is a potent β-catenin inhibitor, compound H1B1, extracted from patent US20150374662A1. β-catenin-IN-2 can be used for the study of colorectal cancer.
|
-
- HY-18309
-
|
|
c-Met/HGFR
VEGFR
|
Cancer
|
|
MET kinase-IN-4 is an orally active Met kinase inhibitor. MET kinase-IN-4 has potent Met kinase inhibitory activity with an IC50 value of 1.9 nM. MET kinase-IN-4 can be used for the research of cancer.
|
-
- HY-13675
-
|
NV-143
|
Endogenous Metabolite
|
Cancer
|
|
ME-143 is a second-generation tumor-specific inhibitor of NADH oxidase. ME-143 inhibits the WNT/β-catenin pathway in colorectal cancer cells. ME-143 has broadly active against cancers in vitro and in vivo.
|
-
- HY-148779
-
|
|
FGFR
|
Cancer
|
|
FGFR3-IN-5 is a potent and selective FGFR3 inhibitor with IC50 values of 3, 44, and 289 nM for FGFR3, FGFR2, and FGFR1, respectively. FGFR3-IN-5 can be used in research of cancer.
|
-
- HY-102010
-
|
(+)-Pancratistatin
|
Apoptosis
|
Cancer
|
|
Pancratistatin is an isoquinoline alkaloid that can be isolated from Hymenocallis littoralis. Pancratistatin induces apoptosis of human melanoma cells. Pancratistatin can be used for the research of neuroblastoma, leukemia and breast cancer.
|
-
- HY-136255
-
|
AZD-9833
|
Estrogen Receptor/ERR
|
Cancer
|
|
Camizestrant (AZD-9833) is a potent and orally active estrogen receptor (ER) antagonist. Camizestrant is used for the study of ER + HER2-advanced breast cancer.
|
-
- HY-149100
-
-
- HY-147790
-
|
|
Others
|
Cancer
|
|
MDH1-IN-1 (Compound 5i) is a potent inhibitor of MDH1 with an IC50 of 6.79 μM. MDH1-IN-1 has the potential for the research of cancer diseases.
|
-
- HY-160046
-
|
|
Others
|
Cancer
|
|
AS2 sodium is an ssDNA aptamer (Kd: 0.7 nM) for prostate-specific antigen (PSA). AS2 sodium does not bind non-specifically to the anti-target and has the potential to be used in diagnostic systems for prostate cancer detection.
|
-
- HY-156881
-
|
|
Poly(ADP-ribose) Glycohydrolase (PARG)
|
Cancer
|
|
PARG-IN-4 (Formula (A)) is an orally active and cell-permeable PARG inhibitor. PARG-IN-4 effectively inhibits tumor growth in mouse models. PARG-IN-4 can be used in cancer research.
|
-
- HY-149996
-
|
|
Pim
|
Cancer
|
|
Pim-1 kinase inhibitor 6 (Compound 4d) is a potent Pim-1 kinase inhibitor with IC50 value of 0.46 μM, and has significant cytotoxic effect on cancer cells.
|
-
- HY-19731
-
|
MiR-544 Inhibitor 1
|
MicroRNA
Apoptosis
|
Cancer
|
|
SID 3712249 (MiR-544 Inhibitor 1) is a miR-544 biogenesis inhibitor. SID 3712249 binds directly to the precursor miRNA. SID 3712249 blocks production of the mature microRNA and decreases miR-544, HIF-1α, and ATM transcripts. SID 3712249 can be used in the research of cancers, such as breast cancer.
|
-
- HY-137881
-
-
- HY-123298
-
|
|
Src
Akt
Apoptosis
|
Cancer
|
|
Chrysotoxine is a dual inhibitor of Src/Akt. Chrysotoxine suppresses cancer stem cells (CSCs) phenotypes by down-regulating Src/Akt signaling. Chrysotoxine reduces cell viability and increases apoptosis level in H460 and H23 cells instead of non-tumor cell lines. Chrysotoxine shows rapid excretion and low bioavailability in rats. Chrysotoxine is used in cancer research.
|
-
- HY-144138
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
Estrogen receptor antagonist 2 is a selective estrogen receptor downregulator. Estrogen (E2) and estrogen alpha receptor (ERα) are important drivers of breast cancer development. Estrogen receptor antagonist 2 has the potential for the research of breast cancer diseases (extracted from patent WO2021228210A1, compound 3).
|
-
- HY-144137
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
Estrogen receptor antagonist 1 is a selective estrogen receptor antagonist. Estrogen (E2) and estrogen alpha receptor (ERα) are important drivers of breast cancer development. Estrogen receptor antagonist 1 has the potential for the research of breast cancer diseases (extracted from patent WO2021249533A1, compound 4).
|
-
- HY-153246
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
ALK2-IN-5, pyrazolopyrimidine compound, is an ALK2 inhibitor. ALK2-IN-5 can inhibit ALK2 activity and FGFR activity. ALK2-IN-5 can be used for the research of disorders associated with ALK2 activity and/or FGFR activity, such as cancer.
|
-
- HY-150073
-
|
|
Others
|
Cancer
|
|
DS01080522 is a Protein Kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor. DS01080522 inhibits PRKACA kinase activity and CREB phosphorylation with IC50s of 0.8 nM and 66 nM, respectively. DS01080522 can be used for the research of cancer.
|
-
- HY-P99961
-
|
JS004
|
CD28
|
Cancer
|
|
Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer.
|
-
- HY-132297
-
|
|
PARP
|
Cancer
|
|
PARP1-IN-5 is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 can be used for the research of cancer.
|
-
- HY-132297A
-
|
|
PARP
|
Cancer
|
|
PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer.
|
-
- HY-133800
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Volvaltrate B is an anticancer agent, iridoid, can be obtained from the root of valerian (Valeriana officinalis). Volvaltrate B is effective against ovarian tumors in female mice. Volvaltrate B has the potential to study cancer.
|
-
- HY-N10542
-
|
|
Others
|
Cancer
|
|
Aplyronine C is an active compound. Aplyronine C shows potent antitumor activity and has cytotoxicity against HeLa-S3 cells with an IC50 values of 22 nM. Aplyronine C can be used for the research of cancer.
|
-
- HY-127009
-
|
Levofolinic acid; Levofolene
|
Endogenous Metabolite
|
Cancer
|
|
Levoleucovorin (Levofolinic acid) is the pharmacologically active levoisomer of racemic leucovorin. Levoleucovorin can be used as a rescue agent after high-dose Methotrexate (HY-14519) therapy, and in combination with fluorouracil for the research of advanced metastatic colorectal cancer.
|
-
- HY-160022
-
|
|
IAP
|
Cancer
|
|
XIAP BIR2/BIR2-3 inhibitor-1 (compound 3) is a dual inhibitor of BIR2 and BIR2-3 with IC50s of 1.9 and 0.8 nM, respectively. XIAP BIR2/BIR2-3 inhibitor-1 can used in study cancers.
|
-
- HY-135312
-
|
|
Estrogen Receptor/ERR
PROTACs
|
Cancer
|
|
AZ'6421 acts as Protcolysis Targeting Chimera (PROTAC) to selectively degrade estrogen receptor alpha. AZ'6421 has a potent anti-tumour effect to inhibit the uncontrolled cellular proliferation which arises from malignant disease. AZ'6421 can be used for the research of cancer such as breast cancer.
|
-
- HY-16212
-
|
|
Others
|
Cancer
|
|
FR901464 is a potent spliceosome inhibitor with prominent anti-tumor and anti-cancer effects.
|
-
- HY-114917
-
|
NSC 254
|
Endogenous Metabolite
|
Cancer
|
|
Aldophosphamide (NSC 254) is a cyclophosphamide metabolite. Aldophosphamide is cleaved intracellularly to phosphoramide mustard, an active metabolite with direct cytotoxicity, and acrolein. Aldophosphamide has potential for cancer research.
|
-
- HY-147135
-
|
|
YAP
|
Cancer
|
|
TEAD-IN-3 (compound I-177) is a potent TEAD transcription factor inhibitor. TEAD-IN-3 can be used for the research of proliferative diseases (such as cancer) .
|
-
- HY-146480
-
|
|
PPAR
|
Cancer
|
|
PPARγ agonist 5 (Compound 1) is a potent and selective agonist of PPARγ. PPARγ agonist 5 has the potential for the research of cancer diseases.
|
-
- HY-147864
-
|
|
c-Fms
c-Kit
Apoptosis
|
Cancer
|
|
c-Fms-IN-12 (Compound 4g) is an FMS kinase inhibitor. c-Fms-IN-12 can also inhibits c-KIT. c-Fms-IN-12 is a potential broad-spectrum anticancer agent against multiple cancer types. c-Fms-IN-12 induces A549 cell apoptosis.
|
-
- HY-145944
-
|
|
Apoptosis
|
Cancer
|
|
ASR-488 activates the mRNA-binding protein CPEB1, induces apoptosis and inhibits bladder cancer growth.
|
-
- HY-156607
-
|
|
Phosphatase
|
Cancer
|
|
Anticancer agent 143 (compound 369) is a dual PTPN2/PTP1B inhibitor with IC50 values <2.5 nM. Anticancer agent 143 can be used in cancer research.
|
-
- HY-156608
-
|
|
Phosphatase
|
Cancer
|
|
Anticancer agent 144 (compound 444) is a dual PTPN2/PTP1B inhibitor with IC50 values <2.5 nM. Anticancer agent 144 can be used in cancer research.
|
-
- HY-147791
-
|
|
Others
|
Cancer
|
|
MDH1-IN-2 (Compound 7c) is a potent and selelctive inhibitor of MDH1 with an IC50 of 2.27 μM. MDH1-IN-2 has the potential for the research of cancer diseases.
|
-
- HY-150040
-
-
- HY-P99589
-
|
16B5; AB-16B5
|
Apoptosis
|
Cancer
|
|
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research.
|
-
- HY-P99192
-
|
LY2875358
|
c-Met/HGFR
|
Cancer
|
|
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.
|
-
- HY-152185
-
|
|
p38 MAPK
|
Cancer
|
|
BSJ-04-122 is a covalent MKK4/7 dual inhibitor. BSJ-04-122 inhibits MKK4 and MKK7 with IC50 values of 4 nM and 181 nM, respectively. BSJ-04-122 can be used for the research of cancer.
|
-
- HY-147710
-
|
|
MicroRNA
|
Cancer
|
|
PIN1 inhibitor 2 (compound 12) is a potent PIN1 inhibitor. PIN1 inhibitor 2 shows antitumor activity with an IC50 of 9.55 µM for MCF7 cells. PIN1 inhibitor 2 has the potential for the research of breast cancer.
|
-
- HY-N10541
-
|
|
Others
|
Cancer
|
|
Aplyronine B is an active compound. Aplyronine B shows potent antitumor activity and has cytotoxicity against HeLa-S3 cells with an IC50 values of 2.9 nM. Aplyronine B can be used for the research of cancer.
|
-
- HY-113293B
-
|
|
Estrogen Receptor/ERR
Endogenous Metabolite
|
Cancer
|
|
Estrone sulfate, a biologically inactive form of estrogen, is a major circulating plasma estrogen that is converted into the biologically active estrogen, estrone (E1) by steroid sulfatase (STS). Estrone sulfate can be used for the research of breast cancer.
|
-
- HY-108695
-
|
|
Apoptosis
Endogenous Metabolite
|
Cancer
|
|
Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Anti-cancer activities.
|
-
- HY-157083
-
|
|
YAP
|
Cancer
|
|
mCMY020 is a covalent inhibitor of TEAD. mCMY020 effectively reduces YAP (Yes-associated protein)-driven transcription and selectively slows the proliferation of Hippo-deficient cancer cells. mCMY020 can be used in cancer research.
|
-
- HY-125335
-
|
Rutamycin A
|
Ras
|
Cancer
|
|
Oligomycin D (Rutamycin A) is an antibiotic. Oligomycin D can be derived from a strain of S. rutgersensis. Oligomycin D also is a potent inhibitors of K-Ras PM localization. Oligomycin D can be used for the research of various cancers.
|
-
- HY-N1039A
-
|
|
Others
|
Cancer
|
|
Manool is a diterpene from Salvia officinalis. Manool induces selective cytotoxicity in cancer cells. Manool arrests the cancer cells at the G(2)/M phase of the cell cycle.
|
-
- HY-145320
-
-
- HY-N8669
-
|
|
LIM Kinase (LIMK)
|
Cancer
|
|
Curcolonol is a furan type sesquiterpene. Curcolonol can be isolated from several medical herbs. Curcolonol has inhibitory activity for LIM kinase 1. Curcolonol can be used for the research of breast cancer.
|
-
- HY-B1787
-
|
|
mTOR
|
Cancer
|
|
Sulindac sulfone is an mTORC1 pathway inhibitor and a metabolite of Sulindac. Sulindac sulfone inhibits colon cancer cell growth and induces cell cycle arrest. Sulindac sulfone is used in cancer research.
|
-
- HY-145572
-
|
LY-3484356
|
Estrogen Receptor/ERR
|
Cancer
|
|
Imlunestrant (LY-3484356) is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC).
|
-
- HY-145572A
-
|
LY-3484356 tosylate
|
Estrogen Receptor/ERR
|
Cancer
|
|
Imlunestrant (LY-3484356) tosylate is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant tosylate results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant tosylate can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC).
|
-
- HY-160024
-
|
|
Others
|
Cancer
|
|
XIAP BIR2/BIR2-3 inhibitor-2 is a dual inhibitor of BIR2 and BIR2-3 with IC 50s less than 1 nM. XIAP BIR2/BIR2-3 inhibitor-2 can used in study cancers.
|
-
- HY-146554
-
|
|
PDHK
|
Cancer
|
|
PDHK-IN-5 (Compound 19) is a potent inhibitor of PDHK with IC50s of 0.006 and 0.0329 μM for PDHK2 and PDHK4, repectively. Pyruvate dehydrogenase kinases (PDHKs) are fascinating agent targets for numerous diseases, including diabetes and cancers. PDHK-IN-5 has the potential for the research of cancer diseases.
|
-
- HY-109184
-
|
AMG 397
|
Bcl-2 Family
|
Cancer
|
|
Murizatoclax (AMG 397) is a potent, selective and orally active inhibitor of myeloid leukemia 1 (MCL-1) inhibitor, with a Ki of 15 pM. Murizatoclax competitive binds to the BH3-binding groove of MCL1 with pro-apoptotic BCL-2 family members. Murizatoclax can be used for the research of cancer.
|
-
- HY-136431
-
|
|
Others
|
Cancer
|
|
BC-DXI-843 is a potent and specific AIMP2-DX2 inhibitor with an IC50 of 0.92 μM, more than 100-fold selectivity over AIMP2 (IC50 >100 μM) in a luciferase assay. BC-DXI-843 acts as a promising lead targeting AIMP2-DX2 in lung cancer.
|
-
- HY-155472
-
|
|
Bcl-2 Family
|
Cancer
|
|
Mcl-1 inhibitor 17 is a Mcl-1 protein inhibitor. Mcl-1 inhibitor 17 can be used for the research of cancer and other diseases.
|
-
- HY-124309
-
|
|
Lactate Dehydrogenase
|
Cancer
|
|
NHI-2 is a potent inhibitor of LDH-A. NHI-2 is an efficient anti-glycolytic agent. NHI-2 has the potential for the research of cancer disease.
|
-
- HY-153457
-
|
|
Hedgehog
|
Cancer
|
|
Hedgehog IN-3 (compound 3) is a hedgehog pathway inhibitor (IC50 = 0.01 µM). Hedgehog IN-3 can be used in cancer research.
|
-
- HY-151382
-
|
|
Casein Kinase
|
Cancer
|
|
CK2-IN-3 is a selective and potent CK2 inhibitor (Kd: 12 nM), with IC50 values of 1.51 μM (CK2α) and 7.64 μM (CK2α’). CK2-IN-3 can be used in the research of cancers.
|
-
- HY-151272
-
|
|
Others
|
Cancer
|
|
ALK5-IN-26 (EX-22) is an ALK (Activin receptor-like kinase) inhibitor. ALK5-IN-26 inhibits ALK5 with an IC50 value ≤10 nM. ALK5-IN-26 can be used for the research of cancer.
|
-
- HY-N9912
-
|
|
Others
|
Cancer
|
|
Physalin D is isolated from the aerial parts of Physalis angulate. Physalin D displays considerable cytotoxicity against several cancer cell lines, showing IC50 values in the range of d 0.28 to 2.43 microg/mL. Physalin D has the potential for the cancer disease.
|
-
- HY-P5021
-
|
c(RGDfE)
|
Biochemical Assay Reagents
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) (c(RGDfE)) is a cyclic RGD peptide that serves as a conjugated multifunctional nanodrug delivery system to target Gemcitabine to pancreatic cancer cells. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) can be used in cancer research.
|
-
- HY-152197
-
|
|
PARP
|
Cancer
|
|
Tankyrase-IN-3 is a tankyrase 1 (TNKS1) inhibitor with an IC50 value of 22 nM. Tankyrase-IN-3 can be used for the research of cancer.
|
-
- HY-132283
-
PF-9363
1 Publications Verification
CTx-648
|
Histone Acetyltransferase
|
Cancer
|
|
PF-9363 (CTx-648) is a first-in-class potent and high selective KAT6A/KAT6B inhibitor. PF-9363 can be used for the research of cancer.
|
-
- HY-16724
-
|
1-Methyl-D-tryptophan; NLG-8189
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
Indoximod (1-Methyl-D-tryptophan) is an orally active indoleamine 2,3-dioxygenase (IDO) pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR. Indoximod is an immunometabolic adjuvant used for the research of cancer.
|
-
- HY-146688
-
|
|
Cytochrome P450
|
Cancer
|
|
SYN20028567 is an aromatase (CYP19) inhibitor with an IC50 of 9.4 nM. SYN20028567 can be used for breast cancer research.
|
-
- HY-105375
-
|
|
Cytochrome P450
|
Cancer
|
|
FR 901537 is a potent and competitive aromatase inhibitor. FR 901537, a novel naphthol derivative, has the potential for breast cancer research.
|
-
- HY-123056
-
|
|
Autophagy
Apoptosis
|
Cancer
|
|
EAD1 is a potent autophagy inhibitor with antiproliferative activity in lung and pancreatic cancer cells. EAD1 also induces apoptosis.
|
-
- HY-P99762
-
|
MGD009
|
CD3
|
Cancer
|
|
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer.
|
-
- HY-W259888
-
-
- HY-117479
-
|
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
CL67 is a potent hypoxia-inducible factor (HIF) pathway inhibitor. CL67 interferes G-quadruplex structures within promoter sequences. CL67 can be used in research of renal cancer.
|
-
- HY-155069
-
|
|
Apoptosis
|
Cancer
|
|
Antiproliferative agent-27 (compound 11) is an antiproliferative agent that significantly reduces the number of tumor cell colonies and induces apoptosis. Antiproliferative agent-27 has the potential to be used in the study of cancer.
|
-
- HY-Y1097
-
|
2-(Methoxycarbonyl)benzoic acid
|
Endogenous Metabolite
|
Cancer
|
|
Monomethyl phthalate is a phthalate metabolite. Monomethyl phthalate acts as a urinary biomarker of phthalates exposure and can be used as a standard for the determination of thyroid cancer and benign nodule.
|
-
- HY-147556
-
|
|
Potassium Channel
|
Cancer
|
|
SK3 Channel-IN-1 (compound 7a) is a potent and specific SK3 channel modulator. SK3 Channel-IN-1 has efficient effect on breast cancer MDA-MB-435 cell migration while exhibiting low cytotoxicity in other cell lines. SK3 Channel-IN-1 can modulate ion channels’activity in cancer.
|
-
- HY-153519
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
WWL0245 is a potent and seletive BRD4 PROTAC. WWL0245 selectively degrades BRD4 with sub-nanomolar DC50 (<1 nM) than BRD2/3 and PLK1 ( DC50>1 μM). WWL0245 shows excellent selective cytotoxicity in the BETi sensitive cancer cell lines, including AR-positive prostate cancer cell lines. WWL0245 is a promising drug candidate for AR-positive prostate cancer research and a valuable tool compound to study the biological function of BRD4.
|
-
- HY-124776
-
|
|
Others
|
Cancer
|
|
NPD8733 is an inhibitor of cancer cell-enhanced fibroblast migration. NPD8733 specifically binds to valosin-containing protein (VCP)/p97, a member of the ATPase-associated with diverse cellular activities (AAA+) protein family. NPD8733 has the potential for the research of cancer diseases.
|
-
- HY-P1408
-
|
|
Integrin
|
Cancer
|
|
Obtustatin is a non-RGD disintegrin of 41 residues. Obtustatin can be isolated from Vipera lebetina obtusa venom. Obtustatin is a potent and selective inhibitor of the adhesion of integrin α1β1 to collagen IV. Obtustatin inhibits angiogenesis, and can be used for research of cancer.
|
-
- HY-146115
-
|
|
Trk Receptor
|
Cancer
|
|
TRK-IN-19 (Compound I-10 ) is a potent inhibitor of TRK (TRKA IC50 = 1.1 nM, TRKA G595R IC50 = 5.3 nM). TRK-IN-19 has the potential for the research of cancer diseases.
|
-
- HY-145857
-
|
|
HSP
Apoptosis
|
Cancer
|
|
GRP78-IN-1 exhibits several interactions with GRP78 residues with binding energy of -8.07 kcal/mol. GRP78-IN-1 shows the potent cytotoxic, anti-proliferative in cancer cells. GRP78-IN-1 exhibits promising apoptosis in breast cancer cells and wound healing properties.
|
-
- HY-145306
-
|
|
Mitochondrial Metabolism
|
Cancer
|
|
DX3-234 is an oxidative phosphorylation (OXPHOS) inhibitor. DX3-234 shows significant tumor suppression in the Pan02 syngeneic model of pancreatic cancer.
|
-
- HY-103053
-
|
|
VD/VDR
Apoptosis
|
Cancer
|
|
PS121912 is a selective vitamin D receptor (VDR)-coregulator inhibitor. PS121912 has acceptable metabolic stability in vivo. PS121912 can be used for the research of cancer.
|
-
- HY-N1012
-
|
|
Others
|
Cancer
|
|
(-)-11,13-Dehydroeriolin (compound 9), a sesquiterpene lactone, is a nature product that could be isolated from Carpesium abrotanoides L. (-)-11,13-Dehydroeriolin has antiproliferative active. (-)-11,13-Dehydroeriolin can be used in research of cancer.
|
-
- HY-15155
-
MLN0905
4 Publications Verification
|
Polo-like Kinase (PLK)
|
Cancer
|
|
MLN0905 is a potent, orally active Polo-like kinase 1 (PLK1) inhibitor. MLN0905 has inhibitory potency against PLK1 with an IC50 value of 2 nM. MLN0905 can be used for the research of cancer.
|
-
- HY-137046
-
|
|
Others
|
Cancer
|
|
Nek2-IN-4 is a potent NEK2 inhibitor with an IC50 value of 15 nM. Nek2-IN-4 inhibits cell proliferation. Nek2-IN-4 has the potential for the research of pancreatic cancer.
|
-
- HY-152198
-
|
|
PARP
|
Cancer
|
|
Tankyrase-IN-4 is a tankyrase 1 (TNKS1) inhibitor with an IC50 value of 0.8 nM. Tankyrase-IN-4 can be used for the research of cancer.
|
-
- HY-129279
-
|
|
Farnesyl Transferase
|
Cancer
|
|
Andrastin A meroterpenoid compound, is a farnesyltransferase inhibitor. Andrastin A inhibits the efflux of anticancer compounds from multidrug-resistant cancer cells. Andrastin A can be isolated from Penicillium species.
|
-
- HY-149622
-
|
|
Bcl-2 Family
|
Cancer
|
|
Bcl-2-IN-12 (Compound 1) is a Bcl-2 inhibitor (IC50: 6 nM). Bcl-2-IN-12 can be used for cancer research.
|
-
- HY-115956
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 18 (compound 5j) is a potent inhibitor of tubulin. Tubulin inhibitor 18 is a chalcone compound. Tubulin inhibitor 18 has the potential for the research of cancer diseases.
|
-
- HY-122568
-
|
|
STING
|
Cancer
|
|
STING agonist-15 (Compound STING agonist-C11) Is a STING agonist. STING agonist-15 can be used for research of cancer and immune response.
|
-
- HY-126370A
-
|
|
Endogenous Metabolite
|
Cancer
|
|
Geranylgeranyl pyrophosphate triammonium is a metabolite involved in protein geranylgeranylation. Geranylgeranyl pyrophosphate triammonium is the common precursor of diterpenoids, for example, Paclitaxel. Geranylgeranyl pyrophosphate triammonium can be used for cancer research.
|
-
- HY-120275
-
|
|
Bcl-2 Family
Apoptosis
|
Cancer
|
|
CYD-2-11 is a selective Bax agonist with a Ki value of 34.1 nM. CYD-2-11 induces cell apoptosis and shows antiproliferative activity to breast cancer MDA-MB-231 and MCF-7 cell lines with IC50 values of 3.22 and 3.81 μM, respectively. CYD-2-11 suppresses tumor growth in MDA-MB-231 tumor models. CYD-2-11 can be used for the research of breast and lung cancer.
|
-
- HY-153414
-
|
|
Epigenetic Reader Domain
PROTACs
|
Cancer
|
|
GXF-111, a PROTAC molecule, can promote selective degradation of cellular BRD3 and BRD4-L. GXF-111 has binding affinities for BRD3 BD1 and BRD3 BD2 with Ki values of 11.97 nM and 2.35 nM, respectively. GXF-111 can be used for the research of cancer.
|
-
- HY-149297
-
|
|
PSMA
|
Cancer
|
|
PSMA-IN-1 (compound 23) is an inhibitor of PSMA with a Ki value of 2.49 nM. PSMA-IN-1 inhibits tumor growth with high selectivity and specificity in PSMA+ xenograft models. PSMA-IN-1 is a NIR probe (λEX: 620 nm; λEM: 670 nm) used for tumor disappearance. PSMA-IN-1 can be used for research on prostate cancer.
|
-
- HY-108345
-
|
|
Antibiotic
|
Cancer
|
|
Bleomycin is a glycopeptide antibiotic. Bleomycin has potent antitumour activities against a range of lymphomas, head and neck cancers and germ-cell tumours. Bleomycin can be used for the research of cancer and chemotherapy.
|
-
- HY-151881
-
|
|
Ras
|
Cancer
|
|
SOS1-IN-15 (Compound 37) is an orally active SOS1 inhibitor with an IC50 of 5 nM. SOS1-IN-15 is a promising agent candidate for the research of KRAS-driven cancer.
|
-
- HY-117078
-
|
|
Apoptosis
|
Cancer
|
|
justicidin A is a nature product that could be isolated form Justicia procumbens. justicidin A decreases the level of Ku70 leading to translocation of Bax from the cytosol to mitochondria to induce apoptosis. justicidin A can be used in research of cancer.
|
-
- HY-139453A
-
|
|
DNA Alkylator/Crosslinker
|
Cancer
|
|
LP-284 is a potent DNA alkylating agent that kills solid tumours. LP-284 can be used in the studies of hematologic cancers with compromised DNA repair, such as mantle cell lymphoma (MCL).
|
-
- HY-126899
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
TPI-287, a blood-brain barrier-permeable microtubule stabilizer, can significantly reduce metastatic colonization of breast cancer in the brain.
|
-
- HY-108932
-
|
Gemcitabine 5′-phosphate
|
Apoptosis
|
Cancer
|
|
Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate shows synergistic anti-cancer effects.
|
-
- HY-155070
-
|
|
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
SRE-II, an amide derivative, is an activatable photosensitizer for photodynamic cancer research with decreased fluorescence and photosensitizing capabilities. SRE-II can be further converted into the active photosensitizer SDU Red via carboxylesterase-catalyzed amide bond cleavage. SRE-II induces DNA damage and cell apoptosis in the presence of light. SRE-II can act as a promising theranostic agent for triple-negative breast cancer.
|
-
- HY-151623
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
ACBI2 is a highly potent and orally active VHL PROTAC SMARCA2 degrader (EC50: 7 nM), which selectively degrades SMARCA2 with a DC50 value of 1 nM in RKO cells. ACBI2 can be used in the research of lung cancer.
|
-
- HY-111292
-
|
|
LPL Receptor
|
Cancer
|
|
CYM-5482 is a potent and selective agonist Sphingosine 1-phosphate receptor 2 (S1PR2) with an IC50 and EC50 of 1.0 and 1.03 μM. CYM-5482 has the potential for the research of cancer diseases.
|
-
- HY-108250
-
|
|
Androgen Receptor
|
Cancer
|
|
(R)-Bicalutamide is the (R)-enantiomer of Bicalutamide (HY-14249). (R)-Bicalutamide is an androgen receptor (AR) antagonist, with antineoplastic activity. (R)-Bicalutamide is widely used for the research of prostate cancer.
|
-
- HY-N7678
-
|
|
Others
|
Cancer
|
|
Gypenoside LXXV, isolated from Gynostemma pentaphyllum, is one of the deglycosylated shapes of ginsenoside Rb1. Gypenoside LXXV significantly reduces cancer cell viability and displays an anti-cancer effect.
|
-
- HY-149380
-
|
|
Raf
|
Cancer
|
|
Vem-L-Cy5 (compound 3)，modified with the NIR fluorophore cyanine-5 (Cy5)，is a Vemurafenib (HY-12057)-based inhibitor of BRAF. Vem-L-Cy5 targets to BRAF V600E，and also inhibits MEK phosphorylation. Vem-L-Cy5 has cell permeability，and inhibits cell growth of many types of cancer.
|
-
- HY-P2615
-
|
|
Fluorescent Dye
|
Cancer
|
|
Ac-VDVAD-AFC is a caspase-specific fluorescent substrate. Ac-VDVAD-AFC can measure caspase-3-like activity and caspase-2 activity and can be used for the research of tumor and cancer.
|
-
- HY-137193
-
|
|
Drug Metabolite
|
Cancer
|
|
5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer).
|
-
- HY-W013523
-
2-NP
1 Publications Verification
|
STAT
|
Cancer
|
|
2-NP is a selective enhancer of STAT1 transcription. 2-NP can enhance the ability of IFN-γ to inhibit the proliferation of human breast cancer and fibrosarcoma cells.
|
-
- HY-13915
-
|
|
Apoptosis
|
Cancer
|
|
NSC348884 is a nucleophosmin (NPM) inhibitor, it disrupts oligomer formation and induces apoptosis, inhibits cell proliferation with IC50s of 1.7-4.0 μM in distinct cancer cell lines. NSC348884 can be used for the research of cancer.
|
-
- HY-155666
-
|
|
Androgen Receptor
|
Cancer
|
|
YXG-158 (Compound 23-h) is an orally active AR degrader and CYP17A1 inhibitor. YXG-158 has AR degradation activity with DC50 value of 1.28 μM. YXG-158 can inhibit CYP17A1 with IC50 value of 100 nM. XG-158 can be used for the research of enzalutamide-resistant prostate cancer.
|
-
- HY-147598
-
|
|
CDK
|
Cancer
|
|
CDK7-IN-14 is a potent inhibitor of CDK7. CDK7-IN-14 is a pyrimidinyl derivative compound. CDK7-IN-14 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 3).
|
-
- HY-147603
-
|
|
CDK
|
Cancer
|
|
CDK7-IN-18 is a potent inhibitor of CDK7. CDK7-IN-18 is a pyrimidinyl derivative compound. CDK7-IN-18 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 15).
|
-
- HY-147597
-
|
|
CDK
|
Cancer
|
|
CDK7-IN-13 is a potent inhibitor of CDK7. CDK7-IN-13 is a pyrimidinyl derivative compound. CDK7-IN-13 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 1).
|
-
- HY-117002
-
|
|
Others
|
Cancer
|
|
SRI 37892 is a small molecule compound inhibitor of Frizzled protein 7 (Fzd7) with inhibitory activity against cancer cell proliferation (IC502μM). SRI 37892 significantly blocks Wnt/Fzd7 signaling. SRI 3789 can be used in the research of developing cancer therapeutic agents [1].
|
-
- HY-147600
-
|
|
CDK
|
Cancer
|
|
CDK7-IN-15 is a potent inhibitor of CDK7. CDK7-IN-15 is a pyrimidinyl derivative compound. CDK7-IN-15 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 8).
|
-
- HY-147602
-
|
|
CDK
|
Cancer
|
|
CDK7-IN-17 is a potent inhibitor of CDK7. CDK7-IN-17 is a pyrimidinyl derivative compound. CDK7-IN-17 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 1).
|
-
- HY-152228
-
|
|
Histone Methyltransferase
Autophagy
|
Cancer
|
|
SMYD3-IN-2 is a SMYD3 inhibitor against gastric cancer via inducing lethal autophagy. SMYD3-IN-2 has inhibitory for SMYD3 and BGC823 cells with IC50 values of 0.81 μM and 0.75 μM, respectively. SMYD3-IN-2 can be used for the research of cancer.
|
-
- HY-P5020
-
|
|
Bacterial
|
Cancer
Infection
|
|
Crotalicidin is an antimicrobial peptide and anti-tumor peptide that can effectively inhibit the activity of Gram-negative bacteria and tumor cells. Crotalicidin can be obtained from rattlesnake venom. Crotalicidin can be used in the study of microbial infections and cancer.
|
-
- HY-148215
-
|
|
HSP
|
Cancer
|
|
Hsp90-IN-17 (Example 5) is an HSP90 inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases.
|
-
- HY-148215A
-
|
|
HSP
|
Cancer
|
|
Hsp90-IN-17 (Example 5) hydrochloride is an HSP90 inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases.
|
-
- HY-P99501
-
|
HS006
|
CD20
|
Cancer
|
|
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma.
|
-
- HY-16488
-
|
m-THPC; KW2345
|
Reactive Oxygen Species
|
Cancer
|
|
Temoporfin (m-THPC), a reduced porphyrin, is a potent second-generation photosensitizer. Temoporfin can be used in the research of photodynamic therapy (PDT) for head and neck cancers.
|
-
- HY-113680
-
|
|
Wnt
β-catenin
Ras
Apoptosis
|
Cancer
|
|
KY1022 is a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway. KY1022 can inhibit cellular EMT, metastasis and apoptosis. KY1022 can be used for the research of metastatic colorectal cancer.
|
-
- HY-116972
-
|
SR 2508
|
Others
|
Cancer
|
|
Etanidazole (SR 2508), a 2-nitroimidazole compound, is a hypoxic radiosensitizer used in cancer diagnosis and chemotherapy research.
|
-
- HY-149862
-
|
|
PROTACs
Androgen Receptor
|
Cancer
|
|
ARD-2051 is a potent and orally active androgen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 can be used for the research of prostate cancer.
|
-
- HY-155533
-
|
|
SHP2
|
Cancer
|
|
YF704 (compound 4w) is a selective allosteric inhibitor of SHP2 (IC50=0.25 μM). YF704 shows antiproliferative activity and induces apoptosis in cancer cells. YF704 also downregulates Erk1/2 and Akt phosphorylation levels in cancer cells.
|
-
- HY-112273A
-
|
|
Aurora Kinase
|
Cancer
|
|
CD532 hydrochloride is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 hydrochloride also can directly interact with AURKA and induces a global conformational shift. CD532 hydrochloride can be used for the research of cancer.
|
-
- HY-139065
-
|
|
Others
|
Cancer
|
|
AMPC is a potent and effective TFF3 inhibitor. AMPC inhibits cell proliferation, survival, oncogenicity, and CSC-like behaviour in TFF3-positive CMS4 CRC cells. AMPC acts as a potential anti-cancer agent alone or in combination with 5-FU, and can be used for cancer research.
|
-
- HY-132292
-
|
|
PROTACs
Androgen Receptor
|
Cancer
|
|
ARD-2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer.
|
-
- HY-112273
-
|
|
Aurora Kinase
|
Cancer
|
|
CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer.
|
-
- HY-P99639
-
|
APL-501; CBT-501; GB-226
|
PD-1/PD-L1
|
Cancer
|
|
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer.
|
-
- HY-N6002
-
|
|
Apoptosis
Autophagy
|
Cancer
|
|
3'-Hydroxypterostilbene is a Pterostilbene (HY-N0828) analogue. 3'-Hydroxypterostilbene inhibits the growth of COLO 205, HCT-116 and HT-29 cells with IC50s of 9.0, 40.2 and 70.9 µM, respectively. 3'-Hydroxypterostilbene significantly down-regulates PI3K/Akt and MAPKs signaling pathways and effectively inhibits the growth of human colon cancer cells by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene can be used for the research of cancer.
|
-
- HY-120075
-
|
|
Apoptosis
|
Cancer
|
|
TJ191 is a potent and specific anti-cancer agent that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. TJ191 has no affects on the proliferation of other cancer cells or normal fibroblasts or immune cells. TJ191 can be used for cancer research.
|
-
- HY-N12097
-
|
|
Others
|
Cancer
Infection
|
|
Qianhucoumarin D, pyranocoumarin, is a nature product. Qianhucoumarin D can be isolated from the roots of Peucedanum praeruptorum. Qianhucoumarin D can be used for the research of inflammation and cancer.
|
-
- HY-144419
-
|
|
Adenosine Receptor
|
Cancer
|
|
Adenosine receptor antagonist 3 is a potent antagonist of adenosine receptor. Adenosine receptor antagonist 3 has the potential for the research of cancer disease (extracted from patent WO2019233994A1, compound 1).
|
-
- HY-P4978
-
|
|
Checkpoint Kinase (Chk)
|
Cancer
|
|
CBP501 Affinity Peptide is a Chk kinase inhibitor that can abrogate G2 arrest induced by DNA-damaging agents. CBP501 Affinity Peptide can be used in cancer research.
|
-
- HY-156642
-
|
|
Others
|
Cancer
|
|
(1-OH)-Exatecan is a quinoline ring compound. (1-OH)-Exatecan has substantial antiproliferative effects. (1-OH)-Exatecan can be used for cancer diseases research.
|
-
- HY-125378
-
|
SBI-0636457; SB1-0636457
|
IAP
|
Cancer
|
|
SBP-0636457 (SB1-0636457) is a SMAC mimetic, and as an IAP antagonist. SBP-0636457 binds to the BIR-domains of the IAP proteins, with a Ki of 0.27 μM. SBP-0636457 can be used for the research of solid tumors and hematologic cancers.
|
-
- HY-124447
-
|
|
c-Myc
|
Cancer
|
|
BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA (IC50=5 μM). BTYNB exhibits selectivity and effectiveness against IMP1-postive cancer cell lines. BTYNB can be used for cancer research.
|
-
- HY-146033
-
|
|
HPV
|
Cancer
|
|
HPV18-IN-1 (Compound H1) is a potent inhibitor of HPV18. HPV18-IN-1 prevents cervical cancer cells from premature cell procession and abnormal proliferation. HPV18-IN-1 supresses E7-Rb-E2F cellular pathway and DNA methylation. HPV18-IN-1 has the potential for the research of cancer diseases.
|
-
- HY-123872
-
|
|
p97
|
Cancer
|
|
MSC1094308 is a non-competitive and reversible VPS4B/p97 (VCP) (I/II type AAA ATPase) allosteric inhibitor, with IC50 values of 0.71 μM and 7.2 μM for VPS4B and p97, respectively. MSC1094308 inhibits the D2 ATPase activity by binding to a agentable hotspot of p97. MSC1094308 can be used in study of cancer.
|
-
- HY-151471
-
|
|
c-Myc
|
Cancer
|
|
Anticancer agent 84 is an anticancer agent. Anticancer agent 84 represses the transcription of c-MYC by stabilizing the G-quadruplex (G4) structure. Anticancer agent 84 can be used for the research of cancer.
|
-
- HY-137552
-
|
MASTL Kinase Inhibitor-1
|
Others
|
Cancer
|
|
MKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer.
|
-
- HY-143301
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase I inhibitor 4 (compound 7a) is a topoisomerase I inhibitor. Topoisomerase I inhibitor 4 inhibits HepG2, A549, MCF-7 and HeLa cancer cells proliferation with IC50s of 1.20, 2.09, 1.56 and 1.92 μM, respectively. Topoisomerase I inhibitor 4 can be used for the research of cancer.
|
-
- HY-110350
-
|
|
Haspin Kinase
|
Cancer
|
|
CHR-6494 TFA is a potent inhibitor of haspin, with an IC50 of 2 nM. CHR-6494 TFA inhibits histone H3T3 phosphorylation. CHR-6494 TFA induces the apoptosis of cancer cells, including melanoma and breast cancer. CHR-6494 TFA can be used in the research of cancer.
|
-
- HY-N1079
-
|
|
Bacterial
Apoptosis
|
Cancer
Infection
|
|
Vitexilactone is a diterpenoid that can be isolated from the leaves of Vitex negundo L. Vitexilactone shows antimicrobial activity towards E. coli. Vitexilactone induces cell apoptosis and inhibits cell cycle of cancer cells. Vitexilactone can be used for the research of cancer.
|
-
- HY-155174
-
|
|
Akt
|
Cancer
|
|
Antiangiogenic agent 4 (Compound 3b) inhibits Akt phosphorylation in HFF and HUVEC cells. Antiangiogenic agent 4 can be used for cancer research.
|
-
- HY-155392
-
|
|
HDAC
Sirtuin
|
Cancer
|
|
Mz325 is a dual inhibitor of HDAC and Sirt2, with the IC50 of 9.7 μM to Sirt2, that play an important role in pathogenesis of cancer and neurodegeneration.
|
-
- HY-151571
-
|
|
Ras
|
Cancer
|
|
ZG1077 is a covalent KRAS G12C inhibitor. ZG1077 can be used in the research of non-small cell lung cancer (NSCLC).
|
-
- HY-15738
-
GNF-5
3 Publications Verification
|
Bcr-Abl
|
Cancer
|
|
GNF-5, the N-hydroxyethyl carboxamide analog of GNF-2, is an orally active Bcr-Abl inhibitor. GNF-5 has Bcr-Abl inhibition activity with an IC50 value of 0.22 µM. GNF-5 has good favorable pharmacokinetic properties. GNF-5 can be used for the research of kinds of cancer including chronic myelogenous leukemia (CML) and breast cancer.
|
-
- HY-153555
-
|
|
Ras
|
Cancer
|
|
KRAS G12D modulator-1 (compound 6) is a potent KRAS G12D modulator with IC50 values of 1-10 μM for NEA-G12D, PPI-G12D, and p ERK-AGS, respectively. KRAS G12D modulator-1 can be used in research of cancer.
|
-
- HY-P99294
-
|
AMG 479; Human Anti-IGF1R Recombinant Antibody
|
IGF-1R
|
Cancer
|
|
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer.
|
-
- HY-145900
-
|
|
MDM-2/p53
|
Cancer
|
|
S100A2-p53-IN-1 (compound 51) is a S100A2-p53 interactions inhibitor. S100A2 is a Ca 2+ binding protein with implications in cell signaling and is known to be upregulated in pancreatic cancer. S100A2-p53-IN-1 can inhibit the growth of the MiaPaCa-2 pancreatic cancer cell line (GI 50 of 1.2-3.4 μM).
|
-
- HY-108510
-
|
BW 234U dihydrochloride
|
Sigma Receptor
Dopamine Receptor
|
Cancer
Neurological Disease
|
|
Rimcazole (BW 234U) dihydrochloride is a carbazole derivative that acts in part as a sigma (σ) receptor antagonist. Rimcazole dihydrochloride also binds with moderate affinity to the dopamine transporter and inhibit dopamine uptake. Rimcazole dihydrochloride can reduce locomotor activity and sensitization. Rimcazole dihydrochloride also can be used for the research of cancer.
|
-
- HY-152210
-
|
|
Cathepsin
|
Cancer
|
|
ASPER-29 is Asperphenamate HY-129578 analog. ASPER-29 also is a dual cathepsin L and S inhibitor with IC50 value of 6.03 μM and 5.02 μM, respectively. ASPER-29 can be used for the research of the migration and invasion of cancer.
|
-
- HY-151463A
-
|
|
CDK
β-catenin
|
Cancer
|
|
CDK8-IN-11 hydrochloride is a potent and selective CDK8 inhibitor with an IC50 value of 46 nM. CDK8-IN-11 hydrochloride inhibits WNT/β-catenin signaling pathway. CDK8-IN-11 hydrochloride can be used in the research of colon cancer.
|
-
- HY-118331
-
|
PD 124895; CL-1957E
|
Antibiotic
|
Cancer
Infection
|
|
Kazusamycin B is an antibiotic that could be isolated from the fermentation broth of Streptomyces sp. No. 81-484. Kazusamycin B inhibits cell growth and arrests cell cycle at G1 phase. Kazusamycin B can be used in research of cancer.
|
-
- HY-119198
-
|
|
Apoptosis
Histone Methyltransferase
|
Cancer
|
|
NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers.
|
-
- HY-133129
-
MS1943
1 Publications Verification
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
|
MS1943 is a first-in-class, orally bioavailable EZH2 selective degrader, with an IC50 of 120 nM. MS1943 significantly reduces EZH2 protein levels in numerous triple-negative breast cancer (TNBC) and other cancer and noncancerous cell lines. MS1943 effectively blocks proliferation of multiple TNBC and other cancer cell lines.
|
-
- HY-147229
-
|
|
Ras
|
Cancer
|
|
GDC-6036-NH is from patent WO2020097537A2, and a precursor of compound 17 a/b. Compound 17 a/b is a RAS inhibitor and can be used in cancer research.
|
-
- HY-N2415
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Podophyllotoxone is isolated from the roots of Dysosma versipellis and has anti-cancer activities.Podophyllotoxone is able to inhibit the tubulin polymerization.
|
-
- HY-W012732
-
|
|
Others
|
Cancer
|
|
Isoquinoline is an analog of pyridine. Isoquinoline structural-based alkaloids, such as tropoloisoquinoline, phthalideisoquinoline, and naphthylisoquinoline has anti-cancer activities.
|
-
- HY-N0732
-
|
|
Apoptosis
|
Cancer
|
|
Jolkinolide B, a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud, is known to induce apoptosis in cancer cells.
|
-
- HY-P1935
-
-
- HY-144651
-
-
- HY-108882
-
|
DNase
|
Others
|
Cancer
Inflammation/Immunology
|
|
DNase I is an enzyme that degrade DNA, it plays a key role in the cleavage of extracellular DNA is crucial for limiting the inflammatory response and maintaining homeostasis. Exogenous deoxyribonuclease shows beneficial effects in inflammatory diseases and cancer.
|
-
- HY-145803
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
KIF18A-IN-3 is a potent KIF18A inhibitor (IC50=61 nM). KIF18A-IN-3 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-3 can be used for researching cancer.
|
-
- HY-145802
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
KIF18A-IN-2 is a potent KIF18A inhibitor (IC50=28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer.
|
-
- HY-13322
-
|
SB939
|
HDAC
Apoptosis
|
Cancer
|
|
Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC50s of 40-140 nM, used for cancer research. Pracinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM.
|
-
- HY-120901
-
|
|
SHP2
|
Cancer
|
|
II-B08 is a reversible and noncompetitive SHP2 inhibitor (IC50: 5.5 μM, 15.7, 14.3 μM for SHP2, SHP1, PTP1B). II-B08 can be used for cancer research.
|
-
- HY-107967
-
|
|
Fluorescent Dye
|
Cancer
|
|
Isosulfan blue is a blue dye for the identification of lymph vessels during lymphangiography. Isosulfan blueis is used during sentinel lymph node biopsies in breast cancer. Isosulfan blue is possible to have an allergic reaction during breast cancer operations.
|
-
- HY-13892
-
|
CHIR-258 dilactic acid; TKI258 dilactic acid
|
VEGFR
|
Cancer
|
|
Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis.
|
-
- HY-155246
-
|
|
PARP
Apoptosis
|
Cancer
|
|
PARP1-IN-15 (Compound 6) is a PARP1 inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations.
|
-
- HY-15985A
-
|
|
Akt
|
Cancer
Metabolic Disease
Inflammation/Immunology
|
|
CTX-0294885 hydrochloride is a broad spectrum kinase inhibitor that can capture 235 kinases from MDA-MB-231 cells, and can capture all members of the AKT family. CTX-0294885 hydrochloride is a powerful reagent for analysis of kinome signaling networks that can be used for the research of diseases like inflammation, diabetes, and cancer.
|
-
- HY-15985
-
|
|
Akt
|
Cancer
Metabolic Disease
Inflammation/Immunology
|
|
CTX-0294885 is a broad spectrum kinase inhibitor that can capture 235 kinases from MDA-MB-231 cells, and can capture all members of the AKT family. CTX-0294885 is a powerful reagent for analysis of kinome signaling networks that can be used for the research of diseases like inflammation, diabetes, and cancer.
|
-
- HY-155120
-
|
|
E1/E2/E3 Enzyme
|
Cancer
Inflammation/Immunology
|
|
Cbl-b-IN-5 (compound 6) is a Cbl-b inhibitor (IC50=3-10 µM). Cbl-b-IN-5 has the potential to be used in the study of cancer and related diseases amenable to immune system modulation.
|
-
- HY-16967
-
|
|
G-quadruplex
|
Cancer
|
|
MM41 is a potent stabilizer of human telomeric and gene promoter DNA quadruplexes. MM41 is potently against the MIA PaCa-2 pancreatic cancer cell line with IC50 value of <10 nM.
|
-
- HY-P0013
-
|
D-21074; ORF 23541
|
GnRH Receptor
|
Cancer
|
|
Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer.
|
-
- HY-118266
-
BTdCPU
1 Publications Verification
|
Phosphatase
Apoptosis
|
Cancer
|
|
BTdCPU is a potent heme regulated inhibitor kinase (HRI) activator that promotes eIF2α phosphorylation and induces apoptosis in Dexamethasone (HY-14648) (Dex)-resistant cancer cells. BTdCPU can be used in the study of cancers such as multiple myeloma and Dex-resistant multiple myeloma.
|
-
- HY-117426
-
|
|
Others
|
Cancer
|
|
MO-I-500 is a pharmacological of FTO inhibitor with an IC50 of 8.7 μM for the inhibition of purified FTO demethylase catalyzing demethylation of an artificial small methylated substrate. MO-I-500 can be used for the research of rare panresistant triple-negative inflammatory breast cancer.
|
-
- HY-145566
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Envonalkib is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib can be used for the research of non-small cell lung cancer.
|
-
- HY-155115
-
|
|
PD-1/PD-L1
Histone Demethylase
|
Cancer
|
|
LSD1-IN-27 (Compound 5ac) is a LSD1 inhibitor (IC50: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer.
|
-
- HY-P5288
-
|
|
Antibiotic
|
Cancer
Infection
|
|
BMAP-28 is an antibiotic peptide and an inducer of the mitochondrial permeability transition pore. BMAP-28 induces cell death through opening of the mitochondrial permeability transition pore. BMAP-28 can be used in study of microbial infections and cancer.
|
-
- HY-N12003
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
19-Hydroxybaccatin V (compound 14) is a diterpenoid that can be obtained from Taxus chinensis. 19-Hydroxybaccatin V has potential in cancer research.
|
-
- HY-153425
-
|
|
PROTACs
|
Cancer
|
|
PROTAC SMARCA2 degrader-2 is a potent and selective SMARCA2/4 PROTAC degrader with an IC50 of <0.1 μΜ in HeLa HiBiT assay. PROTAC SMARCA2 degrader-2 is extracted from patent WO2023287787A1 and has the potential for SMARCA4-related or deficient cancer research.
|
-
- HY-148109
-
|
|
FAK
|
Cancer
|
|
FAK-IN-7 (compound 5r) is a FAK inhibitor (IC50=11.72 µM). FAK-IN-7 has good anti-proliferative activity and can be used in cancer research.
|
-
- HY-125759
-
|
|
HSP
|
Cancer
|
|
3-Phenyltoxoflavin, a derivative of Toxoflavin, is an Hsp90 inhibitor, with a Kd of 585 nM for the interaction of Hsp90-TPR2A. 3-Phenyltoxoflavin has anti-cancer activity.
|
-
- HY-148324
-
|
|
Pyruvate Kinase
|
Cancer
|
|
PKM2 activator 5 (compound 8) is a PKM2 activator with an AC50 value of 0.316 µM. PKM2 activator 5 has the potential to alter the aberrant metabolism of cancer cells.
|
-
- HY-P9958
-
|
Immunoglobulin G2; Ranmark
|
NF-κB
|
Cancer
|
|
Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of RANKL (TNFSF11). Denosumab can reduce the risk of vertebral, nonvertebral and hip fractures, also has anti-cancer activity.
|
-
- HY-148110
-
|
|
FAK
|
Cancer
|
|
FAK-IN-8 (compound 5h) is a FAK inhibitor (IC50=5.32 µM). FAK-IN-8 has good anti-proliferative activity and can be used in cancer research.
|
-
- HY-13566
-
|
CKD-602 free base
|
Topoisomerase
Apoptosis
|
Cancer
|
|
Belotecan (CKD-602 free base) is a DNA topoisomerase I inhibitor. Belotecan induces cell apoptosis and cell-cycle arrest. Belotecan is a camptothecin analogue with anti-tumor effects, it can be used for the research of cancer.
|
-
- HY-15260C
-
|
BMS-863233 hydrochloride
|
CDK
|
Cancer
|
|
XL413 (BMS-863233) hydrochloride is an orally active and selective CDC7 inhibitor (IC50=3.4 nM). XL413 hydrochloride has favorable pharmacokinetic profiles and significantly inhibits tumor growth in rodent models. XL413 hydrochloride can be used in cancer research.
|
-
- HY-151119
-
|
|
Cytochrome P450
|
Cancer
|
|
Anticancer agent 78 is a potent anticancer agent. Anticancer agent 78 shows cytotoxicity. Anticancer agent 78 exhibits anti-aromatase activity with an IC50 value of 0.9 µM. Anticancer agent 78 has the potential for the research of breast cancer.
|
-
- HY-142283BS
-
|
|
EGFR
|
Cancer
|
|
N-Desmethyl dosimertinib-d5 is the deuterium labeled Dosimertinib (HY-142283). Dosimertinib is a highly potent, selective, and orally active deuterated EGFR inhibiotor. Dosimertinib can be used for the research of non-small-cell lung cancer[1][2].
|
-
- HY-142283CS
-
|
|
EGFR
|
Cancer
|
|
N-Methyl-dosimertinib-d5 is the deuterium labeled of Dosimertinib (HY-142283). Dosimertinib is a highly potent, selective, and orally active deuterated EGFR inhibiotor. Dosimertinib can be used for the research of non-small-cell lung cancer[1][2].
|
-
- HY-146406
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 52 is a potent anticancer agent. Anticancer agent 52 shows in vitro cytotoxicity. Anticancer agent 52 induces apoptosis. Anticancer agent 52 shows antitumor effect. Anticancer agent 52 has the potential for the research of bladder cancer.
|
-
- HY-151474
-
|
|
SARS-CoV
|
Cancer
|
|
SARS-CoV-2-IN-31 is an effective COVID-19 inhibitor. SARS-CoV-2-IN-31 exhibits excellent to mild activity against various cancer cell lines with IC50 values range from 28.84 to 38.36 μM. SARS-CoV-2-IN-31 can be used for the research of cancer.
|
-
- HY-152168
-
|
|
PERK
Phosphatase
|
Cancer
|
|
NSC 295642 is a phosphatase inhibitor. NSC 295642 can significantly increase phospho-Erk cytonuclear differences in intact cells. NSC 295642 can be used for the research of cancer.
|
-
- HY-147574
-
|
|
TAM Receptor
|
Cancer
Inflammation/Immunology
Cardiovascular Disease
|
|
Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used for Axl-related diseases research, for example cancers (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors), renal disease, immune system disorders, and cardiovascular disease.
|
-
- HY-N3448
-
|
|
Others
|
Cancer
|
|
Isowigtheone is a cytotoxic isoflavone compound isolated from the root barks of Brosimum utile. Isowigtheone has the potential for the research of cancer diseases.
|
-
- HY-P0237
-
|
|
Kallikrein
|
Cancer
|
|
KKI-5 is a specific inhibitor of tissue kallikrein. KKI-5 can attenuate breast cancer cell invasion.
|
-
- HY-P99484
-
|
AGEN 1181
|
CTLA-4
|
Cancer
|
|
Botensilimab (AGEN 1181), a humanized anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer.
|
-
- HY-N5091
-
|
|
Others
|
Cancer
Inflammation/Immunology
|
|
Physcion 8-O-β-D-glucopyranosideis an anthraquinone compound isolated from Rumex japonicus Houtt. Physcion 8-O-β-D-glucopyranoside exerts anti-inflammatory and anti-cancer properties, can be for common malignancy cancer research.
|
-
- HY-151624
-
|
|
PARP
Apoptosis
|
Cancer
|
|
PARP-2-IN-2 (compound 27) is a PARP‑2 inhibitor with an IC50 value of 0.057 µM. PARP-2-IN-2 induces cell cycle arrest and apoptosis of MCF-7 breast cancer cells. PARP-2-IN-2 can be used for the research of cancer.
|
-
- HY-148381
-
|
|
Epigenetic Reader Domain
PROTACs
Apoptosis
|
Cancer
|
|
A947 is a potent and selective SMARCA2 proteolysis-targeting chimera molecule (PROTAC). A947 also is a potent and moderately selective SMARCA2 degrader. A947 has binding affinity to the SMARCA2 bromodomain with a Kd value of 93 nM. A947 can be used for the research of cancer.
|
-
- HY-150650
-
|
|
Others
|
Cancer
|
|
S07-2001 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 2.08 μM. S07-2001 enhances the activity of Doxorubicin against cancer cells. S07-2001 has potential as a chemotherapeutic potentiator for cancer agent resistance.
|
-
- HY-116501
-
|
|
Androgen Receptor
|
Cancer
|
|
VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer.
|
-
- HY-143466
-
|
|
FAK
ULK
AMPK
Apoptosis
Autophagy
|
Cancer
|
|
ULK1-IN-2 (compound 3s) is a potent ULK1 inhibitor. ULK1-IN-2 shows highest cytotoxic effect against cancer cell lines, with IC50 of 1.94 μM in A549. ULK1-IN-2 can induce apoptosis and simultaneously block autophagy, and can be used to study NSCLC (Non-small cell lung cancer).
|
-
- HY-149394
-
|
|
ROS Kinase
Apoptosis
|
Cancer
|
|
PRDX1-IN-1 is a selective inhibtor of PRDX1 with an IC50 value of 0.164 μM. PRDX1-IN-1 can be used in researches related to cancer.PRDX1-IN-1 promots intracellular ROS accumulation, and inhibits the proliferation, invasion and migration of cancer cells besides inducing apoptosis. PRDX1-IN-1 could be used in cancer research.
|
-
- HY-155040
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Antitumor agent-106 (compound 42) is an anticancer agent that exhibits good inhibitory activity (IC50=4.2-6.6 µM) against both lung cancer and colon cancer cell lines.
|
-
- HY-12442
-
|
|
STAT
Apoptosis
|
Cancer
|
|
LY5 is a STAT3 inhibitor with an IC50 value of 0.5 μM. LY5 induces apoptosis and inhibits STAT3 phosphorylation. LY5 shows antitumor activity in vivo, it can be used for the research of cancer.
|
-
- HY-151905
-
|
|
c-Met/HGFR
|
Cancer
|
|
D6808 is a highly selective and potent c‑Met inhibitor with an IC50 value of 2.9 nM. D6808 induces cell apoptosis and cell cycle arrest. D6808 can be used for the research of NSCLC and gastric cancers.
|
-
- HY-N10952
-
|
|
Others
|
Cancer
|
|
Epicornuin F is a prenylated flavonoid. Epicornuin F can be isolated from the leaves of Epimedium brevicornu. Epicornuin F has the cytotoxic activity against HepG2 cells with an IC50 value of 33.4 μM. Epicornuin F can be used for the research of cancer.
|
-
- HY-N2558
-
|
|
Others
|
Cancer
|
|
Murrayone, a coumarin-containing compound extracted from M. paniculata, is the most bioactive substance in this species and is a cancer metastasis chemopreventive agent based on its unique pharmacological properties.
|
-
- HY-W751152
-
|
|
Others
|
Cancer
|
|
α,β-Thujone is a component of the essential oils of some plants. α,β-Thujone causes cancers in male rats and induces seizures in the highest doses.
|
-
- HY-149529
-
|
|
HDAC
|
Cancer
|
|
HDAC8-IN-5 (Compound 6a) is a HDAC8 inhibitor (IC50: 28 nM). HDAC8-IN-5 can be used for cancer research.
|
-
- HY-12358
-
|
|
MAP3K
p38 MAPK
MAPKAPK2 (MK2)
|
Cancer
Inflammation/Immunology
|
|
Tpl2 Kinase Inhibitor 1 is a 3-pyridylmethylamino analog, and is a selective Tpl2 inhibitor (IC50=50 nM). Tpl2 consists of COT kinase and MAP3K8. Tpl2 Kinase Inhibitor 1 plays an important role in the regulation of the inflammatory response and the progression of some cancers.
|
-
- HY-P4992
-
|
|
Somatostatin Receptor
|
Cancer
|
|
Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11) is a somatostatin agonist that can be used in cancer research.
|
-
- HY-148261
-
|
|
Ras
|
Cancer
|
|
KRAS G12C inhibitor 56 (compound IC-6) is a potent SOS1 inhibitor with an IC50 of 1.6 nM. KRAS G12C inhibitor 56 can be used in cancer research.
|
-
- HY-124676A
-
|
|
Apoptosis
|
Cancer
|
|
DB2115 (tertahydrochloride) is a potent inhibitor of myeloid master regulator PU.1. DB2115 (tertahydrochloride) has the potential for researching cancers, including hematologic cancers such as leukemia, as well as other conditions associated with PU. 1 dysfunction (extracted from patent WO2017223260A1, compound DB2115) .
|
-
- HY-145566A
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Envonalkib citrate is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib citrate can be used for the research of non-small cell lung cancer.
|
-
- HY-155109
-
|
|
STING
|
Cancer
Inflammation/Immunology
|
|
Antitumor agent-114 is a potent stimulator of interferon genes (STING) agonist. Antitumor agent-114 activates immunity and reduces tumor volume in a mouse model of breast cancer. Antitumor agent-114 can be used for immunity and cancer diseases research.
|
-
- HY-122886
-
|
|
Deubiquitinase
|
Cancer
|
|
XL 188 is a potent and selective USP7 inhibitor with IC50 values of 90 nM and 193 nM for USP7 full-length and catalytic domain enzyme, respectively. XL 188 can be used in research of cancer.
|
-
- HY-P99675
-
|
AK112
|
PD-1/PD-L1
VEGFR
|
Cancer
|
|
Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research.
|
-
- HY-114250
-
|
TRX-E-002-1
|
Apoptosis
|
Cancer
|
|
Cantrixil (TRX-E-002-1), an active enantiomer of TRX-E-002, is a second-generation super-benzopyran (SBP) compound. Cantrixil increases phosphorylated c-Jun levels resulting in caspase-mediated apoptosis in ovarian cancer cells. Cantrixil has potent pan anti-cancer activity against a broad range of cancer phenotypes.
|
-
- HY-100399
-
|
PD-132301; ATR-101
|
Acyltransferase
Apoptosis
|
Cancer
|
|
Nevanimibe (PD-132301) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe induces cell apoptosis and has the potential for adrenocortical cancer.
|
-
- HY-110139
-
|
|
Others
|
Cancer
|
|
Procaspase-IN-5 is a human DNA polymerase λ inhibitor. Procaspase-IN-5 has DNA polymerization function and TdT function with an IC50 value of 5.9 μM and 4.5 μM, respectively. Procaspase-IN-5 can be used for the research of cancer.
|
-
- HY-P99734
-
|
ADCT-601
|
TAM Receptor
|
Cancer
|
|
Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers.
|
-
- HY-142743
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
Y08175 is a potent CBP bromodomain inhibitor. Y08175 exhibits considerable inhibitory effect with IC50s of 37 and 178.15 nM against CBP bromodomain in AlphaScreen assay and HTRF assay, respectively. Y08175 can be used for the research of prostate cancer.
|
-
- HY-100399A
-
|
PD-132301 hydrochloride; ATR101 hydrochloride
|
Acyltransferase
Apoptosis
|
Cancer
|
|
Nevanimibe hydrochloride (PD-132301 hydrochloride) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe hydrochloride inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe hydrochloride induces cell apoptosis and has the potential for adrenocortical cancer.
|
-
- HY-N2420
-
|
|
Apoptosis
|
Cancer
|
|
Flavokawain A, a proming anticarcinogenic agent, is a chalcone from kava extract with anti-tumor activity. Flavokawain A induces cell apoptosis by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway. Flavokawain A has the potential for the study of bladder cancer.
|
-
- HY-148225
-
|
|
Others
|
Cancer
|
|
Fulvestrant 3-β-D-Glucuronide, a metabolite, is glucuronide and sulfate conjugates of Fulvestrant (HY-13636), a pure anti-estrogenic steroid. Fulvestrant 3-β-D-Glucuronide can be used for the research of breast cancer.
|
-
- HY-148836
-
|
|
c-Myc
|
Cancer
Infection
Cardiovascular Disease
|
|
c-Myc inhibitor 6 (compound A102) is a c-Myc inhibitor. c-Myc inhibitor 6 decreases cancer cell viability and degrades c-Myc protein. c-Myc inhibitor 6 can be used for the research of c-Myc imbalance, such as cancer, cardiovascular diseases, and viral infection.
|
-
- HY-138298A
-
|
DS-8201; DS-8201a
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
|
-
- HY-151999
-
|
|
Ras
|
Cancer
|
|
KRASG12C IN-1 is a potent and covalent KRAS G12C inhibitor that traps KRAS G12C in the GDP-bound state. KRASG12C IN-1 exhibits potent antitumor activity against KRAS-mutant non-small cell lung cancer.
|
-
- HY-143713
-
|
|
Aurora Kinase
|
Cancer
|
|
Aurora A inhibitor 1 is a potent and selective inhibitor of Aurora A. Aurora A has been implicated in cancers of diverse histological origin and may possess oncogenic properties when overexpressed. Aurora A inhibitor 1 has the potential for the research of cancer diseases mediated by aurora a (extracted from patent WO2021147974A1, compound 49).
|
-
- HY-156574
-
|
|
DGK
|
Cancer
|
|
DGKζ-IN-4 is a DGK-zeta inhibitor. DGKζ-IN-4 can be used as an active component of pharmaceutical compositions. DGKζ-IN-4 is used to treat cancers associated with immune cell activation or cancers resistant to anti-PD-1 antibody/anti-PD-11 antibody treatment.
|
-
- HY-155102
-
|
|
PROTACs
Glutaminase
|
Cancer
|
|
PROTAC TG2 degrader-2 (compound 7) is a selective, competitive degrader targeting Transglutaminase 2 (TG2), with Kd > 100 μM. PROTAC TG2 degrader-2 inhibits the cell migration and decreases the level of TG2 in ovarian cancer cells. PROTAC TG2 degrader-2 can be used for ovarian cancer study.
|
-
- HY-152195
-
|
|
Apoptosis
|
Cancer
|
|
ChoKα inhibitor-5 is a sulphur-containing choline kinase inhibitor. ChoKα inhibitor-5 can inhibit HChoK α1 with an IC50 value of 0.64 μM. ChoKα inhibitor-5 also can induce apoptosis. ChoKα inhibitor-5 can be used for the research of cancer.
|
-
- HY-152191
-
|
|
Apoptosis
|
Cancer
|
|
ChoKα inhibitor-3 is a sulphur-containing choline kinase inhibitor. ChoKα inhibitor-3 can inhibit HChoK α1 with an IC50 value of 0.66 μM. ChoKα inhibitor-3 also can induce apoptosis. ChoKα inhibitor-3 can be used for the research of cancer.
|
-
- HY-151270
-
|
|
TGF-β Receptor
|
Cancer
|
|
ALK5-IN-25 (compound EX-02) is a potent ALK-5 inhibitor with an IC50 ≤10 nM.ALK5-IN-25 also inhibits ALK-2 (selectivity ALK2/ALK5≤10). ALK5-IN-25 can be used for the research of cancer.
|
-
- HY-145709
-
|
|
Androgen Receptor
|
Cancer
|
|
Ar-V7-IN-1 is a potent inhibitor of Ar-V7. AR-V7 is a hormone-independent splice variant of the androgen receptor. Ar-V7-IN-1 has the potential for the research of various indications, in particular cancers such as prostate cancer (extracted from patent WO2018114781A1, compound 43).
|
-
- HY-146983
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAII-IN-3 (compound 7e) is a potent and selective inhibitor of carbonic anhydrase (CA II/IX) with Kis of 124.2 and 30.5 nM, respectively. hCAII-IN-3 has the potential for the research of cancer diseases.
|
-
- HY-145918
-
|
|
Smo
|
Cancer
|
|
MRT-14 is a potent antagonist of Smo. Smo is the major component involved in signal transduction of the Hedgehog (Hh) morphogens. MRT-14 has the potential for the research of several types of cancers linked to abnormal Hh signaling.
|
-
- HY-146982
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAII-IN-1 (compound 7f) is a potent and selective inhibitor of carbonic anhydrase (CA II/IX) with Kis of 1.2 and 113.6 nM, respectively. hCAII-IN-1 has the potential for the research of cancer diseases.
|
-
- HY-154862
-
|
|
Apoptosis
|
Cancer
Infection
|
|
Anticancer agent 119 (compound 15) is an N-acylated ciprofloxacin derivative, which has certain antibacterial activity and induces ROS production to promote cancer cell apoptosis.
|
-
- HY-P4998
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Chemotactic Domain of Elastin is an elastin-derived peptide with chemotactic effects on certain tumor cells, such as M27 tumor cells. Chemotactic Domain of Elastin can be used in cancer research.
|
-
- HY-153662
-
|
|
Ras
|
Cancer
|
|
TH-Z816 is a reversible inhibitor againstKRAS(G12D)mutation with an IC50 value of 14 μM, which can be used in cancer research.
|
-
- HY-151264
-
|
|
STING
|
Cancer
|
|
BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 can selectively stimulate the STING pathway. BSP16 can be used for the research of cancer.
|
-
- HY-151115
-
|
|
Others
|
Cancer
Inflammation/Immunology
|
|
JNJ-1289 is a potent, selective, competitive and allosteric human spermine oxidase (hSMOX) inhibitor (IC50: 50 nM). JNJ-1289 can be used in the research of polyamine catabolism, inflammation and cancers.
|
-
- HY-110266
-
GN44028
4 Publications Verification
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
GN44028 is a potent and orally active hypoxia inducible factor (HIF)-1α inhibitor, with an IC50 of 14 nM. GN44028 inhibits hypoxia-induced HIF-1α transcriptional activity without suppressing HIF-1α mRNA expression, HIF-1α protein accumulation, or HIF-1α/HIF-1β heterodimerization. GN44028 can be used in the research of cancers.
|
-
- HY-156549
-
|
|
ERK
Ras
|
Cancer
|
|
KRAS G12C inhibitor 61 (Example 3) inhibits phospho-ERK 1/2 in MIA PaCa-2 cells with an IC50 value of 9 nM. KRAS G12C inhibitor 61 can be used for research of pancreatic, colorectal, and lung cancers.
|
-
- HY-P99030
-
|
|
EGFR
|
Cancer
|
|
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer.
|
-
- HY-118837
-
|
|
ROCK
|
Cancer
|
|
WF-536 is an orally active inhibitor of Rho-associated coiled-coil-containing protein kinase (ROCK). WF-536 has tumor anti-metastatic activity. WF-536 can be used for the research of cancer.
|
-
- HY-151904
-
|
|
TAM Receptor
FLT3
PDGFR
|
Cancer
|
|
AXL-IN-13 is a potent and orally active AXL inhibitor (IC50: 1.6 nM, Kd: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion.
|
-
- HY-N3059
-
-
- HY-153226
-
-
- HY-P0237A
-
|
|
Kallikrein
|
Cancer
|
|
KKI-5 (TFA) is a specific inhibitor of tissue kallikrein. KKI-5 (TFA) can attenuate breast cancer cell invasion.
|
-
- HY-156077
-
|
|
Apoptosis
|
Cancer
|
|
anti-TNBC agent-2 (3j) an anti-Triple negative breast cancer (TNBC) purine derivative. anti-TNBC agent-2 induces MDA-MB-231 cells apoptosis, and inhibits its migration and angiogenesis. anti-TNBC agent-2 inhibits tumor growth and metastasis and reduces the expression of Ki67 and CD31 protein in TNBC xenograft models. anti-TNBC agent-2 can be used for Triple negative breast cancer (TNBC) research.
|
-
- HY-134259
-
|
|
Others
|
Cancer
|
|
MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer.
|
-
- HY-156579
-
|
|
Others
|
Cancer
|
|
WRN inhibitor 3 (example 110), a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 3 can be used for the research of cancer.
|
-
- HY-156580
-
|
|
Others
|
Cancer
|
|
WRN inhibitor 4 (example 107), a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 4 can be used for the research of cancer.
|
-
- HY-156581
-
|
|
Others
|
Cancer
|
|
WRN inhibitor 5 (example 157), a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 5 can be used for the research of cancer.
|
-
- HY-160068
-
|
|
EGFR
|
Cancer
|
|
2-2(t) aptamer sodium is a 42-nucleotide trimeric complex of aptamer (2-2) targeting ErbB-2. 2-2(t) aptamer sodium inhibits the growth of gastric cancer cells in vitro and in vivo.
|
-
- HY-141551
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
GNE-274 is a non-degrader that is structurally related to GDC-0927 (ER degrader). GNE-274 does not induce ER turnover and functions as a partial ER agonist in breast cancer cell lines. GNE-274 increase chromatin accessibility at ER-DNA binding sites, while GDC-0927 do not. GNE-274 is a potent inhibitor of ER-ligand binding domain (LBD). GNE-274 can be used for cancer research.
|
-
- HY-115957
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 19 (compound 9b) is a potent inhibitor of tubulin. Tubulin inhibitor 19 is an indole chalcone compound. Tubulin inhibitor 19 has the potential for the research of cancer diseases.
|
-
- HY-124292
-
|
Honokiol dichloroacetate
|
Androgen Receptor
|
Cancer
|
|
Honokiol DCA (Honokiol dichloroacetate) is a dichloroacetate analog of Honokiol. Honokiol DCA can inhibit the growth of human prostate cancer cells in vitro and suppress the androgen receptor (AR) protein level.
|
-
- HY-128436
-
|
|
HDAC
|
Cancer
|
|
KT-531 is a potent and selective inhibitor of HDAC6 with an IC50 of 8.5 nM. KT-531 exhibits strong inhibition against SUP-T11 cells with an IC50 of 0.42 μM. KT-531 can be used in study hematological cancers.
|
-
- HY-149631
-
|
|
HDAC
|
Cancer
|
|
HFY-4A is a HDAC inhibitor. HFY-4A inhibits breast cancer cell proliferation, migration, and invasion, and induces cell apoptosis. HFY-4A induces immunogenic cell death (ICD). HFY-4A inhibits tumor growth in breast cancer xenograft mouse models.
|
-
- HY-146213
-
|
|
CDK
|
Cancer
|
|
CDK4/6-IN-12 is a potent cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. CDK4/6-IN-12 has enzymatic inhibitory activity for CDK4 and CDK6 with IC50 of 592.3 nM and 3090 nM, respectively. CDK4/6-IN-12 can be used for the research of cancer.
|
-
- HY-P99386
-
|
MNRP-1685A
|
Complement System
|
Cancer
|
|
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer.
|
-
- HY-P99715
-
|
ABT-806
|
EGFR
|
Cancer
|
|
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers.
|
-
- HY-139434
-
|
|
Histone Demethylase
|
Cancer
|
|
JMJD6-IN-1 (Compound 1-3) is a JMJD6 inhibitor, with an inhibition rate of 82% at 10 μM. JMJD6-IN-1 inhibits MCF-7 and HCC4006 cell proliferation with IC50s of 19.2 μM and 25.2 μM. JMJD6-IN-1 can be used for research of cancers.
|
-
- HY-D1456
-
|
|
Pyruvate Kinase
|
Cancer
|
|
TEPC466 is a novel TEPP-46-based aggregation-induced emission (AIE) probe. TEPC466 shows a high degree of selectivity and sensitivity for the detection of PKM2 protein via the AIE effect. EPC466 can be used for the detection of PKM2. TEPC466 is successfully applied in imaging the PKM2 protein in colorectal cancer cells with low toxicity. TEPC466 is a useful tool for cancer diagnosis and research.
|
-
- HY-143546
-
|
|
RET
|
Cancer
|
|
RET-IN-9 is a potent inhibitor of RET. RET kinase is a single-pass transmembrane receptor tyrosine kinase that plays an important role in the development of the kidney and enteric nervous system, and the maintenance of homeostasis in the nervous, endocrine, hematopoietic, and male reproductive systems. RET-IN-9 has the potential for the research of RET-related disease including non-small cell lung cancer and medullary thyroid cancer (extracted from patent WO2021115457A1, compound 29).
|
-
- HY-N11600
-
|
|
Apoptosis
|
Cancer
|
|
β-Apopicropodophyllin is a nature product that could be isolated from Hyptis wticillata.β-Apopicropodophyllin induces apoptosis by inducing microtubule disruption, DNA damage, cell cycle arrest and ER stress. β-Apopicropodophyllin can be used in research of cancer.
|
-
- HY-151589
-
|
|
Virus Protease
|
Cancer
Infection
|
|
HCVcc-IN-2 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor and antiviral activity. HCVcc-IN-2 has high inhibition against the three cell line from CNS cancer (SF-539 and SNB-75), colon cancer (HCT-116), and renal cancer (A498).
|
-
- HY-107430
-
|
Hydroxythiamin
|
Apoptosis
Endogenous Metabolite
|
Cancer
|
|
Oxythiamine (Hydroxythiamin), an analogue of anti-metabolite, can suppress the non-oxidative synthesis of ribose and induce cell apoptosis. Oxythiamine is a thiamine antagonist and inhibits transketolase (TK). Oxythiamine inhibits cancer cell apoptosis and inhibits cell proliferation.
|
-
- HY-107430A
-
|
Hydroxythiamine chloride hydrochloride
|
Apoptosis
Endogenous Metabolite
|
Cancer
|
|
Oxythiamine (Hydroxythiamine) chloride hydrochloride, an analogue of anti-metabolite, can suppress the non-oxidative synthesis of ribose and induce cell apoptosis. Oxythiamine chloride hydrochloride is a thiamine antagonist and inhibits transketolase (TK). Oxythiamine chloride hydrochloride inhibits cancer cell apoptosis and inhibits cell proliferation.
|
-
- HY-136910
-
|
|
Deubiquitinase
|
Cancer
|
|
USP7-IN-7 (compound 124) is a USP7 inhibitor with an IC50 value ＜10 nM. USP7-IN-7 shows cytotoxicity against p53-mutant cancer cell lines, p53 wild-type blood cancer and neuroblastoma cell lines with low nanomolar values. USP7-IN-7 can be used for cancer research.
|
-
- HY-W145499
-
-
- HY-124909A
-
|
|
Others
|
Cancer
|
|
FR054 is an inhibitor of the HBP enzyme PGM3, with a remarkable anti-breast cancer effect.
|
-
- HY-N2080
-
|
|
GABA Receptor
|
Cancer
|
|
Songorine is a diterpenoid alkaloid isolated from the genus Aconitum. Songorine is a GABAA receptor antagonist in rat brain and has anti cancer, antiarrhythmic and anti-inflammatory activities. Songorine has the potential for the treatment of Epithelial ovarian cancer (EOC).
|
-
- HY-147565
-
|
|
ATM/ATR
|
Cancer
|
|
ATR-IN-13 (compound A9) is a potent ATR kinase inhibitor, with an IC50 of 2 nM. ATR-IN-13 can be used for ATR kinase mediated diseases research, such as proliferative diseases and cancer.
|
-
- HY-N9161
-
|
|
Others
|
Cancer
|
|
Echitoveniline, a monoterpenoid indole alkaloid, can be isolated from Alstonia mairei. Echitoveniline has no significant cytotoxicity against cancer cells (IC50: > 40 μM).
|
-
- HY-111299
-
|
|
Apoptosis
|
Cancer
|
|
Psammaplysene A, a brominated tyrosine derivative, can promote the nuclear localization of FOXO1, leading to cell cycle arrest and apoptosis, and can be used in cancer research.
|
-
- HY-129273
-
|
|
Farnesyl Transferase
|
Cancer
|
|
L-731735 is a selective FPTase inhibitor that can inhibit ras-dependent cell transformation. L-731735 can be used in cancer research.
|
-
- HY-133490A
-
|
|
Apoptosis
|
Cancer
|
|
ST1074 is a dual CerS2/CerS4 inhibitor that induces apoptosis. ST1074 can be used in cancer research.
|
-
- HY-P99911
-
-
- HY-137331
-
|
|
FAP
|
Cancer
|
|
FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation. FAPI-46 can be used for tumor imaging of a multitude of different cancers.
|
-
- HY-144824
-
|
|
Cytochrome P450
Monoamine Oxidase
|
Cancer
Neurological Disease
|
|
Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a highly potent monoamine oxidase (MAO) and aromatase dual inhibitor with IC50s of 39 nM and 31 nM for MAO-B and aromatase, respectively. Monoamine oxidase/Aromatase-IN-1 can be used for researching neurological disorder and breast cancer.
|
-
- HY-143436
-
|
|
Others
|
Cancer
|
|
TNIK-IN-4 is a potent TNIK inhibitor with IC50 of 0.61 μM. TNIK-IN-4 has inhibitory activity against typical colorectal cancer cell line HCT116.
|
-
- HY-110245
-
|
VU364849
|
Apoptosis
|
Cancer
|
|
DMH2 is a potent BMP receptor antagonist. DMH2 downregulates the expression of Id1 and Id3 proteins, and inhibits the proliferation and induces cell death of lung cancer cell lines.
|
-
- HY-151288
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor with an IC50 value of <0.01 μM. KRAS inhibitor-21 can be used in cancer research.
|
-
- HY-118982
-
|
|
Reactive Oxygen Species
|
Cancer
|
|
CT-2584 is a chemotherapeutic compound that reduces the expression of NKEF-B in several tumor cell types and kills tumor cells by inducing the production of ROS in mitochondria, commonly used in cancer research.
|
-
- HY-P99275
-
|
Human Anti-ERBB3 Recombinant Antibody
|
EGFR
Akt
ERK
PARP
Survivin
|
Cancer
|
|
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.
|
-
- HY-18614
-
|
|
Notch
γ-secretase
|
Cancer
|
|
LY900009 is a potent and orally active, First-in-class inhibitor of Notch signaling via selective inhibition of the γ-secretase protein (GSI). LY900009 inhibited Notch signalling in tumor cell lines and endothelial cells (IC50 range: 0.005-20 nM). LY900009 can be used for advanced cancer research.
|
-
- HY-134417
-
|
|
Others
|
Cancer
|
|
NSC2805 is a WWP2 ubiquitin ligase inhibitor that can significant inhibit WWP2 activity with an IC50 of 0.38 μM. NSC2805 can be used for the research of cancer.
|
-
- HY-138269
-
-
- HY-151533
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
PBRM1-BD2-IN-6 is a potent PBRM1 bromodomain inhibitor with an IC50 value of 0.22 µM. PBRM1-BD2-IN-6 shows antiproliferation activity. PBRM1-BD2-IN-6 has the potential for the research of PBRM1-dependent cancer.
|
-
- HY-P5290
-
|
|
PSMA
|
Cancer
|
|
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research.
|
-
- HY-142160
-
|
|
Raf
|
Cancer
|
|
GNE-9815 (compound 7) is a highly selective, pan-RAF inhibitor with good oral bioavailability. GNE-9815 exhibits Ki values of 0.062 and 0.19 nM for CRAF and BRAF, respectively. GNE-9815 combines with MEK inhibitor Cobimetinib (HY-13064) shows synergistic modulation of MAPK pathway. GNE-9815 can be used in studies of KRAS mutant cancers.
|
-
- HY-151361
-
|
|
AMPK
|
Cancer
|
|
AMPK-IN-3 (compound 67) is a potent and selective AMPK inhibitor with IC50s of 60.7, 107 and 3820 nM for AMPK (α2), AMPK (α1) and KDR, respectively. AMPK-IN-3 inhibits AMPK does not affect cell viability or cause significant cytotoxicity in K562 cells. AMPK-IN-3 can be used in study of cancer.
|
-
- HY-144321
-
|
|
Trk Receptor
|
Cancer
|
|
Trk-IN-9 (Compound 12) is a potent inhibitor of TRK. Trk-IN-9 inhibits the proliferation of Km-12 cell lines. Trk-IN-9 induces the apoptosis of Km-12 cells in a concentration-dependent manner. Trk-IN-9 inhibits the phosphorylation of TRK to block downstream pathways. Trk-IN-9 has the potential for the research of NTRK-fusion cancers.
|
-
- HY-150505
-
|
|
Deubiquitinase
Apoptosis
|
Cancer
|
|
DC-U4106 is a USP8 targeting inhibitor with the Kdvalue of 4.7 μM and the IC50 value of 1.2 μM. DC-U4106 can target the ubiquitin pathway and facilitate the degradation of Erα. DC-U4106 inhibits tumor growth with minimal toxicity and has the potential for the research of breast cancer.
|
-
- HY-107999
-
CADD522
1 Publications Verification
|
Reactive Oxygen Species
|
Cancer
|
|
CADD522 is a RUNX2-DNA binding inhibitor (downregulates RUNX2-mediated transcription of downstream target genes), with an IC50 of 10 nM. CADD522 inhibits primary tumor growth and experimental metastasis of tumor cells in the lungs of immune-compromised mice. CADD522 can be used in study of cancer.
|
-
- HY-154313
-
|
Clospirazine
|
Ras
|
Cancer
|
|
Spiclomazine (Clospirazine) is a potent mutant KRAS(G12C) inhibitor that selectively inhibits mutant KRAS-driven pancreatic cancer. Spiclomazine can eliminate KRas-GTP levels in KRAS-driven pancreatic cancer and effectively inhibit RAS-mediated signaling. Spiclomazine significantly inhibits tumor progression in mouse renal capsule xenotransplantation models.
|
-
- HY-P3229
-
SN52
1 Publications Verification
|
NF-κB
|
Cancer
|
|
SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research.
|
-
- HY-N7695
-
|
|
Apoptosis
Autophagy
|
Cancer
|
|
Physalin B, one of the major active steroidal constituents of Cape gooseberry, induces cell cycle arrest and triggers apoptosis in breast cancer cells through modulating p53-dependent apoptotic pathway. Physalin B inhibits the ubiquitin-proteasome pathway and induces incomplete autophagic response in human colon cancer cells in vitro.
|
-
- HY-145341
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
GNE-149 is an orally bioavailable full antagonist of estrogen receptor α (ERα; IC50=0.053 nM). GNE-149 is a selective estrogen receptor degrader (SERD). GNE-149 can be used for the research of breast cancer.
|
-
- HY-148242A
-
|
|
Others
|
Cancer
|
|
BAY-252 is a potent branched-chain amino acid transaminases 1 (BCAT1) and BCAT2 inhibitor with IC50s of 2 μM and 2 μM, respectively. BAY-069 also can be used as a chemical probe. BAY-069 can be used for the research of cancer.
|
-
- HY-145311
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Bis-Pro-5FU (Compound 4) is a 5-FU precursor that confers oral bioavailability and increase the safety profile of 5-Fluorouracil (5-FU) chemotherapy regimens. 5-FU is an antineoplastic antimetabolite that is widely used for the research of colorectal and pancreatic cancer.
|
-
- HY-113825
-
|
|
CDK
|
Cancer
|
|
CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC50 values of 16 nM and 45 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities[1] .
|
-
- HY-N1219
-
|
(-)-Stephanine; l-Stephanine
|
Apoptosis
Parasite
|
Cancer
Infection
Inflammation/Immunology
|
|
Stephanine ((-)-Stephanine) is an isoquinoline aporphine-type alkaloid. Stephanine induce apoptosis through the reverse of mitotic exit. Stephanine exhibits Antiplasmodial activity. Stephanine can be used for the research of stomach pain, abdominal pain, arthritis and cancer.
|
-
- HY-108524
-
-
- HY-77113
-
|
|
Raf
|
Cancer
|
|
B-Raf IN 11 (ZINC72115182) is a selective B-Raf V600E inhibitor (IC50=76 nM), shows selectivity for B-Raf V600E over B-Raf WT with selectivity of 3.1-fold. B-Raf IN 11 can be used in colorectal cancer research
|
-
- HY-163041
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-36 (Compound 2k) is a PD-1/PD-L1 complex inhibitor (IC50: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy.
|
-
- HY-19893
-
|
(+)-Antroquinonol
|
Keap1-Nrf2
|
Cancer
Inflammation/Immunology
|
|
Antroquinonol ((+)-Antroquinonol), a ubiquinone derivative from the mushroom Antrodia camphorata, has hepatoprotective, anti-inflammatory, and anti-cancer effects. Antroquinonol can be used for the research of colon cancer. Antroquinonol reduces oxidative stress by enhancing the Nrf2 signaling pathway and inhibits inflammation and sclerosis in focal segmental glomerulosclerosis mice.
|
-
- HY-151588
-
|
|
Virus Protease
|
Cancer
|
|
Anticancer agent 90 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor activity. Anticancer agent 90 has high inhibition against the two cell line from ovarian cancer (OVCAR-4), renal cancer (A498).
|
-
- HY-139662
-
|
|
E1/E2/E3 Enzyme
|
Cancer
|
|
HB007 is a small ubiquitin-related modifier 1 (SUMO1) degrader. HB007 induces ubiquitination and degradation of SUMO1, resulting in reduced tumor growth in vivo. HB007 can be used for the research of brain, breast, colon, and lung cancers.
|
-
- HY-59001
-
|
|
Apoptosis
|
Cancer
|
|
Sappanchalcone, a flavonoid isolated from Caesalpinia sappan L., induces caspase-dependent and AIF-dependent apoptosis in human colon cancer cells.
|
-
- HY-16477
-
|
ME2906; Mono-L-aspartyl chlorin e6; NPe6
|
Others
|
Cancer
|
|
Talaporfin (ME2906) sodium is a chlorin based photosensitizer. Talaporfin sodium can be used for the research of various cancers by using photodynamic therapy (PDT).
|
-
- HY-148105
-
|
|
MNK
|
Cancer
|
|
DS12881479 is a potent and selective Mnk1 inhibitor with an IC50 value of 21 nM. DS12881479 can be used in cancer research.
|
-
- HY-119108
-
|
BOF-A2
|
Others
|
Cancer
|
|
Emitefur is an orally active and potent anticancer drug. Emitefur can be used for advanced gastric cancer patients.
|
-
- HY-P99802
-
|
BAY 2010112; AMG 212
|
CD3
|
Cancer
|
|
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).
|
-
- HY-143429
-
|
|
CDK
|
Cancer
|
|
Cdc7-IN-15 (Example 108) is a cdc7 kinase inhibitor. Cdc7-IN-15 can be used for cancer research.
|
-
- HY-145868
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin polymerization-IN-3 (compound 4c) is a potent tubulin polymerization inhibitor, with an IC50 of 3.84 µM. Tubulin polymerization-IN-3 can induce apoptosis in colon cancer cells.
|
-
- HY-138794
-
|
|
Deubiquitinase
|
Cancer
|
|
XL177A is a highly potent and selective irreversible USP7 inhibitor with an IC50 of 0.34 nM. XL177A elicits cancer cell killing through a p53-dependent mechanism.
|
-
- HY-111209
-
|
S14161
|
PI3K
|
Cancer
|
|
Pichromene (S14161) is an anticancer agent and weak PI3K inhibitor. Pichromene can effectively inhibit tumor growth in leukemia mouse models and can be used in cancer research.
|
-
- HY-16498
-
|
PCK-3145
|
Apoptosis
|
Cancer
|
|
Tigapotide (PCK-3145) is an anti-tumour peptide that reduces the development of skeletal metastases associated with prostate cancer. Tigapotide induces apoptosis and reduces tumour parathyroid hormone-related peptide (PTHrP) levels.
|
-
- HY-156577
-
|
|
DGK
|
Cancer
|
|
DGKα-IN-7 is a DGKα inhibitor with the IC50 of 6.225 nM, extracted from patent WO2022271684 (compound 100). DGKα-IN-7 has the potential for cancer study.
|
-
- HY-N7924
-
|
|
Others
|
Cancer
Inflammation/Immunology
|
|
Astragenol is an intermediate used for Astragenol derivative synthesis. Astragenol derivatives are promising anti-inflammatory agents for prostate cancer research.
|
-
- HY-148574
-
|
|
Monocarboxylate Transporter
P-glycoprotein
|
Cancer
|
|
MCT1-IN-3 is a monocarboxylate transporter 1 (MCT1) inhibitor with an IC50 value of 81.0 nM. MCT1-IN-3 has also significant inhibitivity against the multidrug transporter ABCB1. MCT1-IN-3 can be used for the research of cancer.
|
-
- HY-149076
-
|
|
Others
|
Cancer
|
|
hGAPDH-IN-1, a 3-bromo-4,5-dihydroisoxazole derivative, is a specific and potent hGAPDH covalent inhibitor. hGAPDH-IN-1 reduces cancer cell growth in different pancreatic cancer cell lines.
|
-
- HY-122197
-
|
|
Apelin Receptor (APJ)
CXCR
|
Cancer
|
|
ML339 is a potent and selective CXCR6 (IC50 of 140 nM) antagonist that is selective (IC50 >79 μM) against CXCR5, CXCR4, CCR6 and Apelin receptor (APJ). ML339 holds potential to advance the field of prostate cancer research.
|
-
- HY-144656
-
|
|
Others
|
Cancer
|
|
Steroid sulfatase-IN-1 is a potent and orally active Steroid sulfatase inhibitor with an IC50 of 1.71 µM. Steroid sulfatase-IN-1 shows antitumor activity (TGI=51%) in vivo. Steroid sulfatase-IN-1 has the potential for the research of breast cancer.
|
-
- HY-151587
-
|
|
Others
|
Cancer
|
|
Anticancer agent 89 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor activity, has high inhibition against the three cell line from ovarian cancer (OVCAR-4), renal cancer (A498), and melanoma (SK-MEL-5).
|
-
- HY-138298
-
|
DS-8201 (solution); DS-8201a (solution)
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
|
-
- HY-138843
-
-
- HY-155610
-
|
|
VEGFR
|
Cancer
|
|
VEGFR-2-IN-32 (Comp 3a) is an inhibitor of VEGFR-2 with an IC50 of 8.93 nM. VEGFR-2-IN-32 has cytotoxic activity against PC-3 cells with an IC50 of 1.22 μM. VEGFR-2-IN-32 can be used for anti-prostate cancer research.
|
-
- HY-147185
-
|
|
Histone Methyltransferase
|
Cancer
|
|
PRMT7-IN-1 (Compound 14) is a PRMT7 inhibitor with an IC50 of 2.1 μM. PRMT7-IN-1 shows anticancer activity against different cancer cells.
|
-
- HY-153764
-
-
- HY-149976
-
|
|
Pim
|
Cancer
|
|
Pim-1 kinase inhibitor 4 (Compound 10f) is a Pim-1 kinase inhibitor (IC50: 17.01 nM). Pim-1 kinase inhibitor 4 also has antioxidant activity and inhibits DPPH. Pim-1 kinase inhibitor 4 induces apoptosis in PC-3 cell, and inhibits PC-3 cell growth with an IC50 of 16 nM. Pim-1 kinase inhibitor 4 can be used for research of prostate cancer.
|
-
- HY-122552
-
|
|
Integrin
|
Cancer
|
|
Chrysotobibenzyl can be isolated from stem of Dendrobium pulchellum. Chrysotobibenzyl inhibits lung cancer cell (H460 and H292) migration, invasion, filopodia formation via Cav-1, integrins β1, β3, and αν, and EMT suppressions. Chrysotobibenzyl also sensitizes lung cancer cell death mediated by Cisplatin (HY-17394).
|
-
- HY-145388B
-
|
|
Others
|
Cancer
|
|
AU-16235 is an inactive epimer of AU-15330. AU-16235 has no effect on cancer cell survival and growth
|
-
- HY-N3999
-
|
ESK246
|
Others
|
Cancer
|
|
Venuloside A is a potent inhibitor of LAT3. Venuloside A inhibits the leucine uptake in LNCaP prostate cancer cells with an IC50 of 8.12 μM.
|
-
- HY-156716
-
|
|
Others
|
Cancer
|
|
MASTL-IN-2 is an MASTL (microtubule-associated serine/threonine kinase-like) inhibitor. MASTL-IN-2 inhibits human epithelial MIA PaCa cancer cell proliferation with IC50 of 2.8 nM.
|
-
- HY-N0819
-
|
|
Apoptosis
|
Cancer
|
|
Raddeanin A is a natural triterpenoid saponin component of Anemone raddeana, with anti-cancer activities. Raddeanin A exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway.
|
-
- HY-10025
-
|
|
Apoptosis
|
Cancer
|
|
(S)-SW IV-52 hydrochloride is a small molecule that can induce apoptosis in ovarian cancer. (S)-SW IV-52 hydrochloride has minimal single-agent activity at concentrations up to 200 μM.
|
-
- HY-149625
-
|
|
Bcl-2 Family
|
Cancer
|
|
Bcl-2-IN-15 (Compound 13d)) is a Bcl-2 inhibitor (IC50: 363 nM). Bcl-2-IN-15 inhibits the proliferation ofNCI leukemia cancer cell line.
|
-
- HY-135124
-
|
|
ADC Cytotoxin
|
Cancer
|
|
DC44SMe, a phosphate proagent of cytotoxic DNA alkylator DC44, can be used in the synthesis of antibody-drug conjugate (ADC). DC44SMe exhibits IC50s of 2.0 nM, 2.8 nM, and 1.9 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively. DC44SMe can be used for the targeted treatment of cancer.
|
-
- HY-135123
-
|
|
ADC Cytotoxin
|
Cancer
|
|
DC4SMe, a phosphate proagent of cytotoxic DNA alkylator DC4, can be used in the synthesis of antibody-drug conjugate (ADC). DC4SMe exhibits IC50s of 1.9 nM, 2.9 nM, and 1.8 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively. DC4SMe can be used for the targeted treatment of cancer.
|
-
- HY-152536
-
|
|
NO Synthase
|
Cancer
|
|
iNOS inhibitor-10 is an iNOS inhibitor (IC50: 65 nM). iNOS inhibitor-10 has antiproliferative effect against triple negative breast cancer cells.
|
-
- HY-153051
-
|
|
Others
|
Cancer
|
|
Antitumor agent-90 has cytotoxicity against PC 14 cell and MKN 45 cell. Antitumor agent-90 can be used for cancer research.
|
-
- HY-109081
-
|
E7727
|
Others
|
Cancer
|
|
Cedazuridine (E7727) (Compound 7a) is an orally active cytidine deaminase (CDA) inhibitor with an IC50 value of 0.4 μM. Cedazuridine can be used for cancer research.
|
-
- HY-109081A
-
|
E7727 hydrochloride
|
Others
|
Cancer
|
|
Cedazuridine (E7727) (Compound 7a) hydrochloride is an orally active cytidine deaminase (CDA) inhibitor with an IC50 value of 0.4 μM. Cedazuridine hydrochloride can be used for cancer research.
|
-
- HY-146552
-
|
|
PDHK
|
Cancer
Metabolic Disease
|
|
PDHK-IN-4 (Compound 30) is a potent inhibitor of PDHK with IC50s of 0.0051 and 0.0122 μM for PDHK2 and PDHK4, repectively. Pyruvate dehydrogenase kinases (PDHKs) are fascinating agent targets for numerous diseases, including diabetes and cancers. PDHK-IN-4 has the potential for the research of cancer diseases.
|
-
- HY-113638
-
|
GS-456332
|
Stearoyl-CoA Desaturase (SCD)
Apoptosis
|
Cancer
|
|
CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer.
|
-
- HY-156820
-
|
|
Others
|
Cancer
|
|
HLDA-221 is a heterobifunctional small molecules called Regulated Induced Proximity Targeting Chimeras (RIPTACs). HLDA-221 elicits a stable ternary complex between a target protein selectively expressed in cancer tissue and a pan-expressed protein essential for cell survival, thus leading to cell death selectively in cells expressing the target protein.
|
-
- HY-156706
-
|
|
JAK
|
Cancer
|
|
JAK-IN-31 (Example 75) is a JAK inhibitor with IC50 ranges of ≤0.01µM, ≤0.01µM, 0.01-0.1 µM and ≤0.01µM for JAK1, JAK2, JAK3 and Tyk2 respectively. JAK-IN-31 can be used in cancer research.
|
-
- HY-157212
-
|
|
Proteasome
PARP
Apoptosis
|
Cancer
|
|
PARP-1/Proteasome-IN-1 (compound 42i) is a dual PARP-1 and proteasome inhibitor with significant inhibitory effects on breast cancer. PARP-1/Proteasome-IN-1 can downregulate the expression of BRCA1 and RAD51 to inhibit homologous recombination repair function and induce apoptosis.
|
-
- HY-15456
-
|
|
c-Met/HGFR
|
Cancer
|
|
NVP-BVU972 is an selective and potent Met inhibitor, with an IC50 of 14 nM. NVP-BVU972 also exhibits good anti-proliferative activity against Met with drug-resistant mutations and inhibits phosphorylation. NVP-BVU972 can be used in study of cancer.
|
-
- HY-105173
-
|
EP 24332
|
GnRH Receptor
Histamine Receptor
|
Cancer
Endocrinology
|
|
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer.
|
-
- HY-19599
-
|
(+)-Vorozole; R83842
|
Cytochrome P450
|
Cancer
|
|
Vorozole is a potent and selective, orally active non-steroidal aromatase inhibitor. Vorozole shows antitumor activity in vivo. Vorozole has the potential for the research of mammary cancer.
|
-
- HY-147785
-
|
|
Pim
Apoptosis
|
Cancer
|
|
Pim-1 kinase inhibitor 2 (Compound 13) is a potent inhibitor of Pim-1 kinase. Pim-1 kinase inhibitor 2 induces apoptosis. Pim-1 kinase inhibitor 2 has the potential for the research of cancer diseases.
|
-
- HY-N0735
-
|
|
Autophagy
|
Cancer
|
|
Phellodendrine chloride is a plant alkaloid found in Phellodendron amurense. Phellodendrine chloride suppresses the proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis . Phellodendrine chloride promotes autophagy by regulating the AMPK/mTOR pathway and reduce the intestinal damage of ulcerative colitis.
|
-
- HY-P4979
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Cdc25A (80-93) (human) is a polypeptide that controls the cell proliferation and tumorigenesis by a change in expression of proteins involved in cyclin D1 regulation and G1/S transition. Cdc25A (80-93) (human) can be used in cancer research.
|
-
- HY-113670
-
|
|
CDK
|
Cancer
|
|
CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC50 values of 1.1 nM and 2.4 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities[1] .
|
-
- HY-18935
-
|
Curaxin 137; CBL-C137
|
Histone Acetyltransferase
MDM-2/p53
NF-κB
|
Cancer
|
|
CBL0137, a curaxin compound, is a histone chaperone facilitates chromatin transcription (FACT) inhibitor. CBL0137 downregulates NF-?B and activates p53. CBL0137 restores both histone H3 acetylation and trimethylation. CBL0137 is an anticancer agent. CBL0137 induces cancer cell apoptosis.
|
-
- HY-122650
-
|
|
Autophagy
|
Cancer
|
|
PHY34 is an inhibitor that inhibits ATP6V0A2 and CAS thereby inhibiting autophagy, and has a nanomolar effect. PHY34 inhibits cancer cell growth by inducing apoptosis and inhibits tumor growth in xenograft models. PHY34 can be used for research on high grade serous ovarian cancer.
|
-
- HY-143253
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
Estrogen receptor antagonist 7 (compound 13) is a potent estrogen receptors (ER) antagonist. Estrogen receptor antagonist 7 has antiproliferative activity against breast and ovarian cancer cells. Anticancer and anti-uterotrophic activities.
|
-
- HY-149877
-
|
|
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
|
Cancer
|
|
hDHODH-IN-12 is a potent DHODH inhibitor with an IC50 value of 0.421 μM. DHODH is the rate-limiting enzyme in the de novo synthesis of pyrimidine which is essential in DNA/RNA Synthesis. hDHODH-IN-12 is present in the inner membrane of human mitochondria.hDHODH-IN-12 can be used for the research of lung cancer.
|
-
- HY-149407
-
|
|
VEGFR
CDK
EGFR
Necroptosis
Apoptosis
|
Cancer
|
|
Multi-kinase-IN-4 (compound 5d) is multi-targeted kinase inhibitor, including VEGFR2, EGFR, HER2, and CDK2, with IC50 values of 0.33, 0.22, 0.18 and 2.09 μM, respectively. Multi-kinase-IN-4 shows broad-spectrum anti-cancer activities against HepG2, MCF-7, MDA-231, and HeLa cell lines (IC50 = 1.94–7.1 µM), but exhibits lower toxicity in the WI-38 cells (IC50 = 40.85 µM). Multi-kinase-IN-4 induces apoptosis and arrests cell cycle at S phase in HepG2 cells. Multi-kinase-IN-4 has the potential for the research of cancer.
|
-
- HY-129156
-
|
|
Apoptosis
|
Cancer
|
|
HS-1793 is a Resveratrol (HY-16561) analogue with antitumor activities in a variety of cancer cell lines. HS-1793 induces cell apoptosis.
|
-
- HY-143587
-
|
|
CDK
|
Cancer
|
|
CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1).
|
-
- HY-118480
-
|
|
Lipoxygenase
Apoptosis
|
Cancer
|
|
4-MMPB is a selective inhibitor of 15-lipoxygenase, with an IC50 of 18 μM. 4-MMPB has IC50s of 19.5 μM and 19.1 μM for soybean 15-lipoxygenase (SLO) and human 15-lipoxygenase-1 (15-LOX-1), respectively. 4-MMPB has potential for the research of prostate cancer.
|
-
- HY-112447
-
|
|
STAT
|
Cancer
|
|
STAT3-IN-5 is a potent STAT3 inhibitor. STAT3-IN-5 inhibits STAT3-Y705 phosphorylation with an EC50 value of 170 nM. STAT3-IN-5 inhibits cytokine induced JAK activation. STAT3-IN-5 induces apoptosis. STAT3-IN-5 can be used in research of cancer.
|
-
- HY-N0988
-
|
|
Others
|
Cancer
|
|
1β,4β,7α-Trihydroxyeudesmane (compound 4) is a nature product that could be isolated from the rhizomes of Homalomena occulta. 1β,4β,7α-Trihydroxyeudesmane has antiproliferative active. 1β,4β,7α-Trihydroxyeudesmane can be used in research of cancer.
|
-
- HY-148243
-
|
STL5-T-0057
|
Aldehyde Dehydrogenase (ALDH)
|
Cancer
|
|
IGUANA-1 free base (STL5-T-0057) is an selective ALDH1 B1 inhibitor with an IC50 value of 30 nM. IGUANA-1 free base inhibits cell growth of SW480 cells in adherent and spheroid conditions with IC50 values of 2.46 and 0.39 μM, respectively. IGUANA-1 free base can be used for the research of cancer.
|
-
- HY-149952
-
|
|
ATM/ATR
|
Cancer
|
|
ATR-IN-23 (Compound 34) is a potent and selective ATR inhibitor with an IC50 of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers.
|
-
- HY-118203
-
|
|
FGFR
PDGFR
Insulin Receptor
|
Cancer
|
|
SU4984 is a protein tyrosine kinase inhibitor, with an IC50 of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer.
|
-
- HY-16079
-
AZD3514
2 Publications Verification
|
Androgen Receptor
|
Cancer
|
|
AZD3514 is an orally activie and selective androgen receptor (AR) inhibitor. AZD3514 androgen-dependently and -independently inhibits AR signal. AZD351 down-regulates nuclear AR levels in human LNCaP prostate cancer cells in the absence of androgen with an pIC50 value of 5.75. AZD3514 can be used for the research of prostate cancer.
|
-
- HY-155522
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
WES-1 (Compound 8g) is an inhibitor of carbonic anhydrase IX (Ki: 55.9 μM). WES-1 has broad spectrum anti-proliferative activity against the cancer cells, such as leukemia (K-562 and MOLT-4), non-small cell lung cancer (NCI–H460), colon cancer (HCT 116 and HCT-15) and melanoma (LOX IMVI) cell lines.
|
-
- HY-145953
-
|
|
Others
|
Cancer
|
|
VY-3-135 is a potent, orally active, and stable ACSS2 inhibitor with an IC50 value of 44 nM. VY-3-135 is specific to ACSS2 among the AcCoA synthetase family of enzymes. VY-3-135 does not inhibit ACSS1 or ACSS3 enzymatic activity. VY-3-135 can be used for the research of breast cancer.
|
-
- HY-151289
-
|
|
TGF-β Receptor
TGF-beta/Smad
|
Cancer
|
|
ALK5-IN-34 is an selective orally active activin receptor-like kinase (ALK) inhibitor. ALK5-IN-34 can inhibit the activity of ALK5-IN-34 with an IC50 value of ≤10 nM. ALK5-IN-34 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer.
|
-
- HY-132817
-
|
ICP-192
|
FGFR
|
Cancer
|
|
Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer. Gunagratinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-115604
-
|
|
Apoptosis
|
Cancer
|
|
Pitstop 2 is a clathrin inhibitor which inhibits clathrin-mediated endocytosis (CME) by associating with the terminal domain of clathrin. Pitstop 2 has the potential for anti-cancer research.
|
-
- HY-124830
-
|
|
Others
|
Cancer
|
|
SPA70 is a potent and selective antagonist of human pregnane X receptor (hPXR), with an IC50 of 540 nM (Ki=390 nM). SPA70 can enhance the chemosensitivity of cancer cells.
|
-
- HY-142820
-
|
|
Raf
|
Cancer
|
|
B-Raf IN 5 (compound 3b) is a potent inhibitor of protein kinase B-Raf with an IC50 of 2.0 nM. B-Raf IN 5 is devoid of binding to the secondary target PXR and resists rapid metabolism. B-Raf IN 6 has the potential for the research of cancer disease.
|
-
- HY-142830
-
|
|
Raf
|
Cancer
|
|
B-Raf IN 6 (compound 2c) is a potent inhibitor of protein kinase B-Raf with an IC50 of 1.7 nM. B-Raf IN 6 is devoid of binding to the secondary target PXR and resists rapid metabolism. B-Raf IN 6 has the potential for the research of cancer disease.
|
-
- HY-141601
-
|
ABBV-399
|
Antibody-Drug Conjugates (ADCs)
c-Met/HGFR
|
Cancer
|
|
Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used in cancer research.
|
-
- HY-108713A
-
|
SHR1020 malate
|
VEGFR
PDGFR
Apoptosis
|
Cancer
|
|
Famitinib (SHR1020) malate, an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib malate induces cell apoptosis. Famitinib malate exerts powerful antitumor activity in human gastric cancer cells and xenografts, it can be used for the research of cancer.
|
-
- HY-146022
-
|
|
PROTACs
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
SIAIS117 is a potent Brigatinib-PROTAC degrader. SIAIS117 is a ALK PROTAC based on Brigatinib and VHL-1 conjunction. SIAIS117 can degrade ALK G1202R point mutation effectively. SIAIS117 blocks the growth of SR and H2228 cancer cell lines. SIAIS117 has the potentially anti-proliferation ability of small cell lung cancer.
|
-
- HY-P9902
-
|
MK-3475; Lambrolizumab
|
PD-1/PD-L1
|
Cancer
|
|
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
|
-
- HY-133223
-
|
|
Others
|
Cancer
|
|
Hispidanin B is a natural product that can be extracted from the rhizomes of Isodon hispida. Hispidanin B has cytotoxic activities against cancer cells.
|
-
- HY-P4138
-
|
|
Fluorescent Dye
|
Cancer
|
|
Antennapedia Peptide FAM-labeled is a fluorophore labeled peptide. Antennapedia Peptide FAM-labeled also can be used for the research of cancer as a molecular probe.
|
-
- HY-N0671
-
|
Rhaponiticin
|
Apoptosis
|
Cancer
|
|
Rhapontin (Rhaponiticin), a component of rhubarb (Rheum officinale Baill), induces apoptosis resulting in suppression of proliferation of human stomach cancer KATO III cells.
|
-
- HY-138843A
-
-
- HY-156556
-
|
|
c-Fms
|
Cancer
Inflammation/Immunology
|
|
c-Fms-IN-14 (Example 76) is a c-Fms inhibitor with an IC50 value of 4 nM. c-Fms-IN-14 can be used for research of cancer and autoimmune diseases.
|
-
- HY-111424A
-
|
|
Others
|
Cancer
|
|
(R)-BDP9066 is a potent inhibitor of myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK). (R)-BDP9066 blocks cancer cell invasion. (R)-BDP9066 has the potential for the research of proliferative diseases, such as cancer.
|
-
- HY-W040118
-
|
|
Lactate Dehydrogenase
|
Cancer
|
|
Galloflavin is a potent lactate dehydrogenase (LDH) inhibitor. The calculated Kis for pyruvate are 5.46 µM (LDH-A) and 15.06 µM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production.
|
-
- HY-19527
-
|
N6-Benzyladenosine-5'-phosphate
|
STAT
Apoptosis
|
Cancer
|
|
IST5-002, a potent Stat5a/b inhibitor, selectively inhibits transcriptional activity of Stat5a/b (IC50s: 1.5 μM for Stat5a, 3.5 μM for Stat5b). IST5-002 inducs cell apoptotic and death of prostate cancer cells and chronic myeloid leukemia (CML) cells. IST5-002 can be used in the research of prostate cancer and chronic myeloid leukemia (CML).
|
-
- HY-17438
-
|
GS 0504; HPMPC; (S)-HPMPC
|
CMV
Apoptosis
DNA/RNA Synthesis
Orthopoxvirus
Endogenous Metabolite
|
Infection
Cancer
|
|
Cidofovir (GS 0504) is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase. Cidofovir induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer. Cidofovir also has anti-orthopoxvirus and anti-variola activities.
|
-
- HY-108433
-
|
Carnitine palmitoyltransferase 2
|
Apoptosis
MDM-2/p53
|
Cancer
Metabolic Disease
|
|
CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research.
|
-
- HY-150586
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
PTG-0861 is a selective histone deacetylase 6 (HDAC6) inhibitor with the IC50 value of 5.92 nM. PTG-0861 induces apoptosis and can be used in the study of acute myeloid leukemia, multiple myeloma and other hematological cancers.
|
-
- HY-146494
-
|
|
Androgen Receptor
|
Cancer
|
|
Androgen receptor antagonist 5 (compound 42f) is a potent androgen receptor (AR) antagonist with an IC50 value of 6.17 μM. Androgen receptor antagonist 5 can effectively impair AR nuclear translocation, reducing the levels of nuclear AR, and disrupts AR-mediated gene regulation. Androgen receptor antagonist 5 has antiproliferative activity against LNCaP and exhibits antitumor activity in LNCaP xenograft tumor mice model. Androgen receptor antagonist 5 can be used for researching prostate cancer.
|
-
- HY-108932A
-
|
Gemcitabine 5′-phosphate disodium
|
Apoptosis
|
Cancer
|
|
Gemcitabine monophosphate (Gemcitabine 5′-phosphate) disodium can be used to synthesis nanoparticles. Gemcitabine monophosphate disodium is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate disodium can be used for bladder cancer research.
|
-
- HY-155964
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 153 (Compound 3) induces apoptosis by Reactive Oxygen Species generation. Anticancer agent 153 increases the loss of mitochondrial membrane potential (MMP) levels. Anticancer agent 153 inhibits cancer cell proliferation.
|
-
- HY-P3717
-
|
|
Ephrin Receptor
|
Cancer
|
|
Targefrin is a potent EphA2-targeting agent, acts as an antagonist. Targefrin binds EphA2-LBD with 21 nM dissociation constant and an IC50 value of 10.8 nM. Targefrin induces cellular receptor internalization and degradation in several pancreatic cancer cell lines.
|
-
- HY-137397
-
|
8-OH-EFV
|
Apoptosis
JNK
|
Cancer
|
|
8-Hydroxyefavirenz (8-OH-EFV) is a primary metabolite of Efavirenz (HY-10572). 8-Hydroxyefavirenz induces apoptosis via a JNK- and BimEL-dependent mechanism in primary human hepatocytes. 8-Hydroxyefavirenz can be used in research of cancer. 8-Hydroxyefavirenz is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-145293
-
|
|
DAPK
|
Cancer
|
|
TNIK-IN-3 is a potent, selective and orally active inhibitor of Traf2- and Nck-interacting protein kinase (TNIK), with an IC50 of 0.026 μM. TNIK-IN-3 could also inhibit Flt4 (IC50=0.030 μM), Flt1 (IC50=0.191 μM) and DRAK1 (IC50=0.411 μM). TNIK-IN-3 can be used for the research of colorectal cancer.
|
-
- HY-124007
-
|
ISAHA
|
HDAC
|
Cancer
|
|
4-Iodo-SAHA (1k) is an orally active class I and class II histone deacetylase (HDAC) inhibitor with EC50s of 1.1, 0.95, 0.12, 0.24, 0.85 and 1.3 μM for Skbr3, HT29, U937, JA16 and HL60 cell lines, respectively. 4-Iodo-SAHA (1k) can be used for the research of cancer.
|
-
- HY-146074
-
|
|
Others
|
Cancer
|
|
RUVBL1/2 ATPase-IN-1 (compound 18) is a potent and selective inhibitor of RUVBL1/2 ATPase with IC50 values of 6.0 and 7.7 μM, respectively. RUVBL1 and RUVBL2 are highly conserved AAA ATPases (ATPases Associated with various cellular Activities) and highly relevant to the progression of cancer. RUVBL1/2 ATPase-IN-1 has the potential for the research of cancer diseases.
|
-
- HY-148764
-
|
|
Apoptosis
|
Cancer
|
|
M47 is a small molecule that selectively destabilizes Cryptochrome 1 (CRY1) and increases degradation of the CRY1 in the nucleus. M47 enhances apoptosis in Ras-transformed P53-deficient mouse skin fibroblast lines and enhances life span in p53 knockout mice. M47 can be used in research of cancer.
|
-
- HY-156328
-
|
|
Apoptosis
|
Cancer
|
|
NSC 48160 inhibits the growth of the pancreatic cancer cells with IC50s of 84.3 μM for CPFAC-1 and 94.5 μM for BxPC-3. NSC 48160 also induces pancreatic cancer cell apoptosis. NSC 48160 can improve metabolic syndromes, such as NASH, obesity and lipid metabolism disorders.
|
-
- HY-139300
-
|
HMPL-813
|
EGFR
|
Cancer
|
|
Epitinib is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib can be used for the research of cancer. Epitinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-118798
-
|
NSC663285
|
Phosphatase
|
Cancer
|
|
DA 3003-2 is a potent and selectively Cdc25 inhibitor. DA 3003-2 shows antiproliferative activity. DA 3003-2 induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr 15 Cdc2. DA 3003-2 has the potential for the research of prostate cancer.
|
-
- HY-152292
-
|
NVL-520
|
ROS Kinase
|
Cancer
|
|
Zidesamtinib (NVL-520) is a potent, selective, orally active and brain-penetrant inhibitor of diverse ROS1 fusions and resistance mutations, with IC50s of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and spares TRK inhibition. Zidesamtinib can be used for the research of cancer.
|
-
- HY-146670
-
|
|
Histone Demethylase
|
Cancer
|
|
KDM5B-IN-3 (Compound 5) is a histone lysine specific demethylase 5B (KDM5B/JARID1B) inhibitor with an IC50 of 9.32 μM. KDM5B-IN-3 can be used for the research of gastric cancer.
|
-
- HY-15772A
-
|
AZD-9291 mesylate; Mereletinib mesylate
|
EGFR
|
Cancer
|
|
Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
|
-
- HY-N11416
-
-
- HY-100199
-
|
|
Others
|
Cancer
|
|
HUHS015 is a potent prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitor with an IC50 of 0.67μM for PCA-1.
|
-
- HY-15453
-
|
CPI-613
|
Apoptosis
Mitochondrial Metabolism
|
Cancer
|
|
Devimistat (CPI-613) is a mitochondrial metabolism inhibitor. Devimistat is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
|
-
- HY-146310
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin polymerization-IN-15 (compound 4) is a potent inhibitor of tubulin polymerization. Tubulin polymerization-IN-15 has the potential for the research of cancer diseases.
|
-
- HY-103656
-
|
TPP; Tetraphenylporphine; meso-Tetraphenylporphyrin
|
Others
|
Cancer
|
|
Tetraphenylporphyrin (TPP) is a symmetrically substituted porphyrin-based heterocyclic compound and used as a structural block for supramolecular synthesis. Tetraphenylporphyrin derivatives can be used for cancer research.
|
-
- HY-N1121
-
|
|
Others
|
Cancer
|
|
Triptonodiol can be isolated from Trypterygium wilfordii. Triptonodiol has anti-inflammatory and anti-cancer activity. Triptonodiol inhibits the biological activity of GSK.
|
-
- HY-148559
-
|
|
Others
|
Cancer
|
|
4A3-SC8 is a modular degradable dendrimer that enables small RNAs to extend survival in an aggressive liver cancer model.
|
-
- HY-134955
-
VT103
1 Publications Verification
|
YAP
|
Cancer
|
|
VT103, an analog of VT101, is an orally active and selective TEAD1 protein palmitoylation inhibitor. VT103 inhibits YAP/TAZ-TEAD promoted gene transcription, blocks TEAD auto-palmitoylation, and disrupts interaction between YAP/TAZ and TEAD. VT103 can be used for the research of cancer.
|
-
- HY-W010482S
-
|
|
Isotope-Labeled Compounds
|
Cancer
|
|
3-Ethylaniline-d5 is the deuterium labeled 3-Ethylaniline (HY-W010482). 3-Ethylaniline is metabolized in vivo to electrophilic intermediates that covalently bind to DNA and that adducts are formed in the DNA of bladder. 3-Ethylaniline can be used for the research of bladder cancer[1][2].
|
-
- HY-148070
-
|
|
FLT3
FAK
Cytochrome P450
|
Cancer
|
|
FLT3-IN-17 inhibits CYPs and FLT3 mutants activity (IC50s: <0.5 nM for D835Y). FLT3-IN-17 is also a FAK inhibitor, with an IC50 value of 12 nM. FLT3 ligand-2 can be used in the research of cancers.
|
-
- HY-115888
-
|
|
Others
|
Cancer
|
|
MIF2-IN-1 (compound 5d) is a potent inhibitor of MIF2 tautomerase with an IC50 of 1.0 μM. MIF2-IN-1 suppresses the proliferation of non-small cell lung cancer cells by the induction of cell cycle arrest via deactivation of the MAPK pathway. MIF2-IN-1 has the potential for the research of cancer diseases.
|
-
- HY-152266
-
|
|
E1/E2/E3 Enzyme
|
Cancer
|
|
Ubiquitination-IN-2 is a potent E1-E2 protein−protein interactions (PPI) inhibitor. Ubiquitination-IN-2 has a Kd value of 0.72 μM for ubiquitin E1 (Uba1). Ubiquitination-IN-2 inhibits blocks ubiquitin transfer from E1 to E2. Ubiquitination-IN-2 can be used in research of cancer.
|
-
- HY-135125
-
|
|
ADC Cytotoxin
|
Cancer
|
|
DC4, an ADC cytotoxin, can be used in the synthesis of antibody-drug conjugate (ADC). DC4 can be used for the targeted treatment of cancer.
|
-
- HY-P99048
-
|
IBI308
|
PD-1/PD-L1
|
Cancer
Inflammation/Immunology
|
|
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer.
|
-
- HY-146673
-
|
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
IDO1/TDO-IN-2 (Compound 1) is a potent inhibitor of IDO1/TDO with IC50s of 0.1 and 0.07 μM. IDO1/TDO-IN-2 has the potential for the research of cancer diseases.
|
-
- HY-153640
-
|
|
Akt
|
Cancer
|
|
AKT-IN-14 (Example 2) is a potent AKTinhibitor with the IC50 values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. AKT-IN-14 can be used in cancer research.
|
-
- HY-151259
-
|
|
JAK
|
Cancer
|
|
TK4b is a Janus kinase (JAK) inhibitor with the IC50 values of 19.40 nM and 18.42 nM for JAK2 and JAK3, respectively. TK4b can be used in lymphoid-derived diseases and leukemia cancer research.
|
-
- HY-156452
-
|
|
VEGFR
|
Cancer
|
|
T-1-MCPAB is a VEGFR-2 inhibitor (IC50=0.135 µM) that effectively inhibits MCF7 migration. T-1-MCPAB can be used in cancer research.
|
-
- HY-156681
-
|
|
PI3K
|
Cancer
|
|
STX-478 (compound 80) is an oral CNS-penetrant allosteric mutant-selective PI3Kα inhibitor. STX-478 shows robust and durable tumor regression and can be used in cancer research.
|
-
- HY-151258
-
|
|
JAK
|
Cancer
|
|
TK4g is a Janus kinase (JAK) inhibitor with the IC50 values of 12.61 nM and 15.80 nM for JAK2 and JAK3, respectively. TK4g can be used in lymphoid-derived diseases and leukemia cancer research.
|
-
- HY-157042
-
|
|
MAGL
|
Cancer
Inflammation/Immunology
|
|
MAGL-IN-11 (compound 29) is a selective and reversible MAGL inhibitor. MAGL-IN-11 has the potential to study inflammation, cancer and antioxidants.
|
-
- HY-136699
-
|
|
Others
|
Cancer
|
|
Excisanin A is a potent anticancer agent. Excisanin A inhibits cell proliferation, migration, adhesion and invasion. Excisanin A decreases the expression of MMP-2, MMP-9, p-FAK, p-Src, integrin β1 protein. Excisanin A has the potential for the research of breast cancer.
|
-
- HY-N0718
-
-
- HY-50733A
-
|
|
Apoptosis
Ras
Casein Kinase
|
Cancer
|
|
CX-5011 is a CK2 inhibitor. CX-5011 also induces Rac1 activation. CX-5011 induces apoptosis and induces cancer cell death.
|
-
- HY-151409
-
|
|
CDK
|
Cancer
|
|
CDK1-IN-5 (10h) is a selective CDK1 inhibitor with IC50s of 42.19, 188.71 and 354.15 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-5 inhibits growth of cancer cells by affecting cell cycle. CDK1-IN-5 can be used for the research of cancer.
|
-
- HY-151407
-
|
|
CDK
|
Cancer
|
|
CDK1-IN-3 (8g) is a selective CDK1 inhibitor with IC50s of 36.8, 305.17 and 369.37 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-3 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-3 can be used for the research of cancer.
|
-
- HY-147259
-
|
|
c-Met/HGFR
|
Cancer
|
|
Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC50: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC).
|
-
- HY-151408
-
|
|
CDK
|
Cancer
|
|
CDK1-IN-4 (10d) is a selective CDK1 inhibitor with IC50s of 44.52, 624.93 and 135.22 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN4 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-4 can be used for the research of cancer.
|
-
- HY-17602
-
|
BBI503
|
Others
|
Cancer
|
|
Amcasertib (BBI503) is an orally active and small-molecule multi-kinase inhibitor. Amcasertib exhibits inhibitory activity against the NANOG and CD133 expression and cell viability in PC-9/GR cells. As an orally available cancer cell stemness kinase inhibitor with potential antineoplastic activity, it is currently being studied in phase I clinical trials in a number of cancers.
|
-
- HY-139300A
-
|
HMPL-813 succinate
|
EGFR
|
Cancer
|
|
Epitinib succinate is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer. Epitinib (succinate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-15772
-
|
AZD-9291; Mereletinib
|
EGFR
|
Cancer
|
|
Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
|
-
- HY-156527
-
|
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
PHD-IN-2 (Compound 91) is a PHD antagonist (IC50: < 5 nM). PHD-IN-2 induces erythropoietin synthesis in HEP3B cells (EC50: <2.5 μM). PHD-IN-2 can be used for research of cardiovascular disorders, metabolic disorders, hematological disorders, pulmonary disorders, kidney disorders, liver disorders, wound healing disorders, and cancer.
|
-
- HY-153245
-
|
|
Btk
|
Cancer
Inflammation/Immunology
|
|
JNJ-64264681 is a potent, orally active, selective and irreversible covalent BTK inhibitor. JNJ-64264681 exhibits good pharmacokinetic characteristics and can be used for cancer and autoimmune diseases research.
|
-
- HY-139203
-
-
- HY-N11777
-
|
NHAP
|
NF-κB
|
Cancer
|
|
(−)-N-Hydroxyapiosporamide (NHAP), an alkaloid, is an NF-κB inhibitor with potent antitumor activity in vitro and in vivo. (−)-N-Hydroxyapiosporamide can be used for the research of colorectal cancer (CRC).
|
-
- HY-W011044
-
|
|
KLF
|
Cancer
|
|
CID 5951923 is a potent inhibitor of Krüppel-like factor 5 (KLF5), with an IC50 of 603 nM. CID 5951923 can inhibit proliferation of cancer cells in vitro.
|
-
- HY-N2689
-
|
(R)-6′,7′-DHB
|
Cytochrome P450
|
Cancer
|
|
(R)-6',7'-Dihydroxybergamottin ((R)-6′,7′-DHB) is a competitive inhibitor of human and rat CYP1A1 activity with Kis of 55 μM and 1.72 μM, respectively. (R)-6',7'-Dihydroxybergamottin has the potential for cancer research.
|
-
- HY-147788
-
|
|
Dihydroorotate Dehydrogenase
|
Cancer
|
|
hDHODH-IN-9 (Compound 3k) is a potent inhibitor of hDHODH with an IC50 of 0.34 μM. hDHODH-IN-9 demonstrates high cytotoxic activity against MCF-7 and A375 cells and good selectivity. hDHODH-IN-9 has the potential for the research of cancer diseases.
|
-
- HY-136726
-
|
CINK4
|
CDK
|
Cancer
|
|
GP-82996 (CINK4) is a pharmacological inhibitor of CDK4/6. GP-82996 has IC50s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer.
|
-
- HY-150968
-
|
|
Apoptosis
|
Cancer
|
|
Antiproliferative agent-11 (compound 7) is an antiproliferative and selective Ruthenium(II)-Tris-pyrazolylmethane complex. Antiproliferative agent-11 shows antiproliferative activity towards MCF-7, HeLa, 518A2, HCT116 and RD with IC50s of 6, 10, 6.8, 6.7 and 6 μM, respectively. Antiproliferative agent-11 can be used for the research of cancer.
|
-
- HY-125378A
-
|
(7R)-SBI-0636457; (7R)-SB1-0636457
|
Others
|
Cancer
|
|
(7R)-SBP-0636457 is the inactive isomer of SBP-0636457 (HY-125378), and can be used as an experimental control. SBP-0636457 (SB1-0636457) is a SMAC mimetic, and as an IAP antagonist. SBP-0636457 binds to the BIR-domains of the IAP proteins, with a Ki of 0.27 μM. SBP-0636457 can be used for the research of solid tumors and hematologic cancers.
|
-
- HY-N0105
-
-
- HY-18964
-
|
Calpain inhibitor I; Ac-LLnL-CHO; ALLN
|
Proteasome
Apoptosis
|
Cancer
|
|
MG-101 (ALLN) is an inhibitor of cysteine proteases which inhibits calpain I, calpain II, cathepsin B and cathepsin L with Kis of 190, 220, 150 and 500 pM, respectively. MG-101 induces apoptosis and inhibits tumor growth, it can be used for the research of colon cancer.
|
-
- HY-138939
-
|
|
Lipoxygenase
|
Cancer
|
|
5-LOX-IN-2, an inhibitor of 5-lipoxygenase (5-LOX) with an IC50 of 0.33 μM, inhibits 5-LOX in a dose-dependent manner . 5-LOX-IN-2, reduces the cell viability of renal cancer cells and induces apoptosis, can be used for cancer research.
|
-
- HY-118618
-
|
Hiyodorilactone A; Schkuhrin I
|
STAT
|
Cancer
|
|
Eucannabinolide is a STAT3 inhibitor. Eucannabinolide suppresses STAT3 activation at tyrosine 705, inhibiteds its translocation to nucleus, and decreases its DNA binding capacity. Eucannabinolide can be used for triple negative breast cancer (TNBC) diseases research.
|
-
- HY-125612
-
|
5'-Hydroxymorusin
|
Apoptosis
|
Cancer
|
|
Artonin E (5'-Hydroxymorusin) is a known prenylated flavonoid that induces apoptosis and arrests the cell cycle in S phase. Artonin E can induce anti-proliferative effects through mitochondrial pathway dysregulation and can be used in cancer research.
|
-
- HY-151255
-
|
|
CDK
|
Cancer
|
|
CDK8-IN-9 (compound 22) is a potent type II CDK8 inhibitor with an IC50 value of 48.6 nM. CDK8-IN-9 can inhibit tumor growth and is used in colorectal cancer studies.
|
-
- HY-15217
-
|
|
Haspin Kinase
|
Cancer
|
|
CHR-6494 is a potent inhibitor of haspin, with an IC50 of 2 nM. CHR-6494 inhibits histone H3T3 phosphorylation. CHR-6494 can be used in the research of cancer.
|
-
- HY-103439
-
|
|
EGFR
|
Cancer
|
|
GW 583340 dihydrochloride is a potent dual EGFR/ErbB2 tyrosine kinase inhibitor (IC50: 0.01 and 0.014 μM respectively). GW 583340 dihydrochloride reverses ABCG2- and ABCB1-mediated drug resistance. GW 583340 dihydrochloride has anti-cancer activity.
|
-
- HY-N3119
-
|
|
Apoptosis
|
Cancer
|
|
Paeoniflorigenone, isolated as an active ingredient from the root of moutan cortex, induces apoptosis selectively in the cancer cell lines and exhibits antiproliferative effect.
|
-
- HY-152099
-
|
|
Apoptosis
|
Cancer
|
|
Antiproliferative agent-19 (compound 4a) is an anti-cancer agent that exerts anti-proliferative effects on lung cancer cells by inducing apoptosis. antiproliferative agent-19 also induces cell cycle arrest in the G2/M phase.
|
-
- HY-107777A
-
|
|
Others
|
Cancer
|
|
LLY-284 is the diastereomer of LLY-283 with much less active. LLY-283 is a potent inhibitor of PRMT5. LLY-284 has the potential for the research of cancer diseases.
|
-
- HY-148719
-
|
|
Topoisomerase
|
Cancer
|
|
ARN24139(compound 3f) is a topoisomerase II (topoII) inhibitor with the IC50 of 7.3 μM. ARN24139 can inhibit cancer cell proliferation and is well tolerated in vivo.
|
-
- HY-156576
-
|
|
DGK
|
Cancer
|
|
DGKα-IN-6 is a DGKα inhibitor with the IC50 of 1.377 nM, extracted from patent WO2022271650 (compound 143). DGKα-IN-6 has the potential for cancer study.
|
-
- HY-10126
-
|
AZD2811; INH-34; AZD1152-HQPA
|
Aurora Kinase
Apoptosis
|
Cancer
|
|
Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells.
|
-
- HY-149439
-
-
- HY-155065
-
|
|
Reactive Oxygen Species
Apoptosis
CDK
|
Cancer
|
|
SB-1295 is an orally active CDK9/T1 inhibitor (IC50=0.17 μM). SB-1295 shows antiproliferative activity in HCT 116 and MIA PaCa-2 cells. SB-1295 also induces MIA PaCa-2 cell death by inducing intracellular ROS production, reducing mitochondrial membrane potential and inducing apoptosis. SB-1295 has the potential to study cancer.
|
-
- HY-N12079
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
(2,4-Dichloro-3,5-dimethoxyphenyl) methyl 6-O-β-D-glucopyranosyl-β-D-glucopyranoside is an anticancer agent that inhibits the proliferation of lung cancer A549 cells (IC50=29 μΜ). (2,4-Dichloro-3,5-dimethoxyphenyl) methyl 6-O-β-D-glucopyranosyl-β-D-glucopyranoside can be obtained from Lilium regale and can be used in cancer research.
|
-
- HY-156088
-
|
|
Apoptosis
Microtubule/Tubulin
|
Cancer
|
|
SSE1806 is a derivative of podophyllotoxin (a natural antimitotic agent) and a microtubule/tubulin inhibitor with significant anticancer and antiproliferative activities. The GI50 of SSE1806 on cancer cell growth ranges from 1.29-21.15 μM. SSE1806 causes mitotic abnormalities and G2/M phase arrest, increases p53 expression, and inhibits colon cancer organoid growth. SSE1806 is able to overcome multidrug resistance in cell lines overexpressing MDR-1.
|
-
- HY-149515
-
|
|
Monoamine Oxidase
|
Cancer
|
|
MAO-IN-3 (Compound 5) is a reversible and competitive MAO inhibitor (Ki: 0.6 and 0.2 μM for MAO A and MAO B). MAO-IN-3 inhibits LN-229 glioblastoma cell proliferation with an IC50 of 0.8 μM. MAO-IN-3 can be used for cancer research.
|
-
- HY-151573
-
|
|
EGFR
CDK
|
Cancer
|
|
EGFR/CDK2-IN-1 (Compound 3b) is an EGFR/CDK2 inhibitor. EGFR/CDK2-IN-1 shows good cytotoxicity against MCF7 and HepG2 cells. EGFR/CDK2-IN-1 can be used in cancer research.
|
-
- HY-153064
-
|
PD-1/PD-L1-IN-30
|
PD-1/PD-L1
|
Cancer
|
|
MAX-10181 (PD-1/PD-L1-IN-30) is a PD-1/PD-L1 binding inhibitor, with an IC50 value of 0.018 μM. MAX-10181 can be used for research of cancers and other related diseases.
|
-
- HY-P5014
-
-
- HY-P5011
-
-
- HY-149408
-
|
|
Monoamine Oxidase
|
Cancer
|
|
MAOA-IN-1 (compound 15) is an orally active MAOA inhibitor with cytotoxicity against prostate cancer cells. MAOA-IN-1 has Caco-2 permeability and lower CNS permeability. MAOA-IN-1 can be further used in the research of anti-cancer and anti-inflammatory indications.
|
-
- HY-108507
-
|
|
Smo
|
Cancer
|
|
MRT-10 is a seven-transmembrane receptor smoothened (Smo) antagonist with an IC50 of 0.65 μM in the micromolar range in various Hedgehog (Hh) assays. MRT-10 binds to the Smo receptor at the level of the Bodipycyclopamine binding site. MRT-10 can be used for the research of cancer.
|
-
- HY-117102
-
|
|
Aryl Hydrocarbon Receptor
Checkpoint Kinase (Chk)
|
Cancer
|
|
ANI-7 is an activator of aryl hydrocarbon receptor (AhR) pathway. ANI-7 inhibits the growth of multiple cancer cells, and potently and selectively inhibits the growth of MCF-7 breast cancer cells with a GI50 of 0.56 μM. ANI-7 induces CYP1-metabolizing mono-oxygenases by activating AhR pathway, and also induces DNA damage, checkpoint Kinase 2 (Chk2) activation, S-phase cell cycle arrest, and cell death in sensitive breast cancer cell lines.
|
-
- HY-P99109
-
|
GLS-010; AB-122; WBP-3055
|
PD-1/PD-L1
|
Cancer
|
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma.
|
-
- HY-137474
-
|
|
Others
|
Cancer
|
|
Purpurin 18 methyl ester, a chlorophyll-a derivative, is a photosensitizer that can be used in photodynamic therapy (PDT). Purpurin 18 methyl ester has photodynamic activity to induce cancer cell death.
|
-
- HY-P5107
-
|
|
VEGFR
|
Cancer
|
|
Protein LMWP is a cell-penetrating peptide with vascular endothelial growth factor (VEGF) inhibitory activity. Protein LMWP can inhibit tumor growth and is used in cancer research.
|
-
- HY-125209
-
|
|
Others
|
Cancer
|
|
TH5427 is a promising, targeted inhibitor that can be used to further study NUDT5 activity and ADP-ribose metabolism. TH5427, blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells. NUDT5 is recently identified as a rheostat of hormone-dependent gene regulation and proliferation in breast cancer cells.
|
-
- HY-152209
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-26 is a bromodomain protein 4 (BRD4) inhibitor/nitric oxide-donator. BRD4 Inhibitor-26 inhibits BRD4 (BD1) and BRD4 (BD2) with IC50 values of 0.82 μM and 1.94 μM, respectively. BRD4 Inhibitor-26 can be used for the research of ovarian cancer.
|
-
- HY-149721
-
|
|
Apoptosis
HDAC
|
Cancer
|
|
HDAC4-IN-1 (compound 1a) is a class IIa HDACI inhibitor (IC50=0.077 μM). HDAC4-IN-1 can enhance Caspase-induced Apoptosis. HDAC4-IN-1 has anticancer activity. HDAC4-IN-1 can be used in the research of drug combination against cancer.
|
-
- HY-148234
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
M4K2234 (compound 26b) is an ALK2 inhibitor. M4K2234 inhibits ALK2 and ALK5 with IC50s of 5 and 2144 nM, respectively. M4K2234 can be used as a chemical probe for ALK1 and ALK2 protein kinases. M4K2234 can be used for the research of cancer.
|
-
- HY-146741
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
SDR-04 is a BET inhibitor and exhibits strong BRD4-BD1 affinity and inhibition activity. SDR-04 potently suppresses MV4;11 cancer cell line proliferation.
|
-
- HY-144005
-
|
|
Liposome
Autophagy
|
Cancer
|
|
C16 PEG-Ceramide is a polyethylene glycolylated ceramide. C16 PEG-Ceramide can be used for lipid carrier to delivery. C16 PEG-Ceramide induces autophagy. C16 PEG-Ceramide can be used for cancer research.
|
-
- HY-N1031
-
|
12-epi-Vitexolide D; Curcucomosin C
|
Others
|
Cancer
|
|
Vitexolide E is a diterpenoid compound isolated from the leaves of the Malaysian species Vitex vestita. Vitexolide E shows cytotoxic activities against the HCT-116 cancer cell line and human fetal lung fibroblast MRC5 cell line.
|
-
- HY-136579
-
|
ERK-IN-3
|
ERK
|
Cancer
|
|
ASN007 (ERK-IN-3) is a potent and orally active inhibitor of ERK. ASN007 inhibits ERK1/2 with low single-digit nM IC50 values. ASN007 can be used for the research of cancers driven by RAS mutations.
|
-
- HY-136579A
-
|
ERK-IN-3 benzenesulfonate
|
ERK
|
Cancer
|
|
ASN007 (ERK-IN-3) benzenesulfonate is a potent and orally active inhibitor of ERK. ASN007 benzenesulfonate inhibits ERK1/2 with low single-digit nM IC50 values. ASN007 benzenesulfonate can be used for the research of cancers driven by RAS mutations.
|
-
- HY-143491
-
|
|
VEGFR
Apoptosis
Reactive Oxygen Species
|
Cancer
|
|
VS 8 (Compound VS 8) is a potent, orally active VEGFR-2 inhibitor with significant anti-angiogenic effects. VS 8 induces cancer cell apoptosis and migration. VS 8 is active against CSCs (Cancer stem cells).
|
-
- HY-120046
-
|
|
HDAC
|
Cancer
|
|
YF479 is a potent inhibitor of histone deacetylase. YF479 abates cell viability, suppresses colony formation and tumor cell motility. YF479 significantly inhibits breast tumor growth and metastasis. YF479 has the potential for the research of clinical trials for breast cancer.
|
-
- HY-108692
-
|
|
Apoptosis
Endogenous Metabolite
|
Cancer
|
|
Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis.
|
-
- HY-148408
-
|
|
Sirtuin
|
Cancer
|
|
SIRT2-IN-11 (AEM1) is a selective SIRT2 inhibitor with an IC50 value of 18.5 μM. SIRT2-IN-11 p53-dependently induces apoptosis, activates expression of CDKN1A, PUMA and NOXA, and increases acetylation of p53. SIRT2-IN-11 can be used for the research of p53-related cancers.
|
-
- HY-13653
-
|
EGCG; Epigallocatechol Gallate
|
Endogenous Metabolite
Apoptosis
|
Cancer
Inflammation/Immunology
|
|
(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma.
|
-
- HY-149830
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-L1-IN-2 is a potential tumor immunological agent by inhibiting PD-L1. PD-L1-IN-2 is a Naamidine J derivative and exerts antitumor effects in vivo by reducing PD-L1 expression and enhancing tumor-infiltrating T-cell immunity. PD-L1-IN-2 is used for colorectal cancer research.
|
-
- HY-N0944
-
|
|
Others
|
Cancer
|
|
(-)-Heraclenol is a derivative of furocoumarin isolated from Ducrosia anethifolia. (-)-Heraclenol shows antiproliferative and cytotoxic activities on cancer cell lines.
|
-
- HY-14585
-
|
Estrone 3-O-sulfamate
|
Others
|
Cancer
|
|
Estrone O-sulfamate (Estrone 3-O-sulfamate) is a potent steroid sulfatase (STS) inhibitor. Estrone O-sulfamate has inhibitory activity for STS in a placental microsomes (P.M.) preparation and in MCF-7 cells with IC50 values of 18 nM and 0.83 nM, respectively. Estrone O-sulfamate can be used for the research of cancer.
|
-
- HY-144893
-
|
|
HDAC
|
Cancer
|
|
OKI-006 is a potent and orally active inhibitor of histone deacetylase (HDAC). OKI-006 is a unique congener of the natural product HDAC inhibitor largazole. Histone deacetylases (HDACs) play critical roles in epigenomic regulation, and histone acetylation is dysregulated in many human cancers. OKI-006 has the potential for the research of cancer disease.
|
-
- HY-130574
-
|
BMX-010 chloride
|
Reactive Oxygen Species
|
Cancer
|
|
MnTE-2-PyP (BMX-010) chloride is a ROS scavenger and potent radioprotector. MnTE-2-PyP also is a manganese porphyrin, protects normal prostate tissue from radiation damage. MnTE-2-PyP can be used for the research of diabetic prostate cancer.
|
-
- HY-N3097
-
|
|
Others
|
Cancer
|
|
Pellitorine is a compound isolated from the roots of Piper nigrum. Pellitorine shows strong cytotoxic activities against HL60 and MCT-7 cell lines. Pellitorine has the potential for the research of cancer diseases.
|
-
- HY-120574
-
|
|
Others
|
Cancer
|
|
TH1338 (compound 3b), an orally active camptothecin derivative and a potent chemotherapeutic agent for cancer, demonstrates excellent cytotoxic potency against human tumor cell lines in vitro. TH1338 (compound 3b) possesses significant brain penetration, favorable efflux pump properties, and hematological toxicity profile.
|
-
- HY-156751
-
|
|
Androgen Receptor
|
Cancer
|
|
Androgen receptor degrader-3 is an androgen receptor degrader. Androgen receptor degrader-3 blocks the process of androgen receptor transduction and also degrades the receptor itself. Androgen receptor degrader-3 can be used for prostate cancer research.
|
-
- HY-147230
-
|
|
Histone Methyltransferase
|
Cancer
|
|
EZH2-IN-13 is a potent EZH2 inhibitor, for details please refer to compound 73 in patent WO2017139404. EZH2-IN-13 can be used to study cancers or precancerous lesions associated with EZH2 activity.
|
-
- HY-19972
-
|
|
Others
|
Cancer
|
|
ML243 is a selective small-molecule inhibitor of breast cancer stem cells. ML243 has 32-fold greater selective inhibition in the breast CSC-like cell line HMLE_shECad than the control cell line HMLE_shGFP.
|
-
- HY-N8475
-
|
|
PKC
|
Cancer
|
|
6-Deoxyisojacareubin is a PKC inhibitor that inhibits the proliferation of QGY-7703 cells in a concentration-dependent manner. 6-Deoxyisojacareubin is also a natural product that can be obtained from Garcinia nervosa. 6-Deoxyisojacareubin can be used in cancer research.
|
-
- HY-153640A
-
|
|
Akt
|
Cancer
|
|
AKT-IN-14 (Example 2) free baseis a potent AKTinhibitor with the IC50 values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. AKT-IN-14 free basecan be used in cancer research.
|
-
- HY-Y1097S
-
|
2-(Methoxycarbonyl)benzoic acid-d4
|
Isotope-Labeled Compounds
|
Cancer
|
|
Monomethyl phthalate-d4 (2-(Methoxycarbonyl)benzoic acid-d4) is the deuterium labeled Monomethyl phthalate. Monomethyl phthalate is a phthalate metabolite. Monomethyl phthalate acts as a urinary biomarker of phthalates exposure and can be used as a standard for the determination of thyroid cancer and benign nodule.
|
-
- HY-110368
-
|
|
CDK
|
Cancer
|
|
BS-181 dihydrochloride is a potent and selective CDK7 inhibitor (IC50=21 nM) than Seliciclib (HY-30237). BS-181 is also against CDK2, CDK5 and CDK9 with IC50 values of 880 nM, 3000 nM and 4200 nM, respectively (fails to block CDK1, 4 and 6). BS-181 dihydrochloride inhibits a panel of cancer cells growth (IC50=11.5 μM-37.3 μM) and induces cell apoptosis. BS-181 dihydrochloride has the potential for the research of cancer therapy.
|
-
- HY-N6253
-
|
(+)-Pinoresinol
|
Apoptosis
|
Cancer
|
|
Pinoresinol is a lignol of plant origin serving for defense in a caterpillar. Pinoresinol drastically sensitizes cancer cells against TNF-related apoptosis-inducing ligand (TRAIL) -induced apoptosis.
|
-
- HY-119808
-
-
- HY-156024
-
|
|
YAP
|
Others
|
|
TEAD-IN-6 (Example 11-1) is a TEAD modulator that blocks the interaction between YAP1/TAZ and TEAD. TEAD-IN-6 can be used in cancer research.
|
-
- HY-P1408A
-
|
|
Integrin
|
Cancer
|
|
Obtustatin triacetate is a 41-residue non-RGD disintegrin. Obtustatin triacetate can be isolated from the venom of Vipera lebetina obtusa. Obtustatin triacetate is a potent and selective inhibitor of integrin α1β1 adhesion to type IV collagen. Obtustatin triacetate inhibits angiogenesis and may be used in cancer research.
|
-
- HY-149075
-
|
|
Salt-inducible Kinase (SIK)
|
Cancer
|
|
MR22 is a potent pan-SIK (salt-inducible kinase) inhibitor. MR22 no longer exhibits activity on STE group kinases and displays excellent selectivity in a representative kinase panel. MR22-dependent SIK inhibition led to centrosome dissociation and subsequent cell-cycle arrest in ovarian cancer cells.
|
-
- HY-16168A
-
-
- HY-16168B
-
|
|
GnRH Receptor
Apoptosis
|
Cancer
Endocrinology
|
|
Degarelix acetate hydrate is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix acetate hydrate can be used for prostate cancer research.
|
-
- HY-125542
-
|
|
Apoptosis
PI3K
Akt
|
Cancer
|
|
DCZ3301 is a potent aryl-guanidino inhibitor. DCZ3301 inhibits cell proliferation, induces G2/M cell cycle arrest and apoptosis. DCZ3301 inhibits the activation of the PI3K/AKT pathway by downregulating the protein expression of PI3K and phosphorylation of AKT. DCZ3301 can be used in research of cancer.
|
-
- HY-P99419
-
|
GEN1046
|
PD-1/PD-L1
|
Cancer
|
|
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer.
|
-
- HY-15772S
-
|
AZD-9291-d6; Mereletinib-d6
|
EGFR
|
Cancer
|
|
Osimertinib-d6 is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1].
|
-
- HY-P99956
-
|
VLS-101; MK-2140
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer.
|
-
- HY-134000
-
|
NSC624610
|
p38 MAPK
NF-κB
ERK
JNK
VEGFR
MMP
|
Cancer
|
|
Emodic acid (NSC624610) is an anthraquinone compound isolated from A. microcarpus, which can inhibit the proliferation of cancer cells by inhibiting the activity of NF-κB. Emodic acid can also inhibit the phosphorylation of p38, ERK and JNK, the secretion of tumor-promoting cytokines IL-1β and IL-6, and the expression of VEGF and MMP, thereby inhibiting the invasion and migration potential of cancer cells.
|
-
- HY-N12078
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
4-Chloro-3-methoxy-5-methylphenyl 6-O-(6-deoxy-β-L-mannopyranosyl)-β-D-glucopyranoside (compound 3) is an anticancer agent and natural product that can effectively inhibit lung cancer proliferation of A549 cells. 4-Chloro-3-methoxy-5-methylphenyl 6-O-(6-deoxy-β-L-mannopyranosyl)-β-D-glucopyranoside is available from Lilium regale and has potential for use in cancer research.
|
-
- HY-151534
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
PBRM1-BD2-IN-7 is a selective and cell-active polybromo-1 (PBRM1) bromodomain inhibitor. PBRM1-BD2-IN-7 has inhibitory activity for PBRM1-BD2 with an IC50 value of 0.29 μM. PBRM1-BD2-IN-7 can be used for the research of cancer.
|
-
- HY-P1416
-
Foxy-5
1 Publications Verification
|
Wnt
|
Cancer
|
|
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.
|
-
- HY-115925
-
|
|
SHP2
Phosphatase
|
Cancer
|
|
SHP2-IN-9 is a specific SHP2 inhibitor (IC50 =1.174 μM) with enhanced blood–brain barrier penetration. SHP2-IN-9 shows 85-fold more selective for SHP2 than SHP1. SHP2-IN-9 inhibits SHP2-mediated cell signal transduction and cancer cell proliferation, and inhibits the growth of cervix cancer tumors and glioblastoma growth in vivo.
|
-
- HY-13721
-
|
Idronoxil; Dehydroequol; Haginin E
|
Caspase
Apoptosis
Topoisomerase
|
Cancer
|
|
Phenoxodiol (Idronoxil), a synthetic analog of Genestein, activates the mitochondrial caspase system, inhibits XIAP (an apoptosis inhibitor), and sensitizes the cancer cells to Fas-mediated apoptosis. Phenoxodiol also inhibits DNA topoisomerase II by stabilizing the cleavable complex. Phenoxodiol induces cell cycle arrest in the G1/S phase of the cell cycle and upregulates p21 WAF1 via a p53 independent manner.
|
-
- HY-155770
-
|
|
FLT3
|
Cancer
|
|
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor with IC50 values of 1 and 4 nM for FLT3-D835Y and FLT3-ITD, respectively. FLT3-IN-20 has anti-proliferation efficacy in FLT3-ITD-positive AML cell lines MV4-11 and MOLM-13 (7 and 9 nM, respectively) and the MOLM-13 variant (4 nM) with the FLT3-ITD-D835Y mutation. FLT3-IN-20 can be used in research of cancer.
|
-
- HY-126379
-
|
|
Apoptosis
|
Cancer
|
|
CDDO-2P-Im is an analogue of CDDO-Imidazolide with chemopreventive effect. CDDO-2P-Im can reduce the size and the severity of the lung tumors in mouse lung cancer model.
|
-
- HY-N10265
-
|
|
Endogenous Metabolite
|
Cancer
|
|
Stephacidin B is a fungal metabolite. Stephacidin B shows in vitro cytotoxicity against a panel of human tumor cell lines. Stephacidin B shows the strongest cytotoxicity against testosterone-dependent prostate LNCaP cancer cells.
|
-
- HY-10127
-
|
AZD1152
|
Aurora Kinase
Apoptosis
|
Cancer
|
|
Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells.
|
-
- HY-W068119A
-
|
2-Maleimidoethylamine hydrochloride
|
Biochemical Assay Reagents
|
Cancer
|
|
N-(2-Aminoethyl)maleimide (2-Maleimidoethylamine) hydrochloride is a cross-linker. N-(2-Aminoethyl)maleimide hydrochloride can be used to prepare MMP-2 sensitive nanosystem, and for cancer research.
|
-
- HY-150636
-
|
|
Autophagy
Apoptosis
|
Cancer
|
|
Autophagy-IN-1 is a potent autophagy/mitophagy inhibitor, acts by selectively increasing the autophagic flux while blocking the autophagosome-lysosome fusion in cancer cells. Autophagy-IN-1 can induce apoptosis and cell cycle arrest. Autophagy-IN-1 significantly inhibits tumor growth in an HCT116 xenograft mouse model and with low toxicity. Autophagy-IN-1 can be used for researching colorectal cancer.
|
-
- HY-B0323
-
|
Sulfafurazole
|
Endothelin Receptor
Bacterial
Antibiotic
|
Cancer
Infection
Endocrinology
|
|
Sulfisoxazole (Sulfafurazole) is an endothelin receptor antagonist with IC50 values of 0.60 μM and 22 μM against endothelin receptor A and endothelin receptor B, respectively. Sulfisoxazole is a sulfonamide antibacterial with an oxazole substituent. Sulfisoxazole inhibits breast cancer exosome release by targeting endothelin receptor A.
|
-
- HY-139077
-
